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ABSTRACT 
 
In this century most major medical advances have resulted in part from research on 
animals and non-human primates such as the African green monkey and therefore 
often serve as a critical link between basic research and human clinical application. 
Due to its close evolutionary relationship to humans, the African green monkey is 
known to be an excellent and most sought after models for studies of human 
cardiovascular disease (CVD). While the human genome project and some others 
related to model organisms are very well advanced or even complete, little sequence 
information has been acquired for the African green monkey. Given the importance of 
this species in biomedical research generally and CVD specifically, and the 
fundamental significance of sequence data, it is critical that this paucity of genome 
information concerning this specific animal model be addressed in order to better 
define the molecular basis and to further understand the mechanism of cholesterol 
metabolism in this species which will also contribute immensely to primatology.  
 
There is a growing interest in the role of genetic polymorphisms in predicting 
susceptibility to disease and responsiveness to drug interventions. Since plasma lipid 
abnormalities are risk factors for coronary atherosclerosis, determination of these 
plasma lipid concentrations, especially for genes involved in lipid transport and 
metabolism may be influenced by genetic variations. In this study, the African green 
monkey was used as a model to evaluate the effect of niacin on plasma lipids and 
reverse cholesterol transport by examine gene expression and the influence of several 
polymorphisms found in genes that are involved in cholesterol metabolism in humans. 
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A survey of genetic variation spanning ten prioritised “candidate” genes was 
conducted, all of which are known to produce proteins that play key roles in the 
reverse cholesterol pathway (RCT), and in the homeostatic regulation of blood lipid 
profiles related to cardiovascular health and disease.  
 
Reverse transcription polymerase chain reaction (RT-PCR) was used to evaluate 
mRNA expression of those “candidate” genes. Twenty two coincident single-
nucleotide polymorphisms (cSNPs), reported to play a vital role in RCT, were 
genotyped within these genes. This study’s findings implicate a subset of six of the 
twenty two genetic variants, spanning five “candidate” genes. To assess possible 
involvement of these prioritised “candidate” genes and their polymorphisms, 
biochemical analyses of known risk factors of coronary artery disease such as HDL-C 
and LDL-C were conducted. Eight healthy African green monkeys were entered in 
this study of which four were treated with niacin at an escalating dosage. Their mean 
lipid-lowering response following drug therapy was analysed, compared to those with 
the same genotype in a control group.  
 
Niacin treatment was associated with a considerable reduction in LDL-Cholesterol, 
up-regulation of HDL synthesis, and increase of apo A-1 levels.  Gene expression had 
minimal effect on niacin treatment, except CYP7A1 which was down-regulated at the 
same time when considerable change in HDL-C, LDL-C and apoA-1 levels was 
observed. The presence of CYP7A1:Asn233Ser polymorphism may have played a 
critical role in metabolising niacin and influencing the up-regulation of HDL-C 
synthesis in the African green monkey. Although cholesterol lowering alone may 
explain the anti-atherosclerotic effect of niacin on HDL-C, in this study, gene 
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expression data also shed some light in supporting the hypothesis that genetic variants 
may influence the expression of genes involved in RCT, which may also have played 
a role in the anti-atherosclerotic effect of the drug.  
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Chapter 1 
 
THE AFRICAN GREEN MONKEY (CHLOROCEBUS AETHIOPS): 
AN APPROPRIATE MODEL FOR ATHEROSCLEROSIS 
 
 
 
1.1      INTRODUCTION 
There are a number of approaches, in terms of basic systems, for studying and/or 
modelling the metabolic syndrome in order to improve our understanding of this 
condition. Using human subjects appear intuitively to be the most obvious choice but 
they have considerable limitations.  This is due to the difficulty in controlling 
variables such as environment and diet, and by the slowness of lesion development. 
Other complicating factors arise from the area of ethics, considering the type of 
interventions typically required to study the pathophysiology and treatment of this 
condition.  In vitro systems are another option in research, and often used as an 
alternative to animal models but they cannot mimic the complex interactions of 
various tissues involved in lipid metabolism and transport (Moghadasian et al., 2001). 
Therefore, animal models offer the best opportunities to study the metabolic 
syndrome including aetiology, pathophysiology and treatment. Variables can be well 
controlled, extensive biochemical, biomechanical and pathophysiological assays can 
be performed, and the necessary experimental interventions can be carried out. This 
way cause-and-effect association can be built.  
 
Animal research has already provided much information about many aspects of 
human biology in health and disease, and has determined the potential benefit of 
many therapeutic interventions. To date, many animal species and models are 
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described in the research literature, however, choosing the appropriate model to 
answer a particular research question can be challenging. 
 
Among the models of dyslipidemia and atherosclerosis, a number of wild-type, 
naturally defective, and genetically modified animals have been utilised. Due to the 
complexity as well as species specificity of lipid and lipoprotein metabolism, all these 
models come with their own limitations. Rodents have been extensively utilized in 
atherosclerosis studies since they are easy to handle and can be genetically 
manipulated. However, atherosclerosis is not a spontaneous disease for them and has 
to be induced because, unlike primates, they have high levels of high density 
lipoprotein (HDL) which plays a protective role through the process of reverse 
cholesterol transport (RCT) (Table 1.1). Rodents lack cholesteryl ester transfer protein 
(CETP) which plays a vital role in RCT by mediating the transfer of lipids between 
lipoproteins (Moghadasian et al., 2001). 
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Table 1.1: Advantages and disadvantages of certain animal species in atherosclerosis 
                  research (Moghadasian et al., 2001) 
 
Animals Advantages Disadvantages 
Mice Well-defined genetically, easily bred, short 
generation time, inbred availability, easy 
handling and housing, availability of several 
transgenic lines 
Highly resistant to atherogenesis, high HDL, no 
CETP, difficulties in frequent blood sampling and 
dissection of medium/ small-size vessels 
Rabbits Naturally LDL-receptor deficient strain, 
naturally  hypertriglyceridemic strain, good 
size, easy to keep and handle, known to many 
investigators, good response to dietary 
cholesterol, availability of transgenic lines 
Lesion locations less similar to those in humans, 
very high plasma cholesterol needed to induce 
atherosclerosis, hepatic lipase deficient, no 
spontaneous atherosclerosis, cholesterol storage 
syndrome on cholesterol feeding 
Pigeons Atherosclerosis susceptible strains, location, 
histology and progress of lesions similar  to 
humans, low cost and easy to handling, 
sufficient size, good response to dietary 
cholesterol, short generation time, relatively 
long life span 
Nonmammalian, lack of apo E, B48, and 
chylomicron formation, viral infection seen 
associated with atherosclerosis, considerable 
changes in lipoprotein metabolism during egg-
laying 
Nonhuman 
primates 
The closest species to humans, some species 
respond well to dietary cholesterol, spontaneous 
early stage atherosclerosis in some species 
Variations in site of lesions, expensive and 
difficult to house and handle, limitations in 
availability, ethical concerns 
Swine Some physiological/anatomical similarities to 
humans, spontaneous atherosclerosis 
particularly in abdominal aorta, availability of 
miniature pigs, natural lipoprotein mutant 
strains 
Require high cholesterol diet (4-5% w/w), less-
known to investigators, very low baseline 
cholesterol level, difficulties in care and high 
maintenance cost 
Dogs Some physiological/anatomical similarities to 
humans, well-characterised lipoprotein profile 
Atherosclerosis-resistant species, high HDL, 
expensive, poor response to dietary cholesterol, 
ethical concerns 
 
 
Amongst the mammals used in the laboratory, Old World nonhuman primates are the 
closest living relatives of humans, both in evolutionary and genetic terms. Although 
Old World monkeys are separated evolutionarily from humans by more than 20 
million years (Bullock et al., 1975), they have a close resemblance to man, and share 
many characteristics (Harris, 1970). Asian Macaca species such as rhesus monkeys 
and cynomolgus monkeys have been used extensively to study experimentally 
induced atherosclerosis (Moghadasian et al., 2001). In general, their responsiveness to 
dietary cholesterol is much exaggerated compared to humans (Pronczuk et al., 1991; 
Shamekh et al., 2011).  
 
Amongst the African primates, a subspecies of the African green monkey, also known 
as the vervet monkey, has been recognised as a good model for the study of diet-
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induced atherosclerosis (Bullock et al., 1975). The distribution and morphology of 
induced atherosclerotic lesions in this species is similar to those in humans, as is the 
degree of responsiveness to dietary cholesterol (Moghadasian et al., 2001).  
 
Due to the close evolutionary relationship between humans and nonhuman primates, 
many basic features of genetics, development, physiology, and metabolism are shared 
(Shamekh et al., 2011). These various similarities at the levels of whole-body 
physiology and metabolism, organ function, cell structure, and even gene organization 
make nonhuman primates such as the African green monkey excellent, and most 
sought after models for studies of human cardiovascular disease (CVD) (Moghadasian 
et al., 2001). Relative scarcity and high cost are the two most important factors that 
prevent many researchers from having access to species of this order.  However, 
notwithstanding their closeness to humans, validity for their use as models still has to 
be demonstrated in the different primates when there is a gap in background 
information, or in the case of using a species not previously applied.  Spontaneous 
development of certain diseases and conditions (i.e. atherosclerosis), with similarities 
in the underlying pathophysiology and subsequent markers, as well as sharing of 
genes and gene expression is the most important validation.  Extensive analysis of 
genome structure and function in this animal model could make immediate and 
significant contributions to the understanding of CVD. Therefore, a primate model of 
a human disease, such as atherosclerosis, is critical to the long-term success of 
biomedical research. 
 
While the human genome project and some others related to model organisms are 
very well advanced or even complete, little sequence information has been acquired 
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for the African green monkey. Given the importance of this species in biomedical 
research generally and CVD specifically, and the fundamental significance of 
sequence data, it is critical that this paucity of genome information concerning this 
specific animal model be addressed. 
 
Studies using animal models of atherosclerosis can help clarify the contribution(s) of 
the factors that alter both concentrations and compositions of plasma lipoproteins in 
atherogenesis. One of these is CETP, which modifies lipid composition in lipoprotein 
particles, and may play a role in atherogenicity (Quinet et al., 1991). In recent years; 
there has been an explosion in the number of in vivo and genetic studies that have 
largely been carried out using rodent models. As mentioned above,  these represent 
the most common animal model for research in coronary heart disease (CHD), 
however, there are several physiological and developmental differences between 
rodents and humans reflective of their relatively ancient evolutionary divergence 
(approximately 65 to 75 million years ago) as compared to nonhuman primates 
(approximately 25 million years ago) (Moghadasian et al., 2001). Therefore, this 
study, sought to systematically examine the genetic basis of HDL-C of one of the 
African nonhuman primate, the vervet monkey, in order to better define the molecular 
genetics of this animal model, and to further understand the mechanism of cholesterol 
metabolism in this species. One of the principle goals was to identify genes 
influencing cardiovascular disease-related phenotypes during therapeutic intervention. 
An important preliminary step in meeting this goal was the identification of a genetic 
contribution to the variation observed in these phenotypes. Data generated in this 
study will enrich accumulating knowledge of the factors influencing CHD in 
primatology, and, importantly, will identify susceptibility genes of relevance to the 
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African green (vervet) monkey, thereby obviating the need to extrapolate data 
generated in humans and other primates such as chimpanzees and rhesus monkeys. 
 
The study applied a number of original approaches to identify candidate susceptibility 
genes in a nonhuman primate model without available genome sequence data. 
Furthermore, the application of bioinformatics with molecular techniques such as 
real-time PCR represented a state of the art approach to use orthologous human 
reference sequence to identify for the first time in the African green monkey specific 
lipid metabolism candidate genes and coincident SNPs corresponding to ancestral 
polymorphisms present in both humans and nonhuman primates, and preserved in 
both lineages. 
 
1.1.1 Use of the African green monkey as an animal model of atherosclerosis 
The African green monkey (Chlorocebus aethiops) which is indigenous to Southern 
Africa is considered to be a most appropriate model for human physiology and for the 
study of cholesterol metabolism (Suckling et al., 1993). Over the past three decades, 
this species also been used in the area ophthalmology, virology and cardiovascular 
disease, amongst others (Suckling et al., 1993).   
 
African green monkeys develop diet-induced atherosclerotic lesions which are 
topographically and morphologically similar to those of humans (Fincham et al., 
1987). Intravascular metabolism of cholesterol appears to be also similar, with the 
presence of an active cholesteryl ester transfer system (Nichols et al., 1965). Humans 
have a well-characterized lecithin:cholesterol acyltransferase (LCAT) enzyme and the 
LCAT levels in the African green monkeys are similar and sensitive to dietary 
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perturbations (Carroll et al., 1981). Like humans, African green monkeys express only 
apolipoprotein B 100 (apoB 100) in the liver (Fernandez et al., 2008). A high 
cholesterol diet leads to the reduction in hepatic LDL receptor mRNA and 
downregulation of cholesterol 7-alpha-hydroxylase (CYP7A) activity (Fernandez et 
al., 2008). To date numerous researchers have studied the relation between dietary fat 
saturation and HDL levels in an attempt to understand the relation between diet and 
CHD. In spite of the comprehensive nature of the studies on cholesterol metabolism in 
this species, much remains to be learned. Furthermore, not much information is 
available on the genetics of the African green monkey. Therefore, the present study 
has been planned to define the molecular basis of lipoprotein metabolism of this 
species. This approach relies on the identification of genetic variants, which influence 
risk factors for the development of atherosclerosis. 
 
The Primate Unit of the Medical Research Council has extensive experience using the 
African green monkey in atherosclerosis research. In order to produce high 
concentrations of LDL and associated atherosclerosis, this group has formulated a diet 
entirely which requires 3 to 4 years of feeding to induce advanced lesions with 
features of human atherosclerosis (Fincham et al., 1998). Since this diet does not 
modulate HDL, it is not useful when investigating this lipoprotein and lipid 
modulating compounds such as CETP inhibitors. Moreover, the African green 
monkey shows a satisfactory response with HDL-C increases to a variety of reference 
compounds used at this unit with inhibition of cholesterol biosynthesis by lowering 
LDL-C by more than 40%. This demonstrates that the African green monkey 
expresses lipoprotein (a) (Lp(a)) unlike rodents (Fincham et al., 1987; Benadé et al., 
1997). 
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The focus of atherosclerosis research is constantly evolving with early studies 
investigating the morphology, physiology and pathogenesis, and recent studies being 
more directed at the molecular and cellular mechanisms, as well as the preventive 
strategies. Numerous studies in humans, animals, and in vitro, are addressing the 
importance of RCT and cholesterol efflux in atherogenesis. It is very possible that 
augmentation of RCT and cholesterol efflux could be therapeutically useful. Potential 
major strategies include accelerating RCT and cholesterol efflux, which can be 
activated by increasing HDL and apolipoprotein A-I (apoA-I) levels, or by stimulating 
phospholipid transfer protein (PLTP) or CETP. Cholesterol efflux can be enhanced by 
facilitating pathways including ATP-binding membrane cassette transport protein A1 
(ABCA1), scavenger receptor B1 (SR-B1), caveolin and sterol 27-hydroxylase 
(Cyp27A1) (Ohashi et al., 2005). However, uncertainties remain about the impact of 
RCT and cholesterol efflux on cardiovascular disease. Further exploration of 
modifiers of RCT and cholesterol efflux is warranted. Gaining insight into the entire 
picture of RCT and cholesterol efflux may enable us to develop more effective 
therapies for atherosclerosis in the future. Since HDL-based therapies have recently 
become the focus of attention, the African green monkey was used in this study to 
determine the effect of niacin on lipid metabolism at genetic level by the expression 
profile of the selected candidate genes of the RCT pathway. 
 
1.1.2 Taxonomy and habitat  
The African green monkey is a member of the subfamily Cercopithecidea, which 
includes the baboon and other Old World monkeys. Taxonomically they belong to the 
genus Chlorocebus. They are widely distributed throughout much of sub-Saharan 
Africa and inhibit diverse habitats, including semiarid Savannah, woodlands and 
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rainforest (Eley, 1992). In the wild, the African green monkeys are able to exploit 
patchily distributed plants and feed on fruits, leaves, insects, eggs, seafood, grasses, 
and seeds (Eley, 1989). Typically free-ranging, African green monkeys live in multi-
male, multi-female groups of between 6 and 60 individuals per troop with a linear 
dominance hierarchy among the males and a matriarchial kin group relationship 
among the females (Eley, 1989). Each troop is led by an alpha male and reproduction 
is characterized by promiscuity, by either the alpha or subordinate mating with more 
than one female, just as females mate with more than one male. Therefore, inbreeding 
is a well-defined genetic consequence of this social system with an increase of 
homozygosity in the whole genome of this species (Charpentier et al., 2007).  This 
situation would invariably be compounded in captivity due to small gene pools. 
 
 
 
1.2 GENERAL BACKGROUND ON REVERSE CHOLESTEROL 
TRANSPORT AND CHOLESTEROL EFFLUX  
Despite considerable progress in the development of new therapies to control 
atherosclerosis and its complications, coronary heart disease (CHD) remains the 
number one cause of death in the world. Atherosclerotic coronary artery disease 
(CAD) constitutes a major public health burden in developed and developing 
countries and by 2020 is predicted to be the single greatest cause of death worldwide 
(Murray et al., 1997). Although the sustained epidemic of HIV/AIDS causes more 
deaths in South Africa, the prevalence of CAD and other metabolic syndrome 
diseases such as type 2 diabetes is increasing dramatically and already account for 
more than a third of deaths in the population (Akinboboye et al., 2003; Sliwa et al., 
2008 and Imoisili et al., 2009). Consistent with data from other parts of Africa 
suggesting a broadening pattern of cardiovascular disease involving a component of 
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greater burden imposed by atherosclerotic disease, it is essential that effective 
strategies for prevention or treatment are identified. 
 
Preventing atherosclerosis holds the key to reduce the burden of cardiovascular 
disease, and a detailed understanding of the pathophysiology of atherosclerosis will 
facilitate the design of innovative therapeutic strategies for the management of 
dyslipidaemia and the prevention of morbid cardiovascular events. 
 
Over the last few decades, our understanding of the basic mechanisms involved in 
atherosclerosis has progressed significantly. Cardiovascular disease (CVD) risk is 
influenced by several well-established risk factors, such as body mass index (BMI), 
an indicator of overweight and obesity, blood lipids, diabetes, and blood pressure 
(Morabia et al., 2003). These are intermediate phenotypes, having their own genetic 
and environmental determinants, including diet, nutrition, hormones, smoking, 
alcohol intake and physical activity (Bernstein et al., 2002). Studies in humans and 
mice indicate that both the type and quantity of blood-borne lipids are predictive of 
cardiovascular health or disease and that a relatively large number of proteins are 
involved directly and indirectly in the transport, maintenance and elimination of blood 
lipids, including high and low density lipoprotein cholesterol (HDL-C and LDL-C, 
respectively) (Fielding et al., 1995; Rader et al., 2000; Tall et al., 2000 and Glomset et 
al., 1973). Therefore, regulation of cholesterol levels is a complicated process, 
involving cholesterol uptake, biosynthesis, transport, metabolism, and secretion.  
 
Since the pioneering work of John Gofman in the 1950s, our understanding of relative 
contributions of individual lipoproteins to overall
 
cardiovascular risk has grown 
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substantially (Kapur et al., 2008) and modern medical therapy has resulted in a nearly 
70% decrease in coronary heart disease (CHD)-related deaths (Choi et al., 2006).  
Preclinical research has gained further insight into the nature of HDL-C metabolism, 
specifically regarding the ability of HDL-C to promote reverse cholesterol transport 
(RCT).  
 
RCT is a pathway that transports cholesterol from extrahepatic cells and tissues to the 
liver and intestine for excretion. By reducing the accumulation of cholesterol in the 
wall of arteries, RCT may prevent development of atherosclerosis. Cholesterol efflux, 
which is part of RCT, is a major process by which macrophages within the vessel wall 
secrete cholesterol outside cells (Khera et al.,2011). Other important factors include 
high-density lipoprotein (HDL), a subfraction of human plasma lipoproteins with 
apolipoprotein A-I (apoA-I.) as its principal apolipoprotein (Ohashi et al., 2005).  
 
1.3 ROLE OF LIPIDS AND LIPOPROTEINS IN CHD 
1.3.1  Lipid profile and CHD 
Disorders in lipid (e.g., cholesterol and triglycerides) and lipoprotein metabolism are 
major established independent risk factors in the development and progression of 
atherosclerotic CHD (Laakso et al., 1993; Vergeer et al., 2010). Lipid-carrying 
proteins, termed as lipoproteins, are classified as 3 major classes, including very low 
density lipoprotein (VLDL), low density lipoprotein (LDL), and high density 
lipoprotein (HDL). VLDL carries mainly triglycerides, and cholesterol is carried 
mainly in LDL, and to a lesser extent in HDL particles. HDLs transport cholesterol 
from peripheral tissues to the liver for excretion and recycling. Several 
epidemiological studies have clearly shown that plasma cholesterol, triglycerides, and 
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LDL are positively correlated to the development of atherosclerotic CHD, whereas 
HDL is negatively correlated to CHD (Kanel et al., 1981; Brewer, 2011). Due to this 
differential correlation to CHD, LDL-cholesterol (LDL-C) is generally termed as “bad 
cholesterol” and HDL-cholesterol (HDL-C) as “good cholesterol”.  
 
1.3.2 Mechanistic role of lipoproteins in the pathogenesis of CHD 
The classical view of atherosclerosis has changed considerably during the past 
decade. The original understanding of atherosclerosis processes include: a) the lipid-
laden material builds up on the surface of a passive artery wall, b) the lipid build up or 
deposit (plaque) grows and eventually closes off an affected artery, c) the obstructed 
arteries limit blood supply to the target tissues, and d) the subsequent loss of viability 
of the blood-starved tissue (Laakso et al., 1993). These events result in several 
atherosclerotic cardiovascular disease complications including myocardial infarction 
such as, stroke and angina. Understanding the dynamic nature of vascular wall cells 
(versus previous notion as a passive carrier of blood) changed this original view 
considerably, and recent studies suggest that the changes in arterial wall cell 
interaction with blood components would lead to the initiation and progression of 
atherosclerosis. The current concepts suggest that the atherosclerotic vascular disease 
is characterized by: vascular endothelial activation and dysfunction, accumulation of 
fat-laden deposits within the arteries, monocyte-endothelial interaction and infiltration 
of monocytes, transformation of monocytes into lipid-laden foam cells, smooth 
muscle cell hypercellularity and intimal migration, dysregulated deposition and 
degradation of extracellular matrix proteins, and plaque rupture (Brewer, 2011).  
 
 
 
 
 
  13 
The anti-atherogenic properties of HDL-C have been mainly attributed to the ability 
of apoprotein A-I containing HDL particles to initiate cholesterol efflux and facilitate 
the removal of excess cholesterol from peripheral tissues such as arteries and its 
delivery to the liver for removal through reverse cholesterol transport pathway 
(Kashyap, 1998; Khera et al., 2011). This highlighted the beneficial effects of HDL-C 
on atherosclerotic processes. The beneficial modulation of HDL particles by 
pharmacologic agents would therefore be of considerable importance in retarding or 
reversing atherosclerosis and CHD. 
 
1.4 OVERVIEW OF RCT AND CHOLESTEROL EFFLUX 
The sequence of events in RCT is described in Figure 1.1. ApoA-1 is first produced 
mainly by the liver, and released into the plasma. Circulating apoA-1 interacts with 
serum phospholipids and forms nascent discoidal HDL (ndHDL). Once the ndHDL is 
generated, it triggers cholesterol efflux in the macrophages and fibroblasts in the 
subendothelial space. Externalised cholesterol is absorbed by ndHDL, and 
subsequently is esterified by lecithin:cholesterol acyltransferase (LCAT). HDL 
particles are enriched with cholesteryl ester and become larger, resulting in HDL3 and 
HDL2. Phospholipid transfer protein (PLTP) is involved in this process by fusing two 
HDL3 into one HDL2 molecule. If HDL molecules are enriched with triglyceride, 
they are processed by the enzyme hepatic lipase (HL) and become smaller and denser. 
Cholesterol ester transfer protein (CETP) facilitates the equimolar exchange of 
cholesteryl esters from HDL for triglycerides in apoB100-containing lipoproteins. 
These cholesteryl esters are then delivered back to the liver via low-density-
lipoprotein receptor (LDL-R), converted to bile salts, and eliminated through the 
gastrointestinal tract (Ohashi et al., 2005).  
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Figure 1.1: Reverse cholesterol transport pathway. Major constituents of RCT include 
acceptors such as high-density lipoprotein (HDL) and apolipoprotein A-I (apoA-I), and 
enzymes such as lecithin:cholesterol acyltransferase (LCAT), phospholipid transfer protein 
(PLTP), hepatic lipase (HL) and cholesterol ester transfer protein (CETP), which regulate 
cholesterol transport. Eventually, cholesterols in the HDL are delivered to the liver via 
scavenger receptor B1 (SR-B1), converted to bile salts and eliminated through the 
gastrointestinal tract. Cholesteryl esters (CE) could also be delivered to the liver via the low-
density-lipoprotein receptor (LDLR). ndHDL, nascent discoidal high-density lipoprotein 
(Ohashi et al., 2005). 
 
 
As acceptors such as apoA-1 and HDL approach macrophages in subintimal space, 
intracellular cholesterol can be released outside the cells for excretion, a process 
termed cholesterol efflux of macrophages (Figure 1.1). In this pathway, ATP-binding 
membrane cassette transport protein A1 (ABCA1) plays a major role in translocating 
cholesterol into the extracellular space (Oram et al., 2000). In addition to ABCA1, 
ABCG1, another member of the ABC transporter superfamily, is capable of mediating 
the active efflux of cholesterol and phospholipids mainly to lipid-rich acceptor 
particles in macrophages through the action of ABCA1 (Hu et al., 2010). This implies 
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a potential synergistic relationship between ABCA1 and ABCG1 in peripheral 
cholesterol export, where ABCA1 lipidates lipid-poor/free apoA-1 to generate nascent 
or preβ-HDL. These particles in turn serve as substrates for ABCG1-mediated 
cholesterol export (Gelissen et al., 2006; de Beer et al., 2011). It is not known whether 
ABCA1 and ABCG1 function dependently or independently in the process of 
macrophage cholesterol efflux and RCT in vivo. Together, ABCA1 and ABCG1 
account for the major portion of the net cholesterol efflux from cholesterol-loaded 
macrophages to plasma lipoproteins in vivo (Tall et al., 2008). Four other factors are 
also known to be involved in this pathway. Scavenger receptor B1 (SR-B1) can 
induce cholesterol efflux by enabling HDL to bind to cells and recognise lipids within 
cholesterol-rich domains in the plasma membrane (William et al., 1999; de la Llera-
Moya et al., 1999 and Hu et al., 2010). Caveolins have the capacity to bind 
cholesterol, and can transport cholesterol from the endoplasmic reticulum to the 
plasma membrane (Smart et al., 1996). Sterol 27-hydroxylase (CYP27A1) is also 
known as a contributor to cholesterol efflux (Escher et al., 2003). In addition to these 
pathways, cholesterol efflux can also occur via passive diffusion, in which cholesterol 
is desorbed down to the concentration gradient onto acceptor molecules (Kawano et 
al., 1993). Thus, RCT and cholesterol efflux constitute an efficient pathway by which 
excess cholesterol can be removed out of the body. Although extensive studies have 
been performed, RCT is a complicated process and its regulation mechanisms are 
largely unknown. Several key factors described above are involved in the RCT and 
cholesterol efflux, but the inter-relationship among these factors is not clear. 
 
Experiments with transgenic animals suggest that disruption of one or more steps in 
RCT results in accelerated atherosclerosis, whereas overexpression of pivotal proteins 
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in RCT, such as apoA-1, PLTP, LCAT and SR-B1, exerts atheroprotective effects 
(von Eckardstein et al., 2000). The important lesson from these experimental 
approaches is that disruption of RCT and resulting atherosclerosis may occur in the 
presence of either decreased or increased HDL-C levels, depending on which step of 
RCT is dysfunctional. 
 
 
1.4.1 Cholesterol efflux 
A variety of evidence shows that RCT and cholesterol efflux play a major role in 
preventing atherosclerosis in humans. In fact, congenital impairment in genes 
involved in cholesterol efflux may augment atherosclerosis in some patients. On the 
other hand, acceleration of RCT and cholesterol efflux by increasing HDL or apoA-I 
levels may result in amelioration of atherosclerosis, suggesting a potential therapeutic 
tool for human atherosclerosis (Ohashi et al., 2005; Khera et al., 2011). 
 
1.4.2 HDL levels and atherosclerosis 
Several studies have shown that low levels of HDL2 and HDL3 are associated with 
increased progression of atherosclerosis and risk of cardiovascular disease (Miller et 
al., 1981; Sweetnam et al., 1994 and Ruotolo et al., 1998). Since HDL and apoA-1 are 
major receptors of cholesterol in the cholesterol efflux, increasing HDL levels may 
increase cholesterol efflux and RCT, contributing to reduced cardiovascular disease 
risks. Many attempts have been made to enhance HDL levels as anti-atherogenic 
therapy (Gordon et al., 1989 and Castelli et al., 1992). The prevention of 
cardiovascular disease is critically dependent on lipid-lowering, including 3-
hydroxymethyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors 
(statins), cholesterol absorption inhibitors, bile acid resins, fibrates, and nicotinic acid 
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(nicin).  Although these drugs are generally well tolerated, severe adverse effects can 
occur in a minority of patients. Significant progress has been made in the 
identification of common DNA sequence variations in genes influencing the 
pharmacokinetics and pharmacodynamics of most of these drugs and in disease-
modifying genes relevant for coronary heart disease (CHD) (Schmitz et al., 2006). 
 
Currently available lipid-modifying drug have generally modest effects on HDL-C 
levels. Statins are first-line drug therapy for treatment of elevated LDL-C as well as 
for most high-risk patients with low HDL-C, but raise HDL-C by only 5-10% (Yim et 
al., 2003). Fibrates, agonists of peroxisome proliferator-activated receptor (PPAR)-α, 
lower triglyceride levels very effectively and raise HDL-C by 5 -20% (Yim et al., 
2003). Nicotinic acid (niacin) is the most effective HDL-raising drug currently 
available, with increases of up to 35% (Ohashi et al., 2005). Gemfibrozil therapy 
significantly reduced cardiovascular disease, with a modest increase in HDL levels 
(Frick et al., 1987). Niacin also lowers triglyceride levels, reduces LDL levels, and 
modestly lowers lipoprotein A [Lp(a)] levels (Canner et al., 1986 and Guyton et al., 
2000). Several clinical trials have found niacin to be effective, alone or in 
combination with other drugs, in preventing coronary events, slowing atherosclerotic 
disease progression, and promoting lesion regression (Brown et al., 2001). 
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1.5 HDL AND REVERSE CHOLESTEROL TRANSPORT 
1.5.1 Mechanisms 
Reverse cholesterol transport describes the transfer of cholesterol
 
from nonhepatic 
cells to the liver (von Eckardstein et al., 2000; 2001).  Lipid-free apo A-I or
 
lipid-poor 
pre–ß-HDL particles produced in the intestine or liver or shed during lipolysis of 
triglyceride-rich
 
lipoproteins (TGRL) initiate efflux of phospholipids and cholesterol
 
from cell membranes in a process facilitated by phospholipid transfer protein (PLTP). 
Cholesterol
 
in these nascent discoidal HDL particles is then esterified
 
by lecithin-
cholesterol acyltransferase (LCAT). Cholesteryl
 
esters readily move to the core of 
HDL particles, producing
 
a steady gradient of free cholesterol and enabling HDL to 
accept
 
cholesterol from various donors. The reciprocal exchange of
 
cholesteryl ester 
for triglycerides mediated by CETP moves the
 
bulk of the cholesteryl esters to 
lipoprotein remnant particles,
 
which are subsequently cleared by the liver. At the same 
time,
 
HDL becomes enriched with triglycerides, which are substrates
 
for hepatic 
lipase (HL). The concerted action of CETP-mediated cholesteryl ester
 
transfer and 
HL-mediated hydrolysis of triglycerides and phospholipids
 
helps to form the smaller 
HDL particles that are the preferred
 
binding partners for scavenger receptor type B1 
(SR-B1), the
 
major HDL receptor on hepatocytes. The binding of HDL with SR-B1
 
mediates the selective uptake of cholesteryl esters that have
 
not undergone CETP-
mediated transfer to apo B–containing particles (intermediate-density lipoprotein and 
low-density
 
lipoprotein [LDL]). Lipid-free apolipoproteins or lipid-poor
 
pre–ß-HDL 
are formed in reactions catalyzed
 
by PLTP, CETP, and HL. Thus, as shown in Figure 
1.2, reverse
 
cholesterol transport can be envisioned as a cycle in which
 
acceptors of 
cellular cholesterol (ie, apo A-I, pre–ß-HDL) are perpetually regenerated to undertake 
their function of inducing
 
cholesterol efflux (Assmann et al., 2004). 
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Figure 1.2: Pathways involved in the generation and conversion of HDL. ABC1 indicates 
adenosine triphosphate-binding cassette transporter 1; apo A-I, apolipoprotein A-I; apo E, 
apolipoprotein E; CE, cholesteryl ester; CETP, cholesteryl ester transfer protein; HDL, high-
density lipoprotein; HL, hepatic lipase; IDL, intermediate-density lipoprotein; LCAT, 
lecithin-cholesterol acyltransferase; LDL, low-density lipoprotein; LDL-R, low-density 
lipoprotein receptor; LDL-RRP, low-density lipoprotein receptor-related protein; Lyso PC, 
lysophosphatidylcholine; PC, phosphatidylcholine; PGN, proteoglycans; PL, phospholipids; 
PLTP, phospholipid transfer protein; SR-B1, scavenger receptor B1; UC, unesterified 
cholesterol; and VLDL, very-low-density lipoprotein. Adapted from Toth PP (Curr 
Atheroscler Rep. 2003;5:386–393). 
 
 
 
1.6 THERAPIES DIRECTED AT THE PROMOTION OF 
CHOLESTEROL EFFLUX AND RCT 
The concept that the promotion of macrophage RCT could prevent progression or 
even induce regression of atherosclerosis is remarkably attractive. Data in animals 
suggest that atherosclerosis regression can be achieved through HDL-based 
interventions. A major area in HDL-based therapeutics involves the exploitation of 
the information to develop pharmacological approaches to enhance components of the 
RCT pathway. The actual mechanism by which HDL protects against atherosclerosis 
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is likely multifactorial and not yet fully elucidated; however, there are several 
proposed major atheroprotective mechanisms of HDL. An important concept is that 
simply raising HDL-C levels may not necessarily be the optimal target for the 
development of new therapies targeted toward HDL (Duffy et al., 2006). Some new 
therapeutic approaches are targeted toward promoting RCT, even if they do not rise 
HDL-C levels per se (Duffy et al., 2006). It could be that the function of HDL is more 
important than its concentration and those therapies that improve HDL “function,” 
even if they do not increase HDL-C levels, may have important antiatherogenic and 
vascular protective effects (Navab et al., 2004). 
 
1.6.1 Drug targets 
A combination of genetic variations and environmental differences defines unique 
human characteristics, including individual responsiveness to drugs or susceptibilities 
to common diseases. Among several types of genetic variation, single-nucleotide 
polymorphisms (SNPs) are the most abundant throughout the genome. SNPs have 
lately received much attention in biomedical fields, because some of them can 
influence the quality and/or the quantity of particular gene products and thereby serve 
as markers of individual risk for adverse drug reactions or susceptibility to complex 
diseases (Ganji et al., 2003). 
 
Proteins that transport drugs in the body play roles in absorption, distribution, and 
excretion of drugs. Hence, genetic variations in genes encoding transporters may 
cause individual differences in drug absorption, elimination and cellular uptake, 
thereby affecting drug response and toxicity (Iida et al., 2003). 
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1.6.1.1 Niacin as a lipid-regulating agent and its effect on atherosclerotic CHD 
The use of niacin as a pharmacological agent has been reported as early as 1955 
(Carlson, 2005), and currently it is a widely used agent in the treatment of 
dyslipidemia (Kamanna et al., 2008). In pharmacologic doses of 1-3 g/day, niacin 
reduces concentrations of total plasma cholesterol, apolipoprotein (apo) B, 
triglyceride, VLDL, LDL, and Lp(a), and increases HDL levels (Carlson, 2005). 
Niacin is the most potent available lipid-regulating agent to increase HDL levels. 
Because of these diverse effects on the lipid profile, niacin is considered as a broad-
spectrum lipid-regulating agent. Several clinical trials (secondary prevention and 
angiographic studies) indicate that the treatment with niacin significantly reduces total 
mortality, coronary events, and retards the progression and induces regression of 
coronary atherosclerosis (Carlson, 2005). Although the use of niacin has in the past 
been associated with adverse effects (e.g., flushing and hepatic toxicity), recent 
studies utilizing newer formulations of niacin have shown a significant reduction in 
flushing with minimal to no hepatic toxicity, and comparable effects on plasma lipid 
profiles (Carlson, 2005; Kang et al., 2011). These newer formulations of niacin 
referred to as “niacin extended-release” have considerably renewed interest in the use 
of niacin as a broad-spectrum lipid-regulating agent and particularly for raising HDL. 
 
1.6.1.2  Role of niacin in HDL metabolism 
HDLs are a complex class of lipoproteins with hydrophobic core of cholesterol esters 
and triglycerides, and an outer hydrophilic layer of apolipoproteins, phospholipids and 
unesterified cholesterol. Apo AI and apo AII are the major proteins of HDL, 
accounting for approximately 70% and 20% of protein mass respectively (Yim et al., 
2003). The liver and intestines are the major organs for synthesis and secretion of 
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HDL and its components. The plasma levels of HDL and its components are finely 
regulated by various synthetic and catabolic processes (Yim et al., 2003). Although 
niacin has long been used specifically to raise HDL, only recently studies are 
beginning to address the cellular mechanisms of action of niacin on HDL metabolism 
(Yim et al., 2003).  
 
There are mainly two mechanisms by which niacin influences plasma lipids and the 
secretion of apo B bearing lipoproteins including VLDL particles in the liver. One 
mechanistic strategy to decrease elevated levels of lipids (e.g., triglycerides) in blood 
may be the inhibition of lipolysis in adipose tissue (Figure 1.3). Niacin, through 
hormone-sensitive lipase-mediated events, inhibits fatty acid mobilization from 
adipose tissue. Inhibition of fatty acid (FA) release from adipose tissue results in 
decreased availability of fatty acids for triglyceride (TG) synthesis (Ganji et al., 
2003). Niacin-mediated inhibition of TG synthesis may decrease the lipidation of apo 
B and translocation through endoplasmic reticular (ER) membrane leading to 
increased intracellular apo B degradation. Increased hepatocyte apo B degradation by 
niacin would decrease the number of VLDL and their catabolic product, LDL 
particles, which explains the lower apo B and LDL concentrations observed clinically 
after niacin treatment (Ganji et al., 2003 and Kamanna et al., 2008). In-vitro studies in 
hepatocytes suggest that niacin inhibits the putative “HDL catabolism receptor” 
involving removal of HDL-apoA-I, but not the SR-BI receptor that mediates selective 
HDL-cholesterol ester removal (Ganji et al., 2003). These mechanisms of decreased 
HDL-apoA-I catabolism by niacin would increase HDL half-life and its concentration 
thereby augmenting cholesterol efflux and reverse cholesterol transport (RCT), and 
other HDL-related vascular beneficial effects. Increased residence time would also 
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allow HDL size to increase (HDL2 > HDL3) from peripheral tissue cholesterol 
uptake. Taken together, niacin, through these collaborative intracellular metabolic 
processes, favourably modulates LDL and HDL levels resulting in decreased 
atherosclerotic coronary artery disease (Ganji et al., 2003 and Kamanna et al., 2008). 
 
 
       
Figure 1.3: Overview of current concepts on mechanism of action of niacin on lipid and 
lipoprotein Metabolism (Kamanna et al., 2008). 
 
 
1.7 GENE ACTIVITIES IN RCT AND CHOLESTEROL EFFLUX 
There is interest in the role of genetic polymorphisms predicting susceptibility to 
disease and responsiveness to dietary and drug interventions. Small-scale studies have 
investigated the effects of polymorphisms on physiological or biological factors and 
have provided useful information on possible mechanistic links between variation at 
the gene level and risk factors for cardiovascular disease (CVD). 
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Plasma measures of lipid metabolism are well-established risk factors of CAD, the 
leading cause of death worldwide (Klos et al., 2006). Increased risk of CAD has been 
associated with elevated TG, TC, and LDL-C, and decreased HDL-C (Austin et al., 
1998; Castelli et al., 1992, Gordon et al, 1989 and Davignon et al., 1996). CAD has 
also been associated with low plasma apoA-I and high apoB (Brunzell et al., 1984). 
These lipids and apolipoproteins are regulated by complex metabolic and cellular 
processes, which, in turn, are influenced by both genetic and environmental factors 
(Sing et al., 2003).  
 
The hypothesis that high-density lipoprotein cholesterol (HDL-C) is protective 
towards atherosclerosis was first proposed by Barr et al. (1951). The protective action 
of HDL may reflect the role of HDL particles in the reverse cholesterol transport 
(RCT) pathway. Indeed, HDL particles are involved in the uptake of cholesterol from 
peripheral tissues and its transport back to the liver for excretion. The molecular 
regulation of HDL metabolism and RCT is complex. RCT is the process by which 
cholesterol is effluxed from peripheral tissues onto acceptor particles, primarily HDL, 
in the plasma for uptake by the liver. HDLs consist of cholesterol, phospholipids, 
triglycerides, and apolipoproteins (Tall, 1990). Lipid-poor apoA-I promotes efflux of 
cholesterol and phospholipids through interaction with ABCA1. The enzyme LCAT 
converts unesterified cholesterol to cholesteryl ester (CE) within the HDL particle. 
HDL CE is subsequently returned to the liver by 3 distinct pathways. In the first 
pathway, the SR-B1 mediates selective uptake of HDL cholesteryl esters by the liver. 
In the second pathway, CETP transfers cholesteryl ester from HDL to apoB-
containing lipoproteins in exchange for triglycerides. Finally, there is a pathway that 
leads to uptake of holo-HDL particles and degradation of HDL-associated proteins 
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such as apoA-I. In part, this pathway may involve the formation of large HDL, 
enriched with apoE (Tall et al., 2000). 
 
RCT involves numerous lipid transfer proteins, enzymes, apolipoproteins, and 
membrane-bound receptors (Fielding et al., 1995; Khera et al., 2011). The genes 
encoding these proteins, as well as genes encoding proteins that regulate their 
transcription, are candidates for influencing variation in plasma levels of apoA-I, 
apoB, HDL-C, LDL-C, TC, and TG. Based on a model RCT pathway (von 
Eckardstein et al., 2001; Ren et al., 2006), to date, a set of 54 genes involved in RCT 
for evaluating the impact of genetic variation on variation in plasma lipid and 
lipoporotein levels have been  identified  by Klos et al., (2006). CETP, lipoprotein 
lipase (LPL), HL and apolipoprotein E (apoE) are key players in the metabolism of 
the major plasma lipoproteins and are potential candidates for the plasma modulation 
of LDL particle size. Disturbances in these systems are integral components of life-
threatening diseases. Enhancement of cholesterol efflux and RCT is considered an 
important target for anti-atherosclerotic drug therapy (von Eckardstein et al., 2000).  
 
CETP mediates the transfer of hydrophobic lipids between VLDL, LDL and HDL. 
Genetic CETP deficiency is associated with markedly elevated concentrations of HDL 
cholesterol and a polydisperse LDL size distribution pattern (Yamashita et al., 2000). 
The first common functional polymorphism in the CETP gene promoter (-629C/A) 
was described by Dachet et al., 2000. The CETP-629C/A polymorphism is in strong 
linkage disequilibrium with the extensively studied TaqIB polymorphism, recently 
reported to be associated with decreased CHD risk (B2 allele) (Ordovas et al., 2000). 
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LPL hydrolyses triglycerides of chylomicrons and VLDL and mediates the cellular 
binding and uptake of lipoproteins. The LPL 447X allele has been associated with a 
beneficial lipid profile and a lower risk of CHD in most studies. HL plays a pivotal 
role in the metabolism of LDL and HDL. Four common polymorphisms in the HL 
promoter are in complete linkage disequilibrium. Recently, the -514T allele was also 
shown to decrease the transcriptional activity of the HL gene in vitro (Deeb et al., 
2000).The common polymorphism in the apoE gene (e2/e3/e4) has been extensively 
studied, and the apoE e4 allele has been reported to be associated with decreased LDL 
particle size, and increased risk of CHD (Wilson et al., 1996).  
 
ABCA1 is a member of the ATP-binding cassette transporter family, which plays a 
most important role in apoA-I-mediated cholesterol efflux from peripheral cells, the 
first step in reverse cholesterol transport (Yamakawa-Kobayashi et al., 2004). ABCA1 
has been identified to be a transporter that effluxes excess cellular cholesterol to 
poorly lipidated apoA-1, thus playing a pivotal role in the reverse cholesterol 
transport process (Brewer et al., 2004). Regulation of ABCA1 transporter gene 
expression plays a key role in determining intracellular cholesterol levels (Brewer et 
al., 2004), therefore, ABCA1 is an attractive candidate gene for the modulation of 
plasma HDL cholesterol concentration (Wang et al., 2000). Common variants of this 
gene may be a genetic factor for atherosclerosis (Kyriakou et al., 2005). 
 
 
1.7.1  Effects of mutations and intervention on HDL metabolism 
 
There is interest in the role of genetic polymorphisms in predicting the susceptibility 
to disease and responsiveness to dietary and drug interventions (Vergani et al., 2006). 
Small-scale studies have looked at the effects of polymorphisms on physiological or 
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biochemical factors and have provided useful information on possible mechanistic 
links between variation at the gene level and risk factors for cardiovascular disease 
(CVD) (Freeman et al., 2003). For the purpose of this study, 10 “candidate” genes 
known to be involved in RCT and HDL metabolism were identified and investigated 
in the African green monkey. Each gene is described below.  
 
Since the African green monkey is closely related to humans, coincident single 
nucleotide polymorphisms (cSNPs) occurring at the same locus in both humans and 
other nonhuman primates were prioritised for this study (Table 1.2). In the absence of 
the African green monkey genome sequence, the rhesus macaque (Macaca mulatta) 
genome was used for comparison with the humans. Since rhesus macaque and African 
green monkey belong to the same family (Cercopithecidae) and are closely related; an 
assumption was made that both species are likely to share the same cSNPs. Shared 
ancestral polymorphisms are polymorphic sites that originated in the ancestral species 
and have survived genetic drift in both the human and other species. The molecular 
mechanism underlying this variation remains unknown. Hodgkinson et al. (2009) 
discovered that a surprising number of human polymorphic sites are also polymorphic 
in nonhuman primates. These cSNPs not only occur significantly more frequently 
than expected under independence but also cannot be easily explained by natural 
selection (Hodgkinson et al. 2009; Hodgkinson and Eyre-Walker 2010). 
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Table 1.2: List of prioritised coincident SNPs  
  
 
 
  
Genes SNPs Human Rhesus  Baboon 
CETP I405V X X X 
  Ala373Pro X X X 
ABCA1 Ile883Met X X X 
  E1172D X X X 
  V771M X X X 
  V825I X X X 
  R219K X X X 
LCAT Ser232Thr X X X 
  LCATu3 X X X 
SR-B1 A350A X X X 
  G2S X X X 
apoA-1 MspI X X X 
  G-75A X X X 
apoB T71I X X X 
  4311S X X X 
apoCI HpaI X X X 
apoCII Lue96Arg X X X 
  62 A>C X X X 
apoE Cys112Arg X X X 
  Arg158Cys X X X 
CYP7A1 Asn233Ser X X X 
  A-278C X X X 
 
 
 
1.7.1.1   Cholesteryl ester transfer protein  
CETP modifies the lipid composition of the plasma by transferring triglycerides and 
cholesterol esters between lipoproteins, thereby decreasing plasma HDL-C 
concentrations and increasing the proportion of lipids present in the atherogenic LDL-
C and VLDL fractions. Increased risk for atherosclerosis with increased CETP 
activity has been shown in CETP transgenic mouse models, and there is inconclusive 
evidence of a similar risk in humans. (Carlquist et al., 2003).  
 
Coincident SNPs  
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It has long
 
been theorized that the atheroprotective effect of HDL is primarily
 
due to 
its role in RCT. RCT is a complex pathway, involving transport proteins,
 
modifying 
enzymes, and cell surface receptors. One of the enzymes
 
with a key role in RCT is 
CETP, which promotes the exchange of cholesteryl esters from
 
HDL to the apoB-
containing lipoproteins, thus, providing an
 
avenue for the uptake of cholesteryl esters 
by hepatic receptors (Bruce et al., 1998). Several common mutations, or
 
polymorphisms, have been identified in the CETP gene (Figure 1.4). Polymorphisms
 
identified in the coding sequence of the CETP gene include A373P, I405V, and 
R451G. Two of these variants, Ala373Pro
 
and R451G, are associated with increased 
CETP activity and
 
reduced HDL-C levels, whereas the I405V variant is associated
 
with reduced CETP mass and increased HDL-C levels (Bruce et al., 1998). Among
 
the most widely studied CETP variants is TaqIB, a silent base
 
change affecting the 
277th nucleotide in the first intron of
 
the CETP gene (Boekholdt et al., 2004).  
 
In this study, the
 
more common I405V polymorphism was selected since it is 
associated with vascular disease. In the homozygous form for the rarest allele (V/V 
genotype) the I405V polymorphism is associated with a reduction in CETP activity, 
and with changes in the levels of HDL-C and the composition of HDL and LDL 
(Okumura et al., 2002, Barzilai et al., 2003, Boekholdt et al., 2004 and Brousseau et 
al., 2004).  
 
CETP deficiency in man is associated with raised HDL-C up to 5 mmol/l (Jukema et 
al., 2004). Several pharmaceutical companies have developed CETP inhibitors, such 
as torcetrapib and JTT-705 (Brousseau et al., 2004). Administration of a high-dose 
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torcetrapib and JIT-705 to humans decreased CETP activity significantly and 
increased HDL-C by 34 to 106% (Jukema et al., 2004).  
 
 
 
 
Figure 1.4: Structure of the CETP gene and the locations of SNPs tested (Bansal et al., 2002). 
 
 
 
1.7.1.2    ATP binding cassette transporter Al  
ABCA1 is a member of the ATP-binding cassette transporter family, which plays a 
most important role in apoAI-mediated cholesterol efflux from peripheral cells, the 
first step in RCT (Yamakawa-Kobayashi et al., 2004). ABCA1 has been identified to 
be a transporter that effluxes excess cellular cholesterol to poorly lapidated apoA-1, 
thus playing a pivotal role in the reverse cholesterol transport process (Brewer et al., 
2004). Regulation of ABCA1 transporter gene expression plays a key role in 
determining intracellular cholesterol levels (Brewer et al., 2004), therefore, ABCA1 is 
an attractive candidate gene for the determination of plasma HDL cholesterol 
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concentration (Wang et al., 2000). Common variants of this gene may be a genetic 
factor for atherosclerosis (Kyriakou et al., 2005). 
 
Twelve SNPs were identified in coding regions of the gene, six of which resulted in 
amino acid substitutions (Frikke-Schmidt et al., 2004). R219K, V771M, V825I, 
I883M, E1172D, and R1587K all substitute similar amino acids. R219K and R1587K 
are located in the two major extracellular loops of the ABCA1 protein, important for 
the interaction with apoA-I and for cholesterol efflux. V771M, V825I, I883M, and 
E1172D are located in the middle part of the protein corresponding to the fifth and 
sixth transmembrane α-helix, the seventh hydrophobic segment (H7), and the first 
regulatory segment (R1), respectively (Figure 1.5). The amino acid residues affected 
by these six non-synonymous SNPs are situated in highly conserved (V771, V825, 
E1172, R1587) or less-conserved (R219, I883) areas of ABCA1, and are either 
completely conserved between species (V771, E1172) or vary between 2 (R219, 
V825, R1587) or more (I883) similar amino acids (Figure 1.5). All six non-
synonymous SNPs are common and have been reported previously (Frikke-Schmidt et 
al., 2004). In this study, five SNPs of ABCA1 were chosen based on their function 
and location within the gene (R219K, E1172D, V771M, V825I and I883M). 
 
Complete ABCA1 deficiency is known as Tangier's disease. This condition leads to 
premature atherosclerosis, because compromised cholesterol efflux from peripheral 
cells to apoA-I results in the accumulation of cholesteryl esters in peripheral tissue 
(Jukema et al., 2004). Since upregulation of ABCA1 in animals has produced positive 
effects by reducing the risk of CAD (Zwart et al., 2002), several pharmaceutical 
companies are working on the development of ABCA1 agonists. However, negative 
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outcomes on lesion development associated with the effect of ABCA1 have also 
reported (Joyce et al., 2002; Van Eck et al., 2006).  
 
 
 
Figure 1.5: Topological model of ABCA1 (Frikke-Schmidt et al., 2004). 
 
 
1.7.1.3     Apolipoprotein A-1 
ApoA-I is the major protein constituent of HDL particles and plays a central role in 
lipid metabolism and CHD risk (Segrest et al., 2000 and Stein et al., 1999). Several 
epidemiological studies have reported that HDL-C and apoA-I are inversely related to 
the incidence and severity of CAD and can independently predict the risk of CAD 
(Stampfer et al., 1991; van der Steeg et al., 2008). Complete apoA-I deficiency results 
in low or absent HDL and is associated with premature atherosclerosis (Funke et al., 
1997). Partial deficiencies decrease HDL and increase the risk for CAD. ApoA-I 
promotes cholesterol efflux from tissues to the liver for excretion. Its anti-atherogenic 
effects are based on its acceptor function for ABCAl-mediated free cholesterol efflux 
from the peripheral cell. It is a cofactor for LCAT which is responsible for the 
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formation of most plasma cholesteryl esters (Fielding et al., 1995). ApoA-1 is 
therefore an important component of reverse cholesterol transport. 
 
The gene for apoA-I is known to be in a cluster with apoC-III and apoA-IV on 
chromosome 11 (Karathanasis, 1985) and several studies have reported an association 
between DNA polymorphisms of this gene cluster and differences in the levels of 
HDL-C and apoA-I in CAD patients and healthy individuals (Ordovas et al., 1991). A 
common G-to-A transition located 75 base pairs (bp) upstream from the transcription 
start site of the apoA-I gene has been described and studied extensively (Pagani et al., 
1990). This substitution destroys an Msp I cutting site and can be easily detected with 
the polymerase chain reaction (PCR). In three independent studies, the A allele has 
been associated with higher levels of both HDL-C and apoA-I (Pagani et al., 1990). It 
has been reported that individuals carrying the A allele show higher concentrations of 
apoA-I and HDL cholesterol than those with the G/G wild type (Pagani et al., 1990). 
In this study, we attempt to identify the role of two polymorphisms (this one included) 
in the African green monkey by modulating HDL metabolism with niacin. 
 
It is interesting to note that niacin extended-release treatment significantly improves 
apoA-1 levels and lowers the number of atherogenic LDL particles, VLDL and 
chylomicron particles (Insull et al., 2010). 
 
A topic of growing interest is the apoA-IMilano mutation (Franceschini et al., 1980). 
Carriers of this mutation have very low HDL-C levels, but surprisingly exhibit a 
decreased risk of CAD.  Its positive effects regarding atherosclerosis and the fact that 
apoA-I has a long elimination half-life make it a promising candidate for therapeutic 
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applications (Jukema et al., 2004). The apoA-IMilano gene possesses structural 
differences that impart a loss in lipid-binding capacity and accelerated catabolism, 
which is the mechanism underlying a more efficient uptake and removal of tissue 
lipids (Futterman et al., 2005). The identification of a naturally occurring variant of 
apoA-I (the apoA-IM) led to the finding that this HDL/apolipoprotein variant was 
antiatherogenic. Its effect is associated with a rapid increase in cholesterol efflux–
promoting capacity, mobilization of free cholesterol from tissues, and reduction of 
lipid and macrophage content within the vascular plaque (Futterman et al., 2005). 
 
 
1.7.1.4    Lecithin-cholesterol acyltransferase 
LCAT is one of the key enzymes controlling cholesterol homeostasis and transport 
and has a pivotal role in HDL-C maturation and remodeling (Asztalos et al., 2007). 
LCAT synthesizes the majority of cholesteryl esters in plasma by transferring a fatty 
acid from lecithin (phosphatidyl choline) to the 3-hydroxyl group of cholesterol. 
Although it accentuates RCT from plasma to liver and induces cholesterol 
degradation, the debate about LCAT’s role in RCT and protection against 
atherosclerosis is ongoing (Brown et al., 2010). In the absence of LCAT, RCT can 
still continue. The main factors that maintain the cholesterol homeostasis within 
macrophages are preβ HDL and ABCA1 transporter. Free cholesterol can also be 
taken up via SR-BI in the liver (Rader, 2009). Although patients with LCAT 
deficiency do not show progressive atherosclerosis, a decrease in LCAT activity is 
associated with an increase in carotid artery intima media thickness (Hovingh et al., 
2005). Increased LCAT activity is thought to be atheroprotective, but there are a 
limited number of studies, and the measurement of LCAT activity is still not 
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standardized. Additional data on LCAT’s genetic and enzymatic properties should 
help to understand the role of LCAT in normal HDL-C function.  
 
Mutations in the LCAT gene can cause complete LCAT deficiency, also known as 
familial LCAT deficiency or a strong decrease in LCAT activity known as Fish-eye 
disease (Jukema et al., 2004). Both conditions are rare, and characterised by extensive 
corneal opacity and very low HDL-C. Although HDL-C is low in these patients, 
premature atherosclerosis is not a prominent characteristic in these conditions. Animal 
studies show that the expression rate of LCAT affects sensitivity to atherosclerosis. 
As the LCAT gene is a relatively small gene, gene therapy might be possible in 
future, but clinical applications still have to be developed (Seguret-Mace et al., 1996). 
 
1.7.1.5    Scavenger receptor class B type I 
SR-B1 is a cell surface glycoprotein that plays an integral part in cholesterol 
homeostasis (Connelly et al., 2004). Identified at first as a HDL receptor, SR-B1 is 
primarily expressed in organs that require free cholesterol, such as the liver and 
steroidogenic tissues. The receptor binds with the highest affinity to HDL; however, it 
also binds less efficiently with apoB-containing lipoproteins (Calvo et al., 1997). 
Upon binding to the lipoprotein particles, SR-B1 delivers cholesterol into the cells via 
a selective uptake process. Thereafter, the cholesterol-depleted lipoproteins are 
recycled back into the circulation. Additionally, SR-B1 stimulates cholesterol efflux 
out of the cell thereby promoting the clearance of cholesterol from the periphery as 
well as the secretion of biliary cholesterol (Connelly et al., 2004). By regulating the 
bidirectional flux of cholesterol between lipoproteins and cells, SR-B1 is a key 
regulator in reverse cholesterol transport.  
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The influence of SR-B1 on plasma HDL concentrations has been demonstrated in 
mouse models where hepatic overexpression of the receptor resulted in lower HDL-
cholesterol, lower apoA-I, and increased biliary cholesterol (Ji et al., 1999). These 
changes are a manifestation of the hindered hepatic uptake of cholesterol ester from 
HDL. Overexpression of SR-BI in mice causes increased HDL-C excretion in bile, 
resulting in a decrease in HDL-C and atherosclerosis (Silver et al., 2001). SR-BI 
knockout mice are characterised by raised plasma HDL levels and an increased 
progression of atherosclerosis (Rigotti et al., 1997). This observation suggests that 
uninhibited reverse transport of cholesterol might be of greater importance than 
elevating HDL-C per se! In addition to selective cholesterol uptake, there is evidence 
of SR-B1 involvement in metabolism of apoB-containing lipoproteins. Through the 
regulation of plasma cholesterol, SR-B1 appears to be protective against the 
development of atherosclerotic lesions in animal models (Kozarsky et al., 1997).  
 
In humans, investigations of sequence variants or polymorphisms in the SR-B1 gene 
have shed light on the influence of this receptor on plasma lipid concentrations. The 
SR-B1 gene has been mapped to human 12q24.31 and encodes a 509 amino acid 
protein (Van Eck et al., 2005). Three common single nucleotide polymorphisms 
(SNP) in exon 1 (p.Gly2Ser), exon 8 (c.1119C>T), and intron 5 (c.795+54C>T) have 
been associated with lipid parameters in epidemiological studies (Morabia et al., 
2003). The c.1119C>T polymorphism also known as A350A was also identified in 
this study and has been associated with higher HDL-C and lower LDL-C 
concentrations, particularly in men (Morabia et al., 2003). In light of prior reports of 
the effect of c.1119C>T on fasted lipid concentration, it was hypothesized that this 
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polymorphism would be associated with an anti-atherogenic profile. This study 
investigated the association between c.1119C>T and niacin drug therapy response.  
 
Currently, human deficiencies of SR-BI have not been described. Epidemiological 
studies have shown that SR-BI variants are associated with HDL-C and LDL-C 
concentrations. There seems to be a connection to triglycerides and obesity as well 
(Osgood et al., 2003).  
 
1.7.1.6    Cholesterol 7-alpha-hydroxylase  
CYP7A1 catalyzes the first reaction in the cholesterol catabolic pathway in the liver 
(Nakamoto et al., 2006). This pathway converts cholesterol to bile acids, which is the 
primary mechanism for the removal of cholesterol from the body. The CYP7A1 
catalytic reaction is the rate-limiting step and the major site for regulating homeostasis 
of cholesterol and bile acids. The gene encoding CYP7A1 was mapped to 
chromosome 8q11 (Cohen et al., 1992). The CYP7A1 gene spans about 10 kb and 
contains 6 exons, 5 introns, one 5'-UTR, and one 3'-UTR (Nakamoto et al., 2006).  
 
In mice and rats the synthesis of bile acids through this pathway is under feed-forward 
regulation by cholesterol via a transcriptional mechanism involving the nuclear 
receptor known as the liver x receptor a (LXRa; NR1H3) (Agellon, et al., 2002). 
LXRa normally binds to a direct repeat of the hexameric hormone response element 
separated by four nucleotides as a heterodimer with retinoid x receptor (RXR; 
NR2B1) and is activated by oxysterols (Gbaguidi et al., 2004). The human and 
nonhuman primate CYP7A1 gene, unlike the rat and murine Cyp7a1 genes, is not 
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stimulated by oxysterols because the CYP7A1 gene promoter does not interact with 
RXR:LXRa (Gbaguidi et al., 2004). 
 
Genetic variations in the CYP7A1 gene associated to disorders of cholesterol and bile 
acid metabolism have been studied extensively in different laboratories, and have 
been associated with metabolic disorders of cholesterol and bile acids, including 
hypercholesterolemia, hypertriglyceridemia, arteriosclerosis, and gallstone disease 
(Nakamoto et al., 2006). The information has indicated that genetic variations in the 
CYP7A1 gene have high impact on human cholesterol metabolic regulation and 
human health. 
 
1.7.1.7    Apolipoprotein C-II  
ApoC-II is a 79-amino acid residue protein that has a crucial role in lipoprotein 
metabolism as a cofactor for lipoprotein lipase (LPL), which catalyzes the lipolysis of 
triglycerides in plasma chylomicrons and VLDL (Chen et al., 2007). ApoC-II is 
synthesized primarily by the liver. The apoC-II gene has been mapped on 
chromosome 19 in a gene cluster containing the apoE/C-I/C-I’/C-IV/C-II gene and 
spans 45 kb of chromosomal region (Chen et al., 2007). The 0.55-kb intergenic region 
between apoC-II and apoC-IV genes is a strong cell type-specific promoter (Vorgia et 
al., 1998). The exact function of apoC-IV is unknown, although it appears to play a 
role in lipid metabolism. Overall, the association of lipid related traits with variants in 
the apoE/C1/C4/C2 gene cluster has been fairly inconsistent, with the exception of the 
apoE gene variants. Such inconsistency is possibly related to the close linkage of 
these genes on chromosome 19q (Chen et al., 2007).  
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In this study, two single nucleotide polymorphisms were identified and investigated to 
determine if they have any influence in the regulation and function of the reverse 
cholesterol transport pathway in the presence of niacin therapy. The distribution of 
apoC-II on plasma lipoprotein is known to continually change between high density 
lipoproteins and triglyceride-rich lipoproteins as a result of the secretion, metabolic 
conversion, and catabolism of plasma lipoprotein (Fojo et al., 1984). 
 
1.7.1.8    Apolipoprotein C-I  
ApoC-I is a constituent of triglyceride-rich lipoproteins and high density lipoproteins 
the importance of which in plasma lipoprotein metabolism is increasingly evident (Xu 
et al., 1999). The apoC-I gene lies in a gene cluster containing apoE and apoC-II on 
chromosome 19 (Gao et al., 2002). Its function is to displace apoE from triglycerides-
rich emulsions and lipoproteins (Xu et al., 1999). ApoC-I decreases binging of VLDL, 
a model of poor-lipolysis lipoprotein remnants, to a remnant receptor, the low density 
lipoprotein receptor-related protein (LRP) (Xu et al., 1999). The presence of the Hpa I 
in the ApoC-I promoter has a significant effect on apoC-I transcription. This 
polymorphism has been associated with lipoprotein metabolism disorder (Gao et al., 
2002).  Based on this information, this particular polymorphism was genotyped in the 
African Green monkey in this study to assess if it might have any involvement in 
niacin therapy response. 
 
1.7.1.9    Apolipoprotein B 
ApoB is an essential structural protein component of LDL and VLDL particles, which 
act as transporters for triglyceride and cholesterol between the liver and peripheral 
tissues and plays an important role in the maintenance of cholesterol homeostasis in 
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all mammals (Chan et al. 2000). Owing to the importance of lipoproteins in lipid 
metabolism, even small changes in the structure or function of the protein may have a 
large impact on plasma lipid levels, and thereby on the risk of CVD (Bentzen et al., 
2002). ApoB circulates in two distinct forms (apoB100 and apoB48), encoded by a 
single gene composed of 29 exons localized on chromosome 2 (Kane, 1983). 
 
Polymorphisms in apoB may associate with increased or decreased levels of 
apolipoprotein B and LDL-C (Humphries, 1988). Several polymorphisms in the apoB 
gene have been described (Humphries, 1988), some of which have an effect on the 
levels of cholesterol and triglyceride. The most frequently investigated are T2488T 
(XbaI), E4154K (EcoRI), R3611Q (MspI), N4311S and an insertion/deletion in the 
signal peptide (AA12ins/del) (Figure 1.6). Various studies have shown an association 
between some of these polymorphisms and lipid or lipoprotein levels (Hansen et al., 
1993; Moreel et al., 1992; Xu et al., 1990).  In this study, two apoB polymorphisms 
(T71I and N4311S) were investigated. T71I and N4311S are known to be associated
 
with lower plasma levels of LDL cholesterol. These sequence
 
variants most likely 
lower LDL cholesterol levels by either
 
interfering with lipidation of nascent 
apolipoprotein B by reducing the production of LDL from VLDL or accelerating LDL 
clearance by the
 
LDL receptor (Benn et al., 2008).  
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Figure 1.6: Location of the 10 SNPs relative to the amino acid sequence and the structural 
and functional domains of apolipoprotein B. T71I located in domains crucial for lipidation of 
the nascent apolipoprotein B; N4311S in domain known to or suspected of regulating binding 
to the LDL receptor (Benn et al., 2008). 
 
 
1.7.1.10     Apolipoprotein E 
ApoE is an exchangeable protein that plays an important role in lipid metabolism, 
especially in the removal of atherogenic remnants of triglyceride-rich lipoproteins 
(Hixson et al., 1990). The human apoE gene spans 3.7 kb including four exons and is 
located on chromosome 19 (Hixson et al., 1990).Three common alleles of apoE 
encoding isoforms e2, e3 and e4 have been identified (Hixson et al., 1990). The 
isoforms are characterized by the presence of amino acid Cys (apoe2 and apoe3) or 
Arg (apoe4) at position 112 of the mature apoE polypeptide chain and Cys (apoe2) or 
Arg (apoe3 and apoe4) at position 158 (Koch et al., 2002). Apoe3 is the most 
common of these isoforms, and is distinguished by cysteine at position 112 (112cys) 
and arginine at position 158 (158arg) in the receptor-binding region of apoE (Koch et 
al., 2002). The presence of apoE allele e4 is known to be associated with the 
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pathogenesis of peripheral and coronary artery disease and the e2 allele is known to 
be protective from atherosclerosis. 
 
The variability of amino acids 112 and 158 is based on SNPs present at nucleotide 
position 334 and 472, respectively, of the apoE gene (Koch et al., 2002).  The SNPs 
are known as 334T/C and 472C/T and both were investigated in this study.  
 
1.8 RESEARCH OBJECTIVES 
The broad focus of this study was to determine the effect of an HDL cholesterol-
raising agent, niacin, on the lipid metabolism or RCT pathway by genetic strategies in 
case-control studies in African green monkeys, since no data are available in this area 
for this species.   
 
The choice of this RCT system is also informed by the fact that currently, there is a 
focus on HDL-based therapies to further reduce atherothrombotic vascular diseases. 
Even though the African green monkey has already provided invaluable insight in 
cardiovascular disease studies, and has been pivotal in defining the cellular events in 
the initiation and development of lesions in atherosclerosis research, the underlying 
molecular dynamics have not been fully explored in this species. The main objective 
of this project was to make an original contribution to primatology by defining the 
molecular genetics of the African green monkey in relation to CHD. This is the first 
study of a controlled pharmacological intervention linked to genetic determinants of 
lipid metabolism in the African green monkey. 
 
 
 
 
 
  43 
At present, there is very little data in GenBank for nonhuman primates, and almost 
none for the African green monkey. As discussed above, nonhuman primates 
including the African green monkey are closely related to humans both in 
evolutionary and genetic terms. Therefore, shared ancestral polymorphisms known as 
coincident SNPs (cSNPs) were prioritized for this study, since they are polymorphic 
sites that originated in the ancestral species and have survived genetic drift in both 
species. 
 
The specific objectives of the study included the following: 
 To use an integrated combination of clinical, molecular biological and 
bioinformatics strategies to identify orthologous human candidate genes for 
lipid metabolism in African green monkeys:   
1. To choose candidate genes which have been reported in literature to be 
linked to lipid metabolism in humans. 
2. To choose (cSNPs) within recognized candidate genes. 
 To assess the levels of HDL-C, LDL-C, TC, TG and lipoproteins after lipid-
modulating niacin administration. 
 To determine the effect of niacin on lipid metabolism at the genetic level by 
the expression profile of the selected candidate genes  
 To assess the possible involvement of these genes in cholesterol metabolism 
pathway or reverse cholesterol transport pathway in case:control studies in a 
colony of African green monkeys after administration of niacin. 
 
 
 
 
 
 
 
 
 
 
  44 
1.8.1 Hypothesis 
The genetic mechanisms and dynamics that control reverse cholesterol transport in the 
African green monkeys (AGM) are similar to those found in other nonhuman primates 
and humans, and make the AGM therefore a useful model for human cardiovascular 
disease.   
 
1.9 OVERVIEW 
The layout of this dissertation contains an introduction, experimental procedures, 
results, discussion and conclusion in the next two chapters to follow. The final chapter 
consists of a general discussion and conclusion to sum-up the findings. Additional 
information on experimental design and data acquisition is included in the Appendix 
section. 
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Chapter 2 
 
EFFECTS OF SHORT-TERM TREATMENT WITH NIACIN AS 
MONOTHERAPY ON PLASMA LIPOPROTEIN IN A 
NONHUMAN PRIMATE MODEL OF ATHEROSCLEROSIS 
 
 
 
 
2.3 INTRODUCTION 
 
In this century many major medical advances have resulted in part from research on 
animals including nonhuman primates such as the African green monkey 
(Chlorocebus aethiops).  These, therefore, often serve as a critical link between basic 
research and human clinical application (Suckling et al., 1993). In this context, the 
establishment of suitable animal models has proven to be invaluable for the study of 
human cardiovascular disease.  
 
The African green monkey has been an excellent model for the study of cholesterol 
metabolism (Weight et al., 1988 and Suckling et al., 1993). Since elevated dietary 
cholesterol levels induce atherosclerosis in this primate (Bullock et al., 1975), and 
many aspects of dietary cholesterol metabolism have been investigated. In spite of the 
comprehensive nature of these studies, much of the molecular basis remains to be 
understood and defined in this species. 
 
In this first study, the effects of niacin (Sigma) were investigated in the African green 
monkey to evaluate the effect of this compound on plasma lipids and reverse 
cholesterol transport pathway. This is in preparation for the second study which is 
investigating the genetic dynamics as a result of this intervention. Since the objective 
of this first part, was to increase HDL-C level through therapeutic intervention; niacin 
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was selected since it is known to be the most potent HDL cholesterol-raising agent 
currently used (Rader 2003; Muller et al., 2007; Kamanna et al., 2008).  
 
Slow-release niacin favourably affects all lipids and lipoproteins (Mckenney, 2004). 
Niacin also enhances the transcription of peroxisome proliferator-activated receptor γ 
(PPARγ) and ATP binding cassette transporter A1 (ABCA1), the latter is a key 
transporter for cellular cholesterol into apolipoprotein A-1 containing HDL particles 
(Rubic et al., 2004). These effects of niacin cause a decrease in LDL and TG, and an 
increase in HDL, which are changes that have demonstrated to reduce the 
complications of atherosclerotic disease.  High-density lipoprotein (HDL)-based 
therapies have recently become the focus of attention (Shah et al., 2005) which is 
shifting from just lowering of the lipid ‘concentrations’ to an emphasis on vascular 
biology, pharmacogenetics and a greater understanding of the importance of HDL 
cholesterol.  
 
A reduced level of HDL-C is an important cardiovascular risk factor (Gordon et al., 
1989). Moreover, HDLs exert various potentially antiatherogenic properties. As a 
consequence, therapeutic modifications of HDL-C levels have attracted considerable 
interest. Drugs increasing HDL-C are sought for antiatherogenic therapies, and drugs 
decreasing HDL-C are suspected to increase cardiovascular risk (von Eckardstein et 
al., 2001). 
 
HDL is involved in RCT and an important antiatherogenic function of HDL, namely, 
the HDL-mediated efflux of cholesterol from non-hepatic cells and its subsequent 
delivery to the liver and steroidogenic organs (von Eckardstein et al., 2001). 
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Enhancements of cholesterol efflux and of RCT are considered important targets for 
antiatherosclerotic drug therapy. Levels and composition of HDL subclasses in 
plasma are regulated by many factors, including apolipoproteins, lipolytic enzymes, 
lipid transfer proteins, receptors, and cellular transporters (von Eckardstein et al., 
2001). These factors have become important targets in the development of effective 
strategies to prevent vascular/atherosclerotic disease. 
 
Via its RCT mechanism, HDL holds the promise of not only halting progression of 
atherosclerosis but also including a true regression of atherosclerotic lesions. A 
number of agents are available that increase HDL cholesterol levels. Statins are the 
most potent LDL cholesterol-lowering agents and produce modest increases in HDL 
cholesterol, although their effects vary. Niacin is the most potent HDL cholesterol-
raising agent currently used and slow-release niacins have reduced the side effects and 
have made this class of drugs more tolerable (Rader, 2003). Other agents that modify 
HDL cholesterol include fibrates, glitazones, omega-3 fatty acids and estrogen. The 
precise mechanisms through which these classes of agents increase HDL cholesterol 
levels generally are not well defined.  
 
2.4 MATERIALS AND METHODS 
The study was approved by the Ethics Committee of the MRC (REF 11/07). The 
project was carried out in the Primate Unit of the Technology and Innovation 
Directorate, MRC, Parow Valley. Selected subjects were healthy adult female 
monkeys with normal plasma HDL.  All individuals were housed singly during the 
study but had regular access to exercise cages and environmental enrichment. All 
individuals were identified with numbers in ink tattoo. 
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2.2.1 Management of animals and environment 
The African green monkeys used in this study were bred and maintained in the 
Primate Unit of the MRC under identical housing conditions according to the South 
African National Standard for the Care and Use of Animals for Scientific Purposes 
(The SANS 10386:2008).  The closed indoor environment was maintained at a 
temperature of 24 – 26ºC, 45% humidity, 15 – 20 air changes/hour and a photoperiod 
of 12h. 
 
The monkeys received a diet of pre-cooked maize meal mixed with a vitamin and 
mineral concentrate, egg powder, bean flour and sunflower oil in the morning. The 
diet was further supplemented with vitamin C and vitamin D3 and each monkey 
received 66g (dry weight) of the diet per day. The diet was mixed with water to make 
a very stiff porridge that can be formed into balls which the monkeys can grasp and 
handle. At lunch the monkeys received fruit (apples, oranges, mandarins) and in the 
evening maize meal without the vitamins but containing milled seeds. The diet 
supplies 2412 kJ/day (range of recommendations for primates is 1380 - 2510), 12% 
energy from protein, 20% energy from fat and 75% energy from carbohydrates. Water 
was available ad lib via an automatic watering device. 
 
2.2.2 Formulations and administration of compounds 
Niacin was supplied in a powder form. An exact amount of niacin based on each 
animal’s body weight was weighed and mixed in a 30g portion of maintenance diet.   
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2.2.3 Selection criteria and treatment 
Selection of animals included in this study was based on genotyping of selected 
cSNPs. Genotypes were obtained from 25 monkeys using polymerase
 
chain reaction 
amplification of genomic DNA and sequencing. However, due to the small gene pool 
of the MRC Primate colony genotype variations were not obtained. Eight healthy 
adult females were therefore selected for this study. The subjects were divided into 2 
groups as indicated in Table 2.1. Four females were assigned to a treatment and the 
other four to a control (placebo) group. The control group received maintenance diet 
throughout the study. The treatment group received an exact amount of niacin based 
on each animal’s body weight which was mixed into a 30 g portion of food (Table 
2.2). The compound was administered once per day at escalating doses for three 
consecutive periods of two weeks, starting at 35 mg/kg. Based upon the effects on 
total cholesterol, HDL-cholesterol and triglycerides as well as clinical examination, 
the dose could be increased to 75 then to 100 mg/kg for the next two-week periods of 
treatment, or maintained at 35 or 75 mg/kg (Table 2.2). Each treated animal received 
niacin daily throughout the treatment period of four months, which was followed by 
two weeks of washout. 
 
 
Table 2.1: Group selection and treatment allocation 
 
Group Treatment Doses mg/kg n Treatment time 
1 Control - 4                     7:00 am 
2 Niacin 
35mg/kg.d 
75mg/kg.d 
100mg/kg.d 
4                     7:00 am 
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Table 2.2:  Treatments to determine efficacy 
Treatment 
Identification 
no. of monkey 
Bodyweight (kg) 
at first baseline 
Total dose (mg) 
Frequency of 
treatment 
 
Group 1 
Control 
 
 
108 
243 
215 
97 
3.55 
3.84 
3.68 
3.50 
N/A 
once/day at  
7H00 am  
 
Group 2 
Niacin 
35mg/kg, 70mg/kg, 
100mg/kg 
 
795 
322 
339 
77 
 
 
3.56 
3.02 
3.29 
3.30 
 
124.6, 249.2, 356 
105.7, 211.4, 302 
115.2, 230.3, 329 
115.5, 231, 330 
once/day at  
7H00 am  
 
 
2.5.4 Duration of treatment 
The study started on 21/01/08 and was completed on 23/06/08.  The duration of the 
treatment was four months with a 4-week washout period (Table 2.3).   
 
 
Table 2.3:  Treatment periods     
Period Weeks Dates 
Baseline -1 and -2 21.01.08 – 04.02.08 
Treatment 1-16 04.02.08– 26.05.08 
Washout 17-20 27.05.08 – 23.06.08 
 
 
2.2.5 Blood sampling 
All blood was obtained via femoral venipuncture after Ketamine anaesthesia at 
5mg/kg bodyweight four hours after compound administration.  Blood was collected 
in EDTA-containing tubes after overnight fasting according to the schedule provided 
in Table 2.4. On each day of sampling, overnight-fasted monkeys received the total 
dose of the compound in small food balls and blood was taken 4 hours after 
compound administration. The rest of the food was given after the blood collection. 
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For plasma isolation, blood was collected in EDTA-containing tubes. Plasma was 
isolated at 4°C (1400 x g, 10 minutes) and maintained at -80°C for biochemical 
analysis. Additionally, for gene expression analysis in chapter 3, more blood was 
collected in PAXgene Blood RNA Tubes (BRT) and stored at room temperature for 2 
hours before being stored at -80°C.  
 
Table 2.4:  Blood sampling schedule and analyses  
Sampling  Day Time of treatment Volume Analysis 
Baseline 1 -14 4h post-dose 2ml TC, HDL, LDL, 
Trigs, Apo A 
Week 2 
(treatment)  
Day 14 4h post-dose 2ml TC, HDL, LDL, 
Trigs, Apo A 
Week 4 
(treatment) 
Day 28 4h post-dose 2ml TC, HDL, LDL, 
Trigs, Apo A 
Week 6 
(treatment) 
Day 42 4h post-dose 2ml TC, HDL, LDL, 
Trigs, Apo A 
Week 8 
(treatment) 
Day 54 4h post-dose 2ml TC, HDL, LDL, 
Trigs, Apo A 
Week 10 
(treatment) 
Day 68 4h post-dose 4ml TC, HDL, LDL, 
Trigs, Apo A 
Week 12 
(treatment) 
Day 82 4h post-dose 2ml TC, HDL, LDL, 
Trigs, Apo A 
Week 14 
(treatment) 
Day 96 4h post-dose 2ml TC, HDL, LDL, 
Trigs, Apo A 
Week 16 
(treatment) 
Day 110 4h post-dose 2ml TC, HDL, LDL, 
Trigs, Apo A 
Week 18 Day 124 Washout 2ml TC, HDL, LDL, 
Trigs, Apo A 
 
 
2.2.6 Observations 
 
2.2.6.1  Clinical examination 
 
Each animal was observed once a day, at approximately the same time twice/week for 
the recording of clinical signs . Niacin is known to cause severe side effects, therefore 
special monitoring was considered for this study. Food intake was measured daily. 
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2.2.6.2  Body weights 
The body weight of each animal was recorded at each blood sampling. 
 
2.2.6.3  Clinical observations   
Clinical observations were recorded twice/week according to three categories 
(Appendix I): 
 Physical:  condition of coat, faeces and urine; discharge from eyes, ears, nose 
genitals or rectum; any other symptoms or lesions. 
 Behaviour:  alert, fearful, aggressive, confused, depressed, vocalization. 
 Motor function and activity:  posture, coordination, locomotion and activity 
level. 
 
2.2.7 Biochemical analysis 
Biochemical analysis of known risk factors of coronary artery disease such as HDL-C 
and LDL-C were conducted for each time point of the two weeks interval throughout 
the study. Levels of HDL-C, LDL-C, TC, TG and apoA-1 were measured at baseline 
and after every two weeks for four months up to the washout period.  Biochemical 
analysis was conducted by PathCare on SYNCHRON LX Systems Manual, 2000 
(Appendix I).  
 
2.2.8 Statistical Analysis 
The lipid profile data presented are the mean ± SEM. The primary end point of the 
study was a reduction in the LDL-Cholesterol concentration, and an increase in HDL-
Cholesterol between the baseline and the end of the treatment phase. Multiple 
comparison analysis was used to determine statistical significance at each time point. 
ANOVA was used to compare baseline levels and changes from baseline between the 
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niacin and control groups. Statistical significance was calculated by using the Student 
t test, and a value of P < 0.05 was considered significant. Under the assumption of an 
α of 5%, 8 African green monkeys were required to show a 39% reduction in LDL-
Cholesterol  and 30% increase in HDL-Cholesterol with a power of 80%. 
 
2.6  RESULTS  
Baseline characteristics of the eight African green monkeys enrolled in this study 
are listed in Table 2.2. All four treated monkeys received a maximum dose of 100 
mg/kg.  
 
2.3.2 Efficacy 
2.3.2.1 Total Cholesterol 
Total plasma cholesterol increased by 31% from week 4 when the dosage was 
increased from 70 mg/kg to 100 mg/kg and decreased by 18% from week 10 to week 
16, while the control decreased by 9% from week 4 to week 16. Differences between 
the two groups were statistically significant at week 8 (p = 0.01) and week 10 (p = 
0.02) (Figure 2.1). The level of total cholesterol in the control group remained 
relatively constant throughout the study as compared to the experimental group, 
which increased during treatment, declined from week 10 and returned back to 
baseline after washout period (Figure 2.1). 
 
2.3.1.2 HDL-Cholesterol 
HDL increased in Group 1 (niacin) from baseline to week 6 by 122% and declined 
thereafter by 28% to the cessation of treatment with the greatest decrease of 37% from 
week 16 to the end of washout period in week 20. The HDL remained higher than that 
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of the control Group 2 which only increased by 30% from baseline to the end of the 
study. Differences between the two groups were statistically significant at week 6 (p = 
0.02) and week 8 (p = 0.01) (Figure 2.2).  The level of HDL-C in the control group 
remained relatively constant throughout the study as compared to the experimental 
group, which increased during treatment and returned back to baseline after the 
washout period at week 16 (Figure 2.2). The strongest increase in HDL-C occurred 
early during treatment from baseline (2.18 ± 0.92 mmol/L) to week 6 (4.85 ± 0.82 
mmol/L). Niacin appeared to have increased HDL-C, but did not sustain the same 
effect after week 6 when the dose was maintained at 100 mg/kg and this lead to a 
decline in HDL-C synthesis (Figure 2.2).  
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Figure 2.1: Total plasma cholesterol. Treatment schedule was as follows: The treatment group received niacin at 35 mg/kg/d (week 2 to week 
3), 70 mg/kg/d (week 4 to week 5), 100 mg/kg/d (week 6 to end of week 16). The control group received the vehicle during the entire study 
period. Differences between the two groups were statistically significant at week 8 (p = 0.01) and week 10 (p = 0.02).
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Figure 2.2: HDL-Cholesterol. The treatment schedule was as follows: Treatment group received niacin at 35 mg/kg/d (week 2 to week 3), 70 
mg/kg/d (week 4 to week 5), 100 mg/kg/d (week 6 to end of week 16). The control group received the vehicle during the entire study period.  
Differences between the two groups were statistically significant at week 6 (p = 0.02) and week 8 (p = 0.01).
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2.3.1.3 LDL-Cholesterol 
LDL decreased in Group 1 (niacin) from baseline to the end of the treatment in week 
16 by 39% and in the control Group 2, by 17%. It remained higher than in Group 1 
throughout (Figure 2.3). Differences between the two groups were statistically 
significant at week 6 (p = 0.04) (Figure 2.3). The strongest decline in LDL-C occurred  
early during treatment from baseline (2.55 ± 0.55 mmol/L) to week 4 (1.28 ± 0.46 
mmol/L) by 53%. The level of LDL-C, increased thereafter to 2.35 ± 0.52 at week 10 
and to 1.58 ± 0.33 at the end of treatment (Figure 2.3).  
 
2.3.1.4 Triglycerides 
In Group 1, Triglycerides decreased by 32% from baseline to week 6, increased by 
298% to week 10, and then decreased again by 56% to the end of treatment in week 
16. Overall, Triglycerides increased by 20% from baseline to the cessation of 
treatment in Group 1 (niacin). The control displayed a similar pattern with 
Triglycerides decreasing by 30% from baseline to week 6, increased by 120% to week 
8, then declined by 54% to week 16 towards the end of treatment. Triglycerides 
decreased by 26% in the control group overall (Figure 2.4). Statistically significant 
differences were not observed between the two groups.  
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Figure 2.3: LDL-Cholesterol. Treatment schedule was as follows: The treatment group received niacin at 35 mg/kg/d (week 2 to week 3), 70 
mg/kg/d (week 4 to week 5), 100 mg/kg/d (week 6 to end of week 16). The control group received the vehicle during the entire study period.  
Differences between the two groups were statistically significant at week 4 (p = 0.04).  
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Figure 2.4: Triglycerides. Treatment schedule was as follows: The treatment group received niacin at 35 mg/kg/d (week 2 to week 3), 70 
mg/kg/d (week 4 to week 5), 100 mg/kg/d (week 6 to end of week 16). The control group received the vehicle during the entire study period.    
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2.3.1.5 ApoA-I 
ApoA-I increased in groups, 1 and 2 from baseline to the end of treatment in week 16 
by 26% and 30% respectively. It remained higher in the treated than the control group 
throughout the treatment period (Figure 2.5). Differences between the two groups 
were statistically significant at week 4 (p = 0.01), week 8 (p = 0.00), week 10 (p = 
0.01), week 12 (p = 0.01) and week 14 (p = 0.00) (Figure 2.5). The level of apoA-1 in 
the control group remained relatively constant throughout the study as compared to 
the experimental group, which increased during treatment phase (Figure 2.5). The 
strongest increase in apoA-I occurred early during treatment from baseline (1.99 ± 
0.37 gl/L) to week 14 (3.10 ± 0.27 gl/L) by 50%, but declined from week 14, two 
weeks before the washout. Niacin appeared to have increased apoA-I, however the 
same effect was not sustained throughout the treatment period (Figure 2.5). 
 
2.3.1.6 Bodyweight  
There were no treatment related changes (Figure 2.6). 
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Figure 2.5: ApoA-1. Treatment schedule was as follows: The treatment group received niacin at 35 mg/kg/d (week 2 to week 3), 70 mg/kg/d 
(week 4 to week 5), 100 mg/kg/d (week 6 to end of week 16). The control group received the vehicle during the entire study period.  Differences 
between the two groups were statistically significant at week 4 (p = 0.01), week 8 (p < 0.001), week 10 (p = 0.01), week 12 (p = 0.01) and week 
14 (p < 0.001).
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Figure 2.6: Bodyweight. Treatment schedule was as follows: The treatment group received niacin at 35 mg/kg/d (week 2 to week 3), 70 mg/kg/d 
(week 4 to week 5), 100 mg/kg/d (week 6 to end of week 16). The control group received the vehicle during the entire study period. 
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2.3.1.7 Summary 
The level of total cholesterol, HDL-C, LDL-C and apoA-I in the control group (Figure 
2.7A) remained relatively constant throughout the study as compared to the 
experimental group (Figure 2.7B), which changed during niacin treatment. Before the 
washout period, HDL-C, LDL-C and apoA-I concentrations in the treated group were 
3.61 ± 0.20, 1.84 ± 0.22 mmol/L and 2.66. ± 0.21 gl/L, respectively (Table 2.5). 
HDL-C and apoA-I levels increased whereas LDL-C decreased during the treatment 
period (P < 0.05 for all) (Figure 2.8). Mean of all values were calculated and 
statistically significant differences between treated and control groups were obtained 
except for triglycerides (Table 2.5, Figure 2.8). 
 
Table 2.5: Total Cholesterol, HDL-C, LDL-C, apoA-I and triglyceride concentrations 
at the end of treatment 
 
  Control Niacin P-value 
T Chol (mmol/L; mean ± SEM) 5.24 ± 0.74 6.28 ± 0.26 0.001 
HDL-C(mmol/L; mean ± SEM) 2.36 ± 0.77 3.61 ± 0.20 0.001 
LDL-C(mmol/L; mean ± SEM) 2.39 ± 0.41 1.84 ± 0.22 0.003 
Trig(mmol/L; mean ± SEM) 0.92 ± 0.42  0.89 ± 0.27 0.850 
apoA-I(gl/L; mean ± SEM) 2.04 ± 0.41 2.66 ± 0.21 0.001 
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Figure 2.7: Levels of TC, HDL-C, LDL-C, TG and apoA-1 throughout the 4 months study period. A: Control group, B: Experimental group. 
The treatment schedule was as follows: The treatment group received niacin at 35 mg/kg/d (week 2 to week 3), 70 mg/kg/d (week 4 to week 5), 
100 mg/kg/d (week 6 to end of week 16). The control group received the vehicle during the entire study period.    
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Figure 2.8: Levels of TC, HDL-C, LDL-C, TG and apoA-1 between control and experimental groups during the treatment period. Niacin 
treatment was associated with reduction in LDL-C, up-regulation of HDL-C synthesis and increase of apoA-1 levels. Data were expressed as 
mean of all values. 
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2.3.1.8 Food intake 
2.3.1.8.1 Treated food bolus  
Group 1 consumed on average 1.5% less than the controls (Figure 2.9). Fluctuations 
in food consumption were of higher magnitudes in Group 1 when compared to the 
controls (Figure 2.10).  
 
2.3.1.8.2 Bulk food 
The total average consumption of the bulk food bolus was similar for the controls and 
the treated individuals (Figure 2.11), and fluctuations were minimal (Figure 2.12). 
 
2.3.1.9 Other clinical observations 
No sign indicative of unwell-being or distress could be observed throughout the study. 
No symptoms as defined in our observation logs (Appendix I) could be observed.  
Motor function and behaviour were normal. 
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          Figure 2.9: Total average treated food consumption. 
 
 
         
                Figure 2.10: Fluctuations in the consumption of treated food. 
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Figure 2.11: Total average consumption of bulk food.               Figure 2.12: Fluctuations in the consumption of bulk food. 
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2.4 DISCUSSION 
In this study, the efficacy of a low dose of niacin was evaluated in the African green 
monkey over a period of four months. High-density lipoprotein (HDL) cholesterol 
increased significantly from the beginning of treatment to week 6 and the LDL 
cholesterol ratio decreased significantly during the same period of treatment. The 
concentration of HDL-C peaked at week 6, and increased at this stage by about 122% 
from its own baseline and the control group, although this was not sustained at this 
level during the remainder of the treatment period.  However, differences of between 
42 and 55% from baselines and controls were maintained for 12 weeks (between 
weeks 4 and 16) of the treatment.  Considering that a HDL-C increase of 37% would 
be considered clinically significant in the treatment of dyslipidaemia, the niacin 
treatment was therefore effected satisfactory changes to further investigate the 
underlying genetic mechanisms.     
 
Niacin treatment was associated with a reduction in LDL-C, up-regulation of HDL-C 
synthesis and increase of apoA-I levels when compared to the control group, and 
statistically significant differences were observed between the two groups illustrated 
in Figure 2.8. Even though this high level of HDL-C was not sustained throughout the 
entire intervention period, it remained higher than in the control group until the end of 
the treatment period. Considerable changes in HDL-C, LDL-C and apoA-I 
concentrations were observed specifically in week 6 of treatment and this may suggest 
a change that may be taking place at a cellular level to modify or reduce the effect of 
niacin when administered at a dose higher than 70 mg/kg in the African green 
monkey. Further investigation is required at a molecular level to assess and identify 
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genetic determinants that may be involved in regulating this process, particularly at 
this point.  
 
Significant changes in triglycerides were not observed since similar patterns were 
obtained for both treated and control groups. 
 
CONCLUSION 
For the purpose of this study, niacin was validated for use as a tool to effect changes 
in lipid metabolism in preparation for investigating the genetic dynamics of the 
African green monkey during therapeutic intervention. Results obtained from this 
study showed that niacin treatment was associated with a reduction in LDL-
Cholesterol and a less significant decline in triglycerides. Niacin up-regulated HDL 
synthesis and also increase apoA-1 levels in the African green monkeys.  
 
Although niacin treatment has been associated with several side effects in humans, the 
treatment in this study was free of any observable side effects and no sign indicative 
of unwell-being or distress could be seen throughout Motor function and behaviour 
were also normal.  
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Chapter 3 
 
EFFECTS OF GENETIC VARIATIONS ON HDL METABOLISM 
AND REVERSE CHOLESTEROL TRANSPORT PATHWAY IN A 
NONHUMAN PRIMATE MODEL OF ATHEROSCLEROSIS 
 
 
 
3.1 INTRODUCTION 
 
Cardiac and vascular complications are complex multifactorial pathologies, in which 
both genetic and environmental factors are implicated, thus making them very 
difficult to prevent. The use of animal models of cardiovascular disease has 
contributed to increase our knowledge and provided an important insight into the 
genetic basis of human cardiovascular diseases. This has led to new approaches 
focused to improve the diagnosis and the treatment of these pathologies.  
 
The availability of genetically modified mouse strains has enabled the elucidation of 
new pathways involved in the development of cardiovascular disease (Vilahur et al., 
2011). However, although their usefulness in uncovering specific gene functions is 
overwhelming, their utility to extrapolate the findings to human disease or as 
preclinical models to prove validity pharmacologic agents is less appealing. 
Furthermore, it has been questioned whether these models are reliable, since 
compensating mechanisms and redundancies may affect their atherothrombotic 
phenotype (Moghadasian et al., 2001). In contrast, the development and 
implementation of animal models of atherosclerosis and thrombosis, has provided 
valuable tools for the discovery of a number of compounds that, in fact, are now 
successfully being used for the treatment and prevention of the atherothrombotic 
diseases (Vilahur et al., 2011).  
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Rats, rabbits, dogs, pigs, and monkeys are well-established animal models of 
atherosclerosis. Because of similarities between human and nonhuman primates 
(Moghadasian et al., 2001), nonhuman primate animal models are believed to be 
better suited to investigate human cardiovascular pathology. In 1965 Malinov and 
Maruffo published studies performed using the monkey as animal model to evaluate 
aortic atherosclerosis (Vilahur et al., 2011) and familial LDL receptor deficiency with 
atherosclerosis has been reported in rhesus monkey (Kusum et al., 1993).  
 
In addition to shared physiological properties, nonhuman primates and humans 
possess similar genes of lipid metabolism with similar linkage relationships (Hixson 
et al.,1990). Nonhuman primate models with mutations affecting various aspects of 
lipid metabolism have been valuable in the study of the genetic and biochemical basis 
of similar disorders in human (Vilahur et al., 2011). However, the objective of most 
animal studies is not to duplicate precisely genetic variations that occur in humans, 
but rather to understand better the biochemical mechanisms and types of 
polymorphisms that underlie heritable variations of lipoproteins. Thus, animal models 
provide a means for defining in detail the molecular mechanisms involved in lipid 
transport (Reue et al., 1990).  
 
Most research in the field of lipid metabolism is motivated by a desire to understand 
normal lipid transport in the body and the consequences of abnormalities related to 
several human diseases, most commonly atherosclerosis (Reue et al., 1990). There are 
more than 54 genes that code for proteins that directly control lipid metabolism, 10 
apolipoproteins that control lipoprotein synthesis, four processing proteins (LPL, HL, 
LCAT and CETP) and there are at least three receptors (LDL, chylomicron and scavenger 
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receptors) (Klos et al., 2006). Since 1982, the genes for all of these proteins have been 
isolated, sequenced and mapped in the human genome (Reue et al., 1990). The exact role 
of those genes and their proteins in lipid metabolism and lipid transport can only be 
inferred by physiological studies that perturb the human or animal and affect the level or 
function of each. To determine their role more precisely, primary genetic alterations must 
exist that affect the amount or quality of these proteins (Klos et al., 2006). 
 
The application of molecular genetics to inherited cardiovascular disorders has been very 
successful, especially in the field of single gene disorders. Low levels of HDL-C are a 
major independent risk factor for atherosclerotic cardiovascular disease and events; and 
the high prevalence of heart disease is related primarily to CAD.  Genetics is known to 
account for more than 50% of the risk of CAD (Roberts et al., 2007). Genetic screening 
and early prevention in individuals identified as being at increased risk could 
dramatically reduce the prevalence of atherosclerotic cardiovascular disease and events, 
thus necessitating the identification of genes predisposing to these diseases.  
 
Although existing drugs have modest effects on HDL-C levels, this area remains a major 
unmet medical need in cardiovascular medicine (Duffy et al., 2006). HDL metabolism is 
exceedingly complex and the protective ability of HDL may relate to the flux of 
cholesterol through the RCT pathway and to other aspects of HDL functionality.  
 
As with most areas of human biology, studies of human cardiovascular diseases have 
been enriched and complemented by investigations of animal models. There are, of cause, 
differences between species that must be considered such as quantitative differences, 
different biochemical pathways, and different developmental pathways. However, certain 
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pathological processes, such as atherosclerosis, may occur at similar absolute rates in two 
species instead of being related to the life span (Reue et al., 1990). Among the nonhuman 
primates, the African green monkey has been validated to be an excellent animal model 
for the study of atherosclerosis; and it is pathophysiologically and genetically similar to 
humans (Moghadasian et al., 2001). This similarity makes the African green monkey 
particularly useful as an animal model for therapeutic intervention of cardiovascular 
diseases. 
 
In spite of the comprehensive nature of the studies on cholesterol metabolism in this 
species, few data are available on the African green monkey’s genetics. To date, there 
is little sequence information on the GenBank database for the African green monkey. 
Given the importance of this animal model in lipid metabolism research and the 
fundamental significance of sequence data, it is critical that this information gap be 
addressed. 
The recent focus on HDL-based therapies, presented an opportunity to study the 
protective action of HDL, its role in the reverse cholesterol transport (RCT) pathway 
and the expression profile of genes regulating HDL metabolism in the African green 
monkey. Results obtained from this study will be used as a reference for human 
studies. Cross-species amplification and genotyping were used to identify SNPs in 
closely related nonhuman primate species, the African green monkey and humans. 
Cross-species amplification uses known polymorphisms identified in one species to 
find potential polymorphic sites in closely related species known as coincident SNPs 
(cSNPs) (Hodgkinson et al., 2009; Laurent, 2009 and Malhi et al., 2011). A SNP is a 
polymorphism that occurs within a species and only needs to be present in 1% of a 
population (Houghton et al., 2006) while a cSNP is defined as a polymorphism that 
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occurs at the same locus in multiple species (Laurent, 2009). Coincident SNPs are 
either due to identity by descent (IBD) or identity by state (IBS) (Malhi et al., 2011). 
For cSNPs that result from IBD, balancing selection near genes may maintain 
polymorphism in different species. Likewise, cSNPs due to independent mutations 
would result in IBS and might be expected to occur near CpG dinucleotides and CpG 
islands at the 5’ end of genes (Lloyd et al., 2005 and Hodgkinson et al., 2009). 
 
In this study, SNP genotyping assays developed for humans were used to identify 
cSNPs in African green monkeys. First, a literature search was conducted to look for 
previously identified genes and polymorphisms involved in lipid metabolism. These 
genes were selected for further analyses based upon literature evidence. Those which 
have been previously implicated in lipid metabolism, and which are the key players in 
lipid metabolism were selected for further analysis, and were screened for cSNPs 
previously associated with lipid level changes according to the literature. After careful 
selection of the genes and prioritized cSNPs, 25 African green monkeys were 
genotyped and gene expression protocols were standardised. Genotyping protocols 
including PCR and sequencing were developed and mRNA expression profiles were 
determined using Real-time PCR in both case and control subjects.  
 
The possible involvement of these prioritized candidate genes and their 
polymorphisms in cardiovascular disease were assessed by relating them to 
biochemical factors such as HDL-C and LDL-C, determined in the first study (chapter 
2). Drug response (niacin) was correlated to gene expression or single-nucleotide 
polymorphisms, which is discussed in detail in chapter 4.  
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3.4    MATERIALS AND METHODS 
3.2.1 Identification of candidate genes, sequence variants/polymorphisms and 
genotyping 
Genes were located within the previously published CAD-linked loci by bioinformatic 
searches of public domain databases, containing annotated genes (NCBI GENBANK), 
as well as by applying gene prediction programs (ENSEMBL). Previously reported 
polymorphisms in the prioritized candidate genes were retrieved electronically 
(NCBI.NIH.NLM.GOV/LOCUSLINK). Potentially new sequence variants were 
sought by comparing multiple database sequence deposits, and/or by polymerase 
chain reaction (PCR) and sequencing of specific regions with particular functional 
significance (thereby increasing the chance of identifying functionally significant 
polymorphisms). Genotyping protocols were developed, thereafter, the possible 
involvement of the prioritized candidate susceptibility genes were assessed by 
analyzing the allelic and genotypic distribution of their polymorphisms in the treated 
and control groups. 
 
Selection of candidate genes was based on their role in the reverse cholesterol 
transport process. RCT involves numerous lipid transfer proteins, enzymes, 
apolipoproteins,
 
and membrane-bound receptors (Fielding et al., 1995). The genes 
encoding these proteins,
 
as well as genes encoding proteins that regulate their 
transcription,
 
are candidates for influencing variation in plasma levels of
 
apoA-I, 
apoB, HDL-C, LDL-C, TC, and TG. Based on a model RCT
 
pathway (von 
Eckardstein et al., 2001), 10 genes involved in RCT were selected for this study
 
for 
evaluating the impact of genetic variation on variation
 
in plasma lipid and lipoprotein 
levels after drug therapy response (Table 3.1). 
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Table 3.1: Selected candidate genes for RCT 
Gene Symbol Map position 
1. ATP-binding membrane cassette transport protein A ABCA1 9q31.1 
2. Apolipoprotein A-1 apoA-1 11q23.3 
3. Apolipoprotein B apoB 2p24 
4. Apolipoprotein C-I apoC-I 19q13.2 
5. Apolipoprotein C-II apoC-II 19q13.2 
6. Apolipoprotein E apoE 19q13.2 
7. Cholesteryl ester transfer protein CETP  16q13 
8. Cholesterol 7 alpha-hydroxylase CYP7A1 8q11-q12 
9. Lecithin-cholesterol acyltransferase LCAT 16q22.1 
10. Scavenger receptor class B  member 1 SR-B1 12q24.31 
 
 
Coincident SNPs were identified from the
 
NCBI dbSNP database in the 10 selected 
candidate genes (Table 3.1). Twenty two cSNPs
 
were selected for genotyping (Table 
3.2). Prioritisation of these cSNPs was based on their function and location within 
their respective candidate gene and their associated with vascular disease.  
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Table 3.2: Genotyping for cSNPS in the following genes: CETP. ABCA1, CYP7A1,                              
apoA-1, apoB, apoE, SR-B1, LCAT, apoC-I and apoC-II (Lloyd et al., 2005; 
Malhi et al., 2011) 
 
GENES cSNPs Position 
1. CETP 
 
1.     CETPu2/I405V (rs5882) 
2.     Ala373Pro/CETPu1(rs5880) 
Exon 14 (A/G) 
Exon 12 (C/G) 
 
2. ABCA1 
 
3.     A3044G, Ile883Met (rs4149313) 
4.     G3911C, E1172D (Glu/Asp) (rs33918808)  
5.     G2706A, V771M (rs2066718) 
6.     G2868A, V825I (rs4149312) 
7.     R219K (Lys) (rs2230806) 
Exon 18 (T/C) H7 
Exon 24 (C/G) R1 
Exon 16 (G/A) 5th trm 
Exon 17 (G/A) 6th trm 
Exon 7 (C/T) Ex N-term loop 
3. CYP7A1 
 
8.     A-278C (rs3808607) 
9.     Asn233Ser (rs8192874) 
Promoter (T/G) 
Exon 3 (C/T) 
4. apoE 
 
  
10.   Cys112Arg (rs429358) – E4 
        = (334T/C - 472C/T) 
 
11.   Arg158Cys (rs7412) – E2 
        = (334T/C - 472C/T) 
 
Exon 3 (T/C) 
 
 
Exon 3 (C/T) 
 
5. apoA-1 
 
12.   Msp1;C+83T (rs5069) 
13.   G-75A (rs670) 
5’UTR (G/A) 
Promoter (G/A) 
6. apoB 14.   T71I (rs1367117 or rs17246849) 
15. 4311S (rs1042034 or rs17240958) 
Exon 4 (C/T) 
Exon 29 (T/C) 
 
7. LCAT 16. Ser232Thr (rs4986970) 
17. LCATu3 (rs5923) 
Exon 5 (T/A) 
Exon 6 (C/T) 
8. apoC-I 18.   HpaI Promoter (T/A) 
9. apoC-II 19.   Leu96Arg (rs5167) 
20.   -62 A>C (rs2288911) 
Promoter (T/G) 
Promoter (A/C) 
10. SR-B1 21.   A350A (rs5888) 
22.   G2S (rs4238001) 
Exon 8 (C/T) 
Exon 1 (G/A) 
 
 
Genotypes were obtained from 25 monkeys (Table 3.3) and genotyping was 
performed using polymerase
 
chain reaction amplification of genomic DNA and 
sequencing. Due to the small gene pool of the MRC Primate colony, same inbreeding 
occurred resulting in genetic similarity. Genotype variations were therefore not 
expected, and results obtained for each cSNP were of the same genotype (Table 3.4).  
 
Since genotype variations between case and control subjects were not obtained, four 
wild caught monkeys from a different animal unit in Potchefstroom University were 
included in the study. However, similar results were obtained with no genotypic 
variations. Therefore, eight monkeys (4 controls/group 1 and 4 case subjects/group 2) 
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were selected out of the original 25 MRC genotyped monkeys for the intervention 
study discussed in chapter 2 (Table 2.2). 
 
 
Table 3.3: Selected individuals for genotyping  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.4: Genotyping results obtained from 25 African green monkeys  
 
SNPs Genotypes Allele frequency 
1. CETP:I405V  G/G Minor 
2. CETP:Ala373Pro G/G Major 
3. ABCA1:Ile883Met G/G Minor 
4. ABCA1:E1172D  G/G Minor 
5. ABCA1:V771M  G/G Major 
6. ABCA1:V825I  T/T Minor 
7.ABCA1: R219K C/C Major 
8. CYP7A1:A-278C  T/T Major 
9. CYP7A1:Asn233Ser  G/G Minor 
10. apoE:Cys112Arg – E4 
 = (334T/C - 472C/T) 
C/C Minor 
11. apoE:Arg158Cys– E2 
 = (334T/C - 472C/T) 
T/T Minor 
12. apoA-1:Msp1;C+83T  T/T Minor 
13. apoA-1:G-75A A/A Minor 
14.apoB:T71I  T/T Minor 
15. apoB:4311S C/C Major 
16.LCAT:Ser232Thr  T/T Minor 
17.LCAT:LCATu3  C/C Minor 
18.apoC-I: HpaI T/T Minor 
19. apoC-II:Leu96Arg G/G Minor 
20. apoC-II:-62 A>C C/C Major 
21. SR-B1:A350A  T/T Minor 
22. SR-B1:G2S  A/A Minor 
 
 
 
 
 
Monkey ID Weight (Kg) Monkey ID Weight (Kg) 
77 3.92 243 4.04 
81 4.04 250 3.16 
97 4.59 283 3.09 
101 4.34 298 3.84 
108 3.78 310 3.80 
136 4.24 322 3.24 
140 4.04 339 4.02 
168 3.10 795 3.82 
181 3.96 1088 6.22 
186 4.12 1080 4.66 
215 3.61 1075 5.12 
234 3.92 1109 6.52 
240 3.52   
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3.4.1.1 Standard PCRs for genotyping 
In order to amplify target DNA, 0.2 ml thin walled tubes were used in a GeneAmp 
PCR system 2700 (Applied Biosystem) or Eppendorf Mastercycler gradient 
thermocycler equipped with a heated lid. Unless otherwise stated, the standard 25 μl-
PCR reaction contained the following reagents: 2x PCR Mater Mix (Promega), DNA 
template (50 ng), 0.5 μl of the upstream and downstream primers were made up to 25 
μl with Nuclease-Free water (Table 3.5). 
 
Thermocycling conditions: 95 ºC for 5 min followed by 30 cycles of  95 ºC for 30 sec, 
X ºC for 30 sec and 72 ºC for 1 min; then an extension period of 5 min at 72 ºC (Table 
3.6). X denotes the relevant annealing temperature which was chosen 5 ºC below the 
assumed primer melting temperatures calculated using the following formula (Tm= 
[no. of GC] x 4 + [no. of AT] x 2 ºC. The oligonucleotides used in this study are listed 
in Appendix II, Table A9(1). References with regard to which experiments the 
primers were implemented is included in the text. A DNA Sequencer (Applied 
Biosystems ABI3730xl DNA analyser) was used to obtained genotyping results.  
 
Table 3.5: PCR reaction used for genotyping 
Reagent (Promega) Volume (μl) Final Concentration 
PCR Master Mix, 2X 12.5 1X 
Forward primer, 10μM 1.25 0.5 μM 
Reverse primer, 10μM 1.25 0.5 μM 
DNA template 1 50 ng 
Nuclease-Free Water to 25 N.A 
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Table 3.6: PCR program used for genotyping 
Step Temp (ºC) Time Cycles 
Denaturation 95 5 min 1 
Denaturation 
Annealing 
Extension 
95 
Primer dependent 
72 
30 sec 
30 sec 
1 min 
 
30 
Extension 72 5 min  
 
 
3.4.2 Gene Expression analysis 
Quantitative real-time PCR (qRT-PCR) is one of the most sensitive and commonly 
used techniques to study gene expression. In this study SYBR
® 
Green gene expression 
assays from Applied Biosystems were used. SYBR Green bonded to double-stranded 
DNA, and upon excitation emitted light. Thus, as a PCR product accumulated, 
fluorescence increased.  
 
SYBR Green is the most economical choice for real-time PCR product detection. 
Since the dye bonded to double-stranded DNA, there was no need to design a probe 
for any particular target to be analyzed. However, detection by SYBR Green required 
extensive optimization. Since the dye could not distinguish between specific and non-
specific product accumulated during PCR, follow up assays were needed to validate 
results. 
 
3.4.2.1 Isolation and quantification of mRNA cDNA synthesis 
The PAXgene Blood RNA Kit (PreAnalytiX, Qiagen) was used to isolate and purify 
intracellular RNA from whole blood collected in the PAXgene Blood Tube (BRT) 
from eight monkey subjects (4 cases and 4 controls) during the 10 intervention study 
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time points (Chapter 2). BRT contained a reagent that protected RNA molecules from 
degradation by RNases and minimised ex vivo changes in gene expression. BRT were 
intended for the collection of whole blood and stabilisation of cellular RNA for up to 
5 days at 2-8 ºC or up to 24 months at -20 ºC or -70 ºC. The procedure was simple and 
purification began with a centrifugation step to pellet nucleic acids in the BRT. The 
pellet was washed and resuspended, followed by RNA purification as per manual 
instructions. 
 
The resuspended pellet was incubated in optimised buffer together with proteinase K 
to bring about protein digestion. An additional centrifugation through the PAXgene 
Shreder spin column was carried out to homogenise the cell lysate and remove 
residual cell debris, and the supernatant of the flow-through fraction was transferred 
to a fresh microcentrifuge tube. Ethanol was added to adjust binding conditions, and 
the lysate was applied to a PAXgene RNA spin column. During a brief centrifugation, 
RNA was selectively bonded to the PAXgene silica membrane as contaminants pass 
through. Remaining contaminants were removed in several efficient wash steps. 
Between the first and second wash steps, the membrane was treated with DNase I 
(TURBO DNA-free Kit, AEC Amersham)) to remove trace amounts of bound DNA. 
After the wash steps, RNA was eluted in elution buffer and heat-denatured. RNA 
yields from 2.5 ml whole blood were ≥ 3 μg for ≥95% of samples processed. Since 
yields were donor-dependent, individual yields varied. RNA purities were checked 
using OD260/OD280 ratio and by confirming integrity using Agilent 2100 bioanalyzer 
(Agilent technologies, Germany). 
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3.2.2.1.1 RNA quantification and purity 
Nucleic acids (RNA and DNA) absorb at 260 nm (A260), while proteins and other 
contaminants absorb at 280 nm (A280). Thus, the ratio of 260 nm to 280 nm is used to 
assess the purity of a sample. A ratio of two is generally accepted as pure for RNA. 
The ratio of A260 to A230 is used as a secondary measure of purity, and indicates 
contaminants that absorb at or near 230 nm.  
 
RNA concentration and purity was determined by measuring the absorbance at A260, 
A280 and A230 in a Nanodrop 1000 spectrophotometer. The spectrophotometer was 
initialised by pipetting 2 l distilled water onto the pedestal of the spectrophotometer, 
and blanked with 2 l RNase free water. Thereafter, 2 l sample was pipetted onto the 
pedestal and the absorbance determined. Each sample was read in triplicate. 
 
3.2.2.1.2 Analysis of RNA integrity  
In eukaryotes, total RNA is comprised of approximately 80% rRNA, whereas only 1 
to 3 % is comprised of mRNA. Traditionally, it is assumed that rRNA quality reflects 
mRNA quality. Thus, mRNA quality is assessed by visualising the 18S or 28S rRNA 
peaks; a 28S:18S rRNA ratio of 2 indicative of intact RNA.  
 
RNA integrity was determined with the Agilent 2100 bioanalyser (Agilent 
technologies, Germany) in conjunction with the RNA 6000 Nano-kit as recommended 
by the manufacturer. The Agilent 2100 bioanalyzer is an improved analytical tool for 
total RNA analysis, and offers a number of advantages over agarose gel 
electrophoresis, the traditional method of assessing RNA quality. The bioanalyser 
uses a combination of microfluidics, capillary electrophoresis, and fluorescence to 
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evaluate both RNA concentration and integrity. The software assigns an RNA 
integrity number (RIN) to the RNA sample. The RIN is a numerical assessment of the 
integrity of the RNA sample, taking into account the entire electrophoretic pattern of 
the RNA sample (28S:18S ratio) and the presence or absence of degradation products. 
The RIN ranges from one to 10, with 10 representing high quality RNA. An 
electrophoregram representative of an intact RNA sample is illustrated in Figure 3.1.  
 
 
  
 
 
 
 
 
 
 
 
To perform the assay, the RNA 6000 Nano-kit and filtered dye were removed from 
4°C
 
and allowed to equilibrate to room temperature for at least 30 minutes.  The gel-
dye mix was prepared by adding 1 µl of dye to 65 µl of filtered gel, mixed by  
RNA Nano 
marker 
 
Figure 3.1: An electrophoretogram of an intact RNA sample.  Distinct 18S and 28S rRNA bands are 
noted. The marker peak is a control included in the RNA 6000 Nano-kit to correctly align 
electrophoretograms. Smaller peaks present after the marker may represent 5S and 5.8D subunits, tRNAs 
and small RNA fragments about 100 bp. 
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vortexing for 10 seconds and then centrifuged at 12 000 g for ten minutes. A RNA 
600 Nano chip was placed in the priming station and the well marked dark G was 
filled with 9 µl of gel-dye mix and primed by depressing the syringe in the chip 
priming station for 30 seconds. Thereafter, the two wells marked light G were filled 
with 9 µl of gel-dye mix. Five microlitres of RNA 6000 Nano marker was added to 
the 12 sample and one ladder well. The RNA ladder and samples (50 to 500 ng/l) 
were denatured by placing them at 70°C for two minutes. After brief centrifugation, 1 
µl of RNA ladder or RNA sample was pipetted into their respective wells. The chip 
was vortexed at 2400 g for one minute and then placed in the chamber of the Agilent 
Bioanalyser which had been decontaminated with RNaseZap and RNase-free water. 
For decontamination, an electrode cleaner chip containing 350 µl of RNaseZap 
solution was placed in the bioanalyser for one minute. Thereafter, another electrode 
cleaner chip, containing 350 µl of RNase-free water was placed in the bioanalyser for 
10 seconds, removed and the electrodes allowed to air dry for a further 10 seconds. 
After selecting the (RNA Eukaryote total RNA Nano series II) programme on the 
2100 Agilent Expert software the assay was run. 
 
3.2.2.1.3 DNase treatment  
RNA samples were DNase treated to remove contaminating genomic DNA from RNA 
preparations. For this the TURBO DNase kit was utilized as recommended by the 
manufacturers. Briefly, 5 µl of 10x DNase buffer and 1.5 µl of DNase was added to 
20 µg of RNA and RNase-free water in a total reaction volume of 50 µl. Samples 
were mixed and incubated at 37°C for 30 minutes, after which another 1.5 µl of 
DNase was added and incubated at 37°C for a further 30 minutes. The reaction was 
stopped by adding 10 µl DNase inactivation reagent and mixed by placing tubes on an 
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orbital shaker for two minutes. Thereafter, the tubes were centrifuged at 10 000 g for 
1.5 minutes and the supernatant transferred to a new tube. RNA concentrations were 
determined using a Nanodrop 1000 spectrophotometer.  
 
3.4.2.2 Reverse Transcription: cDNA synthesis  
Total RNA was reverse transcribed into cDNA using the High-Capacity cDNA kit 
according to the manufacturer’s instructions. One microgram DNase treated RNA 
sample was added to 10 l RNase-free water and placed on ice. A reaction mix 
consisting of reaction buffer, dNTPs, random primers, RNase-inhibitor (5000 
units/ml), reverse transcriptase and nuclease-free water was prepared into two 
separate tubes labelled RT plus and RT minus. The RT minus reaction mix tube 
(negative control) contained the same reaction mix as the RT plus tube, but with the 
reverse transcription enzyme replaced by water (Table 3.7). After adding the RT plus 
and RT minus mix components, the prepared reaction mixes were mixed by pipettting 
and the tubes centrifuged briefly. 
 
Table 3.7: Reaction components for the reverse transcription reaction 
 
Component 
Volume (µl) 
Plus RT Minus RT 
1 g DNase-treated RNA in RNase-free water 10 10 
10 x RT buffer 2 2 
25 x dNTP mix 0.8 0.8 
10 x random primers 2 2 
RNase inhibitor 1 1 
Nuclease-free water 3.2 4.2 
Reverse Transcriptase 1 0 
Total volume 20 20 
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Ten microlitres of plus or minus RT reaction mixes were added to 0.2 ml tubes 
containing RNA samples. The tube contents were mixed, briefly centrifuged and 
placed in a 2720 thermal cycler. Reactions were incubated at 25°C for 10 minutes, 
37°C for 120 minutes, and 85°C for five seconds to inactivate the reverse transcriptase 
enzyme. Samples were stored at -20°C until gene expression analysis. The RT minus 
tube (negative control) was used to calculate the amount of genomic DNA 
contamination.  
 
3.2.2.1.3 Quantitative Real-time PCR to assess genomic DNA contamination 
To assess the extent of genomic DNA contamination in RNA samples, cDNA 
generated from plus and minus reverse transcription reactions were amplified with 
exon spanning primers that would amplify both mRNA and genomic DNA. A reaction 
mix consisting of 12.5 l SYBR Green mix, 1 l of 10 M ActB Forward Primer (400 
nM), 1 l of 10 M ActB Reverse Primer (400 nM) and H2O to a final volume of 24 
µl was prepared. The reaction mix was scaled up according to the number of test 
samples. The reaction mix is indicated in Table 3.8.  
 
Twenty four microlitres of reaction mix was aliquoted into the PCR plate, followed by 
1 µl (50 ng) of undiluted cDNA (plus or minus RT reactions). The plate was sealed 
with adhesive film, mixed on a plate shaker for ten minutes and then briefly 
centrifuged at 3 000 g. The PCR reactions were conducted on the ABI 7500 Sequence 
Detection System Instrument (Applied Biosystems) using the Absolute Quantification 
(AQ) Software (SDS V1.4). Universal cycling conditions; 50ºC for two minutes and 
95ºC for ten minutes, followed by 40 cycles of 95ºC for 15 seconds and 60ºC for one 
minute were used. A dissociation curve was added for secondary product detection. 
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Data was acquired during the extension step (60°C for one minute). After the run, 
default settings for the threshold cycle (Ct) and baseline were used and Ct values were 
exported to Microsoft Excel for analysis.  
 
Table 3.8: Reaction mix for quantification of genomic DNA contamination 
 
Component Volume (l) Final Concentration 
2x master mix 
12.5 
 
1X 
ActB Forward primer (10 µM) 
1 
 
400 nM 
ActB Reverse Primer (10 µM) 1 400 nM 
Water 9.5 - 
cDNA 1 50 ng 
Final volume 25 - 
 
 
3.4.2.3 Primers design 
Twelve QuantiTect Primer Assays (Qiagen) (Table 3.9) were used instead of designed 
primers since they enable fast and affordable RNA analysis, and eliminate tedious 
primer design and assay optimization steps. These assays are derived from gene 
sequences contained in the NCBI Reference Sequence database 
(www.ncbi.nlm.nih.gov/RefSeq). They are bioinformatically validated, and they 
detect RNA only, provided that no pseudogenes with high cDNA similarity exist or 
that the transcript is not derived from a single-exon gene.  
 
Each 10 X QuantiTect Primer Assay contains a mix of forward and reverse primers 
for a specific target and supplied lyophilized. To reconstitute a tube of 10x QuantiTect 
Primer Assay a 1.1 ml TE, pH 8.0 was added and mixed by vortexing 4–6 times 
before being frozen at -20ºC. 
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Table 3.9: QuantiTech Primer Assay (Qiagen) used in the study 
 
QuantiTech Primer Assay Assay ID 
Cholesteryl ester transfer protein, plasma (CETP) QT00015344 
ATP-binding cassette, sub-family A (ABC1), member 1 (ABCA1 ) QT00064869 
Cytochrome P450, family 7, subfamily A, polypeptide 1 (CYP7A1)  QT00001085 
Apolipoprotein A-I (APOA-1) QT00015841 
Apolipoprotein B (APOB)  QT00020139 
Apolipoprotein C-II (APOC-II) QT00013020 
Apolipoprotein E (APOE) QT00087297 
Scavenger receptor class B, member 1 (SCARB1)  
other names: SR-BI QT00033488 
Lecithin-cholesterol acyltransferase (LCAT)  QT00049336 
Apolipoprotein C-I (APOC-1) QT00018501 
Phosphoglycerate kinase 2 (PGK2) QT00219023 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) QT01192646 
 
 
3.4.2.4 Generating a Standard Curve 
A standard curve was prepared from Total Rat Liver RNA (Ambion) to test the 
monkey gene expression assays. The reaction mix was scaled up according to the 
number of samples to be analysed. Nine microlitres of the reaction mix was aliquoted 
into a well of the PCR plate, followed by 1 µl of a 10-fold dilution series of the 
standard curve or test samples cDNA. A no-template control (NTC) using water 
instead of cDNA was used as a negative control in all PCR reactions. All samples 
were analysed in duplicate. PCR plates were covered with adhesive film and briefly 
centrifuged. Thereafter, plates were placed in a shaker for 10 minutes and briefly 
centrifuged at 3 000 g. The PCR reactions were conducted on the ABI 7500 Sequence 
Detection System Instrument (Applied Biosystems) using universal cycling conditions 
as described before. Data generated on the ABI 7500 Instrument was analysed with 
the ABI Standard Quantification (AQ) software (SDS V1.4) using a Ct of 0.1 and a 
baseline of between 3 and 15 cycles. SYBR
®
 Green
 
gene expression assays, 
QuantiTech Primer Assay (Qiagen) of Phosphoglycerate kinase 2 (PGK2) and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Table 3.9) were used as 
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endogenous controls to normalize mRNA levels in test samples. Data was normalised 
to the average of the two endogenous controls.  
 
To generate the standard (or calibration) curve, the threshold cycle for the standard 
curve reactions was plotted against the fold dilution of the template cDNA on a semi-
logarithmic (base 10) plot. The fit to a straight line including the slope and the 
correlation factor (R
2
) was determined. The efficiency and slope obtained for each 
standard curve was between -3.3 and -3.8. 
 
 
3.4.2.5 Real-time Quantitative RT-PCR 
To determine the yield of the cDNA from the reverse transcription of mRNA, 
quantitative PCR was used to test various input amounts of RNA for the cDNA yield 
of different gene targets.  
 
PCR was performed using Power SYBR Green PCR Master Mix kit (Applied 
Biosystems), 7500 Real-Time PCR System SDS software (Applied Biosystems), 
optical 96-well plates and optical adhesive covers (Applied Biosystems). The cycling 
parameters for all genes were the following: hot-start 95 ºC, 15 minutes, 45 cycles of 
(denaturation 94 ºC, 15 seconds; annealing 56 ºC, 30 seconds; elongation 72 ºC, 30 
seconds);final elongation 72 ºC, 5 minutes; melting curve 65-95 ºC.  
 
A 10 μl reaction mixture was prepared in 96-well reaction plates according to Table 
3.10. cDNA template(≤5 ng/reaction) was added to the wells containing the reaction 
mixture. The real-time cycler was then programmed as described above and results 
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were analysed with the 7500 Real-Time PCR System SDS software (Applied 
Biosystems). 
 
Table 3.10: Reaction setup for RT-PCR 
 
 
 
 
 
3.4.3 Statistical analysis 
 
Results are presented as means ± SD or as means ± SEM. The association of HDL-C 
with gene expression was assessed with the use of Pearson’s correlation coefficients.  
Student t-tests (unpaired) were used to assess the effect of pharmacologic intervention 
(niacin therapy) on gene expression. These changes were compared between the 
experimental and the control group. All reported p-values are two-tailed, with a p-
value < 0.05 indicating statistical significance. Analyses were performed with the use 
of Minitab software, version 16.2. 
 
 
3.3 RESULTS 
3.3.1 Sequence variants/polymorphisms identification and genotyping 
In this chapter an integrated combination of molecular biological and bioinformatic 
strategies was used to identify reciprocal candidate genes for lipid metabolism in 
African green monkeys. Literature search was conducted to look for previously 
reported genes and polymorphisms which are key players in lipid metabolism in 
humans. Ten genes (CETP. ABCA1, CYP7A1, apoA-1, apoB, apoE, SR-B1, LCAT, 
apoC-I and apoC-II) were chosen for this study based on their role in the reverse 
PCR reaction 1X (μL) 
2X SYBR Green Mix 5 
10X Primer assay 1 
cDNA 0.8 
Water 3.2 
Final volume 10 
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cholesterol transport process and twenty two cSNPs (reported to play a vital role in 
RCT) were selected from these genes and genotyped in African green monkeys (Table 
3.2). Selection of cSNPs was also prioritized based on their known associated with 
vascular disease and their function and location within the gene of interest. 
 
 
Since animal selection for this study was based on results obtained from genotyping, 
AxyPrep whole blood genomic DNA kit (Axygene Biosc.) was used to isolate DNA 
from twenty five monkeys. Oligonucleotide primer sets were synthesized and PCR 
conditions were optimized for all cSNPs (Table 3.6 and Appendix II, Table A9). DNA 
was amplified and PCR products were sequenced. Genotype variations were not 
observed due to small gene pool of the MRC Primate colony. Similar results were also 
obtained from four other wild-caught monkeys acquired from Potchefstroom 
University. Eight monkeys from the MRC colony were then selected and entered in 
this study for further analysis. Four monkeys were treated with niacin at an escalating 
dosage (35, 70 and 100 mg/kg) and the other four were chosen as controls. Their 
mean lipid-lowering response following drug therapy was analysed, compared to 
those with the same genotype in a placebo (control) group in chapter 2.  
 
Out of the twenty two cSNPs genotyped in Table 3.2, six cSNPs were identified 
(Table 3.11). All six cSNPs identified (I405V, I883M, Asn233Ser, cL96R, -62A>C 
and A350A) have a significant influential role to play in the regulation of reverse 
cholesterol transport and lipid-lowering drug therapy in both humans and nonhuman 
primates (Quinet et al., 1991; Lloyd et al., 2005; Isaacs et al., 2007; Nakamoto et al., 
2006 and Malhi et al., 2011). 
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Table 3.11: cSNPs identified in the African green monkeys 
 
Gene cSNP Accession 
number 
Chr Exon Nucleotide 
change 
Amino acid 
change 
Polarity 
CETP I405V rs5882 16 14 A/G I/V Nonpolar-nonpolar 
ABCA1 Ile883Met rs4149313 9 18 A/G I/M Nonpolar-nonpolar 
CYP7A1 Asn233Ser rs8192874 8 3 A/G N/S Polar-polar 
apoC-II Leu96Arg 
-62A>C 
rs5167  
rs2288911 
19 3 
Promoter 
T/G L/R Nonpolar-polar 
SR-B1 A350A rs5888 12 8 C/T A/A Nonpolar 
 
 
3.3.2 Gene expression analysis  
3.3.2.1 RNA concentrations and purity  
One of the main objectives of this study was to assess the influence of genetic 
variation on drug response (niacin) by correlating gene expression or single-
nucleotide polymorphisms with a drug’s efficacy and also to determine the possible 
involvement of these genes in cholesterol metabolism pathway or reverse cholesterol 
transport pathway, particularly those identified with cSNPs in our animal model, the 
African green monkeys.  
 
Gene expression protocols were standardised and mRNA expression profiles were 
determined using Real-time PCR in both case and control subjects. mRNA was 
extracted using PAXgene Blood RNA Kit (PreAnalytiX, Qiagen) for all the time 
points of intervention study described in chapter 2. To remove contaminating 
genomic DNA, 20 µg of RNA was DNase treated with the TurboDNase kit as 
described in section 3.2.2.1.3. To assess whether genomic DNA was efficiently 
removed by DNase treatment, reverse transcription reactions containing (plus RT) or 
without (minus RT) the reverse transcription enzyme were subjected to quantitative 
real-time PCR. Taq polymerase, the enzyme responsible for the polymerase chain 
reaction (PCR), will only amplify double stranded DNA, thus RNA must be reverse 
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transcribed before being used as a template in PCR. Amplification in minus RT 
reactions represents genomic DNA contamination. A Ct difference of more than 10 
cycles between the plus and minus RT reactions indicate negligible genomic DNA 
contamination. cDNA prepared from rat liver RNA (Ambion) was included as a 
positive control, while water was used as a negative control.  
 
RNA integrity was confirmed using Agilent 2100 bioanalyzer (Figure 3.2). Amount 
and purity of RNA (Table 3.12) were evaluated by Nanodrop 1000 spectrophotometer 
(Thermo Scientific). cDNA was synthesised with High-Capacity cDNA Reverse 
Trancsription Kit (Applied Biosystems) in accordance with the manufacturer’s 
recommendations. A standard curve was created and real-time PCR was performed in 
duplicate for all 10 prioritised genes. As illustrated in Table 3.13, DNase treatment 
significantly reduced genomic DNA contamination. 
 
 
Table 3.12: Yield of DNase I treated RNA samples (ng/ul) 
 
 
 
 
 
 
 
 
Monkey 
ID 04.02.08 18.02.08 03.03.08 17.03.08 31.03.08 14.04.08 29.04.08 12.05.08 26.05.08 09.06.08 
795 4584.8 2369.6 1092.8 3420.0 3084.0 2932.8 4080.0 2100.0 3076.0 5682.4 
322 3488.8 3488.8 4797.6 2684.8 3134.4 10871. 7004.0 9062.4 6411.2 14789 
339 2466.4 5070.4 4315.2 3580.8 3809.6 7660.8 5742.4 7264.8 4269.6 9602.4 
77 7472.8 100.00 5728.8 5701.6 5150.4 9766.4 5681.6 9198.4 6628.0 5392.8 
108 2959.2 5962.4 2753.6 4968.8 4800.8 4647.2 1756.0 1656.0 4786.4 884.80 
243 2880.0 3421.6 5064.0 8033.6 6002.4 1548.0 6260.8 5671.2 6308.0 4130.4 
215 13573 8520.0 8347.2 5515.2 8554.4 3676.0 5508.0 5206.4 2224.0 5919.2 
97 5144.8 3956.0 3629.6 5383.2 4352.8 3771.2 1906.4 6796.8 5907.2 2786.4 
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Table 3.13: Quantitative Real Time PCR analysis of DNase treated RNA 
 
Sample 
Ct
#
 Ct
$
 
Ct 
diff† 
Ct
#
 Ct
$
 
Ct diff† 
(minus 
RT) (plus RT) 
(minus 
RT) (plus RT) 
Time point: 1 (04.02.08) Time point: 6 (14.04.08) 
795 35.16 16.51 21.65 37.21 20.86 16.35 
322 35.46 16.82 18.64 37.21 16.35 20.86 
339 35.19 17.55 17.64 37.26 15.95 21.31 
77 34.53 17 17.53 36.44 16.12 20.31 
108 36.5 18.03 18.47 36.15 16.65 19.5 
243 35.78 16.51 19.27 36.96 16.18 20.78 
215 35.24 17.71 17.53 34.88 18.43 18.43 
97 35.7 18.14 17.56 36.06 16.78 19.28 
Time point: 2 (02.18.08) Time point: 7 (29.04.08) 
795 35.86 18.54 17.32 37.68 18.25 19.43 
322 36.63 18.59 18.03 37.68 18.25 19.42 
339 37.69 17.95 19.74 39.82 16.51 23.31 
77 36.88 19.35 17.52 38.42 17.16 21.26 
108 36.48 17.33 19.15 39.1 21.85 17.25 
243 36.4 18.58 17.81 34.83 18.17 16.65 
215 36.35 17.6 18.75 36.26 15.92 18.09 
97 37.7 17.92 1977 36.48 18.09 20.56 
Time point: 3 (03.03.08) Time point: 8 (12.05.08) 
795 35.18 16.45 18.73 39.06 18.42 20.63 
322 35.18 18.73 16.45 39.96 19.6 20.36 
339 37.39 16.93 20.46 36.15 17.25 18.89 
77 37.07 17.21 19.86 33.91 17.58 16.32 
108 36.02 19.08 16.94 36.25 18.95 17..29 
243 35.41 17.67 17.74 34.32 17.76 16.55 
215 35.78 19.26 19.26 33.99 17.53 16.46 
97 35.68 17.71 17.96 35.24 18.39 16.84 
Time point: 4 (17.03.08) Time point: 9 (26.05.08) 
795 35.01 17.99 17.02 35.51 17.05 18.45 
322 35.01 17.02 17.99 37.43 17.22 20.21 
339 36.15 16.65 19.5 37.12 17.47 19.64 
77 34.37 16.95 17.41 37.29 17.74 19.55 
108 36.18 19.59 16.59 36.88 19.35 17.52 
243 35.23 16.97 18.26 38.28 17.16 21.11 
215 34.2 16.35 16.35 37.71 17.9 19.81 
97 37.06 16.8 20.26 >40 17.24 >23 
Time point: 5 (31.03.08) Time point: 10 (09.06.08) 
795 35.9 16.99 18.91 39.96 19.6 20.36 
322 37.38 16.95 20.43 39 20.45 18.55 
339 34.17 16.41 17.76 >40 19.79 >23 
77 38.59 16.73 21.86 36.88 19.35 17.52 
108 35.57 17.04 18.53 36.25 18.95 17.29 
243 37.29 17.74 17.33 19.15 21.03 >23 
215 35.26 17.13 18.12 36.35 17.6 19.31 
97 35.3 17.51 17.78 35.17 18.19 16.98 
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Figure 3.2: mRNA agilent analysis. Results were the same for all 10 time points.
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3.5.2.2 PCR efficiency  
The slope of a standard curve is used to evaluate the performance of real time PCR 
reactions and to determine PCR efficiency. Optimal PCR efficiency is indicated by a 
slope of -3.3. Slopes between -3.1 and -3.6 are acceptable. The slope and R
2
 (correlation 
co-efficient) values obtained for the SYBR
®
 Green gene expression assays used in this 
study was calculated using a rat cDNA standard curve (Table 3.14). The slopes for all 
the genes investigated were within the acceptable range.  
 
Table 3.14: Slope and R
2 
values of the genes investigated in the study 
 
Gene Slope R
2
 
Cholesteryl ester transfer protein, plasma (CETP) -3.1 0.99 
ATP-binding cassette, sub-family A (ABC1), member 1 (ABCA1 ) -3.2 0.99 
Cytochrome P450, family 7, subfamily A, polypeptide 1 (CYP7A1)  -3.4 0.99 
Apolipoprotein A-I (APOA-1) -3.3 0.99 
Apolipoprotein B (APOB)  -3.1 0.97 
Apolipoprotein C-II (APOC-II) -3.1 0.99 
Apolipoprotein E (APOE) -3.3 0.99 
Scavenger receptor class B, member 1 (SCARB1)  
other names: SR-BI -3.3 0.99 
Lecithin-cholesterol acyltransferase (LCAT)  -3.3 0.98 
Apolipoprotein C-I (APOC-1) -3.2 0.99 
Phosphoglycerate kinase 2 (PGK2) -3.1 0.97 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) -3.2 0.97 
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3.3.2.3 The effect of niacin treatment on gene expression 
 
The effects of niacin treatment on the expression of the ten prioritized reverse 
cholesterol transport genes (CETP. ABCA1, CYP7A1, apoA-1, apoB, apoE, SR-B1, 
LCAT, apoC-I and apoC-II) were determined using quantitative real time PCR (qRT-
PCR). The expression of the reference genes PGK2 and GAPDH was used to normalize 
mRNA levels.  
 
The treatment of niacin affected the expression of genes differently at each time point 
and this is illustrated in Figures 3.3 to 3.12. Gene expression differences that were 
statistically significant were only observed in four genes (CETP with p = 0.04 at time 
point 14.04.08, CYP7A1 with p = 0.04 at baseline and time point 17.03.08, SR-B1 with 
p = 0.03 at washout (09.06.08) and apoC1 with p = 0.04 at time point 14.04.08).  Up-
regulation of the level of mRNA in the treated group compared to the controls was only 
seen in SR-B1 from the time point when niacin treatment was maintained at 100 mg/kg, 
however statistically significant differences were not obtained throughout the treatment 
phase (Figure 3.6). mRNA expression level of CETP, ABCA1, LCAT, apoC-I, 
CYP7A1 and apoE in the treated group compared to the controls were decreased with 
increased dosage of niacin leading to a downregulation (Figures 3.3, 3.4, 3.5, 3.7and 
3.12). ApoB mRNA was only expressed at a very low level in both experimental and 
control groups after two months of intervention treatment with niacin (Figure 3.8). 
ApoA-1 and apoC-II were poorly expressed in both experimental and control groups 
throughout the study (Figure 3.9 and 3.10). 
 
During the intervention phase of this study (described in chapter 2), levels of total 
cholesterol, HDL-C, LDL-C, triglycerides and apoA-1 were determined at different time 
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points from baseline to the end of the washout period. The effect of niacin treatment was 
also determined at genetic level by the expression profile of the selected candidate genes 
at these time points as mentioned above. A considerable change in the concentrations of 
HDL-C, LDL-C and apoA-1 was observed at week 6 (time point 17.03.08).  A change in 
gene expression of CYP7A1 mRNA was also observed at this time point with a statistical 
significant difference of p-value 0.04 (Figure 3.13).  
 
Since the levels of HDL-C are significant determinant of cholesterol efflux capacity a 
correlation analysis was conducted to determine the relationship between the levels of 
HDL-C and mRNA expression of the 10 selected RCT candidate genes. HDL-C 
concentrations showed a strong inverse correlation with CETP, SR-B1, apoA-1, apoB, 
CYP7A1, apoC-I and apo C-II concentrations (r = -0.14, -0.27, -0.01, -0.95, -0.30, -0.69, 
-0.33; p < 0.001) and a positive correlation with ABCA1, LCAT and apoE concentrations 
(r = 0.48, 0.16, 0.56; p < 0.001) (Appendix II, Table A10). 
 
 
 
 
 
 
100 
 
    
 
 
Figure 3.3: The effect of niacin treatment on mRNA expression of CETP in the African green monkey.  The experimental group received niacin 
at an escalating dose (35 to 100 mg/kg) while the control group received a maintenance diet throughout the study period of four months. 
Messenger RNA levels were determined by quantitative real time PCR for all 10 sampling points of the study period from baseline (04.02.08) to 
washout (09.06.08). CETP expression decreased when niacin treatment was maintained at a higher dosage and increased again after the washout 
period. Data were expressed as mean ± SD and mRNA expression. A p-value of 0.04 was calculated at time point 14.04.08 when the treatment 
of niacin was maintained at 100 mg/kg. P-values for other time points were greater than 0.05, therefore no difference indicated between the 
groups. 
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Figure 3.4: The effect of niacin treatment on mRNA expression of ABCA1 in the African green monkey.  The experimental group received 
niacin at an escalating dose (35 to 100 mg/kg) while the control group received a maintenance diet throughout the study period of four months. 
Messenger RNA levels were determined by quantitative real time PCR for all 10 sampling points of the study period from baseline (04.02.08) to 
washout (09.06.08). ABCA1 expression of the experimental group decreased with increased dosage of niacin treatment as compared to the 
control group. Data were expressed as mean ± SD and mRNA expression in a.u. (arbitrary units). P-values for all time points were greater than 
0.05, therefore no difference between the groups. 
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Figure 3.5: The effect of niacin treatment on mRNA expression LCAT in the African green monkey.  The experimental group received niacin at 
an escalating dose (35 to 100 mg/kg) while the control group received a maintenance diet throughout the study period of four months. Messenger 
RNA levels were determined by quantitative real time PCR for all 10 sampling points of the study period from baseline (04.02.08) to washout 
(09.06.08). LCAT expression decreased from the time niacin was administered at 70 mg/kg (03.03.08) until the end of treatment (26.05.08). 
Data were expressed as mean ± SD and mRNA expression in a.u. (arbitrary units). P-values for all time points were greater than 0.05, therefore 
no difference indicated between the groups. 
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Figure 3.6: The effect of niacin treatment on mRNA expression of SR-B1 in the African green monkey.  The experimental group received 
niacin at an escalating dose (35 to 100 mg/kg) while the control group received a maintenance diet throughout the study period of four months. 
Messenger RNA levels were determined by quantitative real time PCR for all 10 sampling points of the study period from baseline (04.02.08) to 
washout (09.06.08). SR-B1 expression of the experimental group increased as compared to the controls from the time niacin was maintained at 
100 mg/kg (14.04.08). Data were expressed as mean ± SD and mRNA expression in a.u. (arbitrary units). A p-value of 0.03 was calculated at 
washout. P-values for other time points were greater than 0.05, therefore no difference indicated between the groups. 
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Figure 3.7: The effect of niacin treatment on mRNA expression apoC-1 in the African green monkey.  The experimental group received niacin 
at an escalating dose (35 to 100 mg/kg) while the control group received a maintenance diet throughout the study period of four months. 
Messenger RNA levels were determined by quantitative real time PCR for all 10 sampling points of study period from baseline (04.02.08) to 
washout (09.06.08). ApoC-1 expression of both experimental and control groups decreased after the 5
th
 time point (31.03.08). Reduced 
expression of apoC-1 was observed in the experimental group as compared to the controls, and a p-value of 0.04 was calculated at time point 
14.04.08 when the treatment of niacin was maintained at 100 mg/kg. P-values for other time points were greater than 0.05, therefore no 
difference indicated between the groups. Data were expressed as mean ± SD and mRNA expression in a.u. (arbitrary units).  
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Figure 3.8: The effect of niacin treatment on mRNA expression apoB in the African green monkey.  The experimental group received niacin at 
an escalating dose (35 to 100 mg/kg) while the control group received a maintenance diet throughout the study period of four months. Messenger 
RNA levels were determined by quantitative real time PCR for all 10 sampling points of the study period from baseline (04.02.08) to washout 
(09.06.08). The expression of apoB for both experimental and control groups was very low and only observed from time point 14.04.08. Data 
were expressed as mean ± SD and mRNA expression in a.u. (arbitrary units). P-values for all time points were greater than 0.05, therefore no 
difference indicated between the groups. 
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Figure 3.9: The effect of niacin treatment on mRNA expression of apoC-II in the African green monkey.  The experimental group received   
niacin at an escalating dose (35 to 100 mg/kg) while the control group received a maintenance diet throughout the study period of four months. 
Messenger RNA levels were determined by quantitative real time PCR for all 10 sampling points of the study period from baseline (04.02.08) to 
washout (09.06.08). The apoC-II expression of both experimental and control groups was weak and only observed in some of the time points. 
Data were expressed as mean ± SD and mRNA expression in a.u. (arbitrary units). P-values for all time points were greater than 0.05, therefore 
no difference indicated between the groups. 
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Figure 3.10: The effect of niacin treatment on mRNA expression of apoA-1 in the African green monkey.  The experimental group received 
niacin at an escalating dose (35 to 100 mg/kg) while the control group received a maintenance diet throughout the study period of four months. 
Messenger RNA levels were determined by quantitative real time PCR for all 10 sampling points of the study period from baseline (04.02.08) to 
washout (09.06.08). ApoA-1 was weakly expressed in both experimental and control groups throughout the study period. Data were expressed as 
mean ± SD and mRNA expression in a.u. (arbitrary units). P-values for all time points were greater than 0.05, therefore no difference indicated 
between the groups. 
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Figure 3.11: The effect of niacin treatment on mRNA expression of CYP7A1 in the African green monkey.  The experimental group received 
niacin at an escalating dose (35 to 100 mg/kg) while the control group received a maintenance diet throughout the study period of four months. 
Messenger RNA levels were determined by quantitative real time PCR for all 10 sampling points of the study period from baseline (04.02.08) to 
washout (09.06.08). A decline in CYP7A1 expression was observed in the experimental group from baseline to washout period. P-values of 0.04 
were calculated at baseline (04.02.08) and at time point 17.03.08. P-values for the other time points were greater than 0.05, therefore no 
difference were indicated between the groups. Data were expressed as mean ± SD and mRNA expression in a.u. (arbitrary units).  
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Figure 3.12: The effect of niacin treatment on mRNA expression of apoE in the African green monkey.  The experimental group received niacin 
at an escalating dose (35 to 100 mg/kg) while the control group received a maintenance diet throughout the study period of four months. 
Messenger RNA levels were determined by quantitative real time PCR for all 10 sampling points of the study period from baseline (04.02.08) to 
washout (09.06.08). ApoE expression of experimental group decreased after the 5
th
 time point (31.03.08) when niacin treatment was maintained 
at 100 mg/kg. P-values for all time points were greater than 0.05, therefore no difference indicated between the groups. Data were expressed as 
mean ± SD and mRNA expression in a.u. (arbitrary units).  
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Figure 3.13: The effect of niacin treatment on Total Cholesterol, HDL-C, LDL-C, Triglycerides, and apoA-1 in the African green monkey. Overall, 
niacin treatment decreased LDL-C by 39%, increased HDL-C by 37% and apoA-I by 26%. Considerable changes in the concentrations of HDL-C, 
LDL-C, apoA-1 and a significant decline of CYP7A1 mRNA expression were observed at time point 17.03.08. 
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3.4 DISCUSSION 
This study has shown for the first time that the African green monkey share six cSNPs 
(I405V, I883M, Asn233Ser, cL96R, -62A>C and A350A) with humans (Table 3.11).  
These cSNPs are known to have a significant influential role in the regulation of 
reverse cholesterol transport and lipid-lowering drug therapy.   
 
To genetically and phenotypically characterise the African green monkey, 22 cSNPs 
found at the same position in both humans and nonhuman primates were prioritised 
and blasted against a dataset of human and monkey SNPs. Six out of the 22 genotyped 
cSNPs were identified. Since genotype variations between case and control subjects 
were not obtained in this study, four wild caught monkeys from Potchefstroom 
University were included. However, no genotypic variations were obtained with these 
individuals, presumably due to the small gene pool. Therefore, inbreeding is a well-
defined genetic consequence with an increase of homozygosity in the whole genome 
of this species (Charpentier et al., 2007). Based on this information and the fact that 
MRC wild caught monkeys used as controls originated from the same area than the 
monkeys from Potchefstroom, associating the effect of niacin with the individual 
genotypes could not be achieved.  
 
Exploring the genetic basis of HDL-C, a well-studied endophenotype for 
cardiovascular disease (CVD), has several attractive features as a target for genetic 
analysis. Since the prevention of CVD is critically dependent on lipid-lowering 
therapy, in this study six cSNPs in five “candidate genes” associated with HDL-C 
levels, lipid-lowering drugs response and known to regulate RCT were identified and 
subsequently genotyped in niacin treated cases and controls of the African green 
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monkey. The rationale for using the African green monkey in this study was based on 
the knowledge that this animal model shares a common ancestor with humans, is 
known to develop atherosclerosis in a fashion similar to humans with respect to 
morphology and cytology (Fernandez et al., 2008), and is well suited and established 
as translational model for drug testing (Ebeling et al., 2011). Niacin therapy response 
was evaluated in healthy monkeys since this model has shown response to HDL-C 
increases with other reference lipid-lowering compounds such as statin (Yin et al., 
2011).  
 
In the last few years there has been growing evidence of the influence of genetic 
variation/polymorphisms in the determination of plasma lipid concentrations, 
especially for genes involved in lipid transport and metabolism. More recently, there 
is a growing interest in the role of these genetic polymorphisms in predicting 
susceptibility to disease and responsiveness to drug interventions. Plasma lipid 
abnormalities are risk factors for coronary atherosclerosis and determination of these 
plasma lipid concentrations may be influenced by genetic variations.  
 
This study presented several challenges. Firstly, spontaneous or induced primate 
models of low plasma HDL are not available.  This is unlike LDL, which can be 
easily modulated by diet.  Secondly, the availability of African green monkeys for 
research is limited and maintenance is expensive hence the relatively small sample 
size in the intervention study. Thirdly the reference sequence of the African green 
monkey is currently unavailable and fourthly, the MRC Primate colony utilized for 
this study is captive-bred and genetically very similar. Identification of genotypes 
linked with a particular SNP was therefore not possible due to the small gene pool of 
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the colony. Additionally, invasive techniques such as liver biopsies would have been 
required for gene expression analysis of genes involved in lipid metabolism and RCT 
pathway.  
 
CETP 
The relationship of I405V polymorphism in CETP gene expression with plasma 
CETP level, HDL-C and RCT was investigated in this study. It was shown that 
carriers of 405V allele have increased HDL-C concentration. Niacin treatment 
appeared to have decreased CETP mRNA expression as compared to the control 
mRNA expression profile. However, a statistically significant difference between the 
experimental and control group was only observed at one time point (14.04.08) with a 
p-value of 0.04 (Figure 3.3). The lack of statistically significant differences in other 
time points could be attributed to the fact that this might be a conservative 
modification of CETP at residue 405 from an isoleucine to a valine and this might not 
be a direct cause for the alteration in CETP activity and HDL-C values. Therefore, the 
amino acid change may not have altered the specific activity values of CETP, but its 
presence may have influenced the effect of lipid-lowering treatment. A negative 
correlation coefficient of -0.14 with a p < 0.001 was obtained between the level of 
HDL-C and the mRNA expression profile of CETP (Appendix II, Table A10).  
 
It is apparent that a change in the up-regulation of HDL-C by the niacin treatment was 
accompanied by down-regulation of CETP gene expression especially at time point 
14.04.08 when it was statistically significant (p=0.04). These findings suggest that 
CETP I405V polymorphism could modify the effect of niacin on TG reduction and 
HDL-C elevation at that particular time point. This observation could support the 
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hypothesis (Brousseau, 2004) that V405 alleles are associated with reduced CETP 
activity and increased HDL-C levels, however, based on this current study, it cannot 
be concluded up to  what extent physiological variation of CETP could influence RCT 
pathway, particularly in the African green monkey. 
 
Several studies have reported that carriers of 405V allele have increased HDL-C 
concentration (Lewis et al., 2005). The I405V polymorphism is located in exon 14 of 
the CETP gene and is caused by A to G transition in position 20206. It is 
characterized by alteration in the primary structure of the protein having either an 
isoleucine or a valine at codon 405. VV genotype of this polymorphism has been 
associated with lower plasma CETP concentration, higher HDL-C concentration and 
elevation of the risk for CHD (Isaacs et al., 2007 and Okumura et al., 2002). Since 
plasma CETP plays a key role in RCT, the presence of I405V polymorphism may 
therefore alter the susceptibility to atherosclerosis and may have an influential role to 
play in the effect of niacin therapy to the African green monkeys.  
 
CETP has both pro- and anti-atherogenic effects (Shah, 2007). If CETP is totally 
absent the lipoprotein profile is atherogenic (Berard et al., 2003 and Tall et al., 1999) 
though some studies found that low CETP activity correlated with an anti-atherogenic 
state (Barter, 2001). VV genotype of I405V polymorphism is reported with low 
CETP, high cholesterol and elevation of the risk for CHD (Isaacs et al., 2007).  
 
 
 
 
 
 
 
 
115 
 
ABCA1 
 
A cSNP analysis of the ABCA1 gene provided evidence here that common genetic 
variations within ABCA1 are associated with altered plasma lipid levels and risk of 
CAD in the vervet monkey. Five cSNPs (I883M, E1172D, V771M, R219K and 
V825I) known to influence plasma lipid levels and CAD were genotyped and only 
one cSNP (Ile883Met) was identified. Clee et al., (2001) have shown that I883M is a 
common variant that is possibly associated with an increased risk of coronary artery 
disease (CAD) in the homozygous state. I883M is located in the middle part of the 
protein corresponding to the seventh hydrophobic segment (H7) (Frikke-Schmidt et 
al., 2004). Because this variant is associated with little functional effect, it might 
demarcate the border of the region in which structural alterations significantly impair 
ATP-binding cassette function. Kyriakou et al., 2007 have reported that I883M has an 
effect on the activity of ABCA1 in facilitating cholesterol efflux. They observed a 
trend towards an increased rate of apoAI-mediated cholesterol efflux in cells 
expressing the 883M variant compared with cells expressing the wild-type (883I).)  
 
Results obtained in mRNA expression of ABCA1 in the African green monkey may 
have shed some light on the involvement of I883M in RCT regulation, and may play 
any significant role in influencing ABCA1 activity to niacin therapy in this species. 
During the experimental intervention the levels of ABCA1 mRNA expression of the 
experimental group appeared to have been down-regulated  as compared to the control 
group (Figure 3.4) along with increased level of HDL-C and apoA-1 (Figures 2.2 and 
2.5). However, statistically significant differences between the two groups were not 
observed. A negative correlation coefficient was obtained between the level of HDL-
C and the mRNA expression profile (r = -0.17, p < 0.001).  Since I883M is known to 
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increase the risk of CAD, its presence which did not show any relevant statistical 
significance, did not appear to have influenced the effect of ABCA activity in 
facilitating cholesterol efflux with niacin up-regulating HDL-C synthesis in the 
African green monkey.  
 
SR-B1 
A polymorphism in exon 8 of the SR-B1 gene (c.1119C.T) was identified in the 
African green monkey for the first time. This polymorphism is also known as A350A 
and SR-B1 is best known for its role in facilitating the uptake of cholesteryl esters 
from high-density lipoproteins in the liver. This process drives the movement of 
cholesterol from peripheral tissues towards the liver for excretion. This movement of 
cholesterol is known as reverse cholesterol transport and is a protective mechanism 
against the development of atherosclerosis. The identification of a polymorphism in 
the SR-B1 of the African green monkey has possibly shed some light in evaluating the 
influence of SR-B1 in niacin therapy within this species. SR-B1 A350A is known to 
have gender-specific and age-related effects on cholesterol transport (Morabia et al., 
2004). The common T variant of exon 8 (A350A) has been reported to be 
significantly associated with having an atherogenic versus non-atherogenic lipid 
profile, with significantly opposite gender-specific clinical effects, atheroprotective 
HDL-C-wise in men and atherogenic LDL-C-wise in women (Morabia et al., 2004). 
Although this polymorphism is a synonymous mutation, it is likely to be a marker for 
another functional mutation. 
 
In light of prior reports of the effect of this polymorphism on fasted lipid 
concentration (Morabia et al., 2003), It can be speculated that that this polymorphism 
 
 
 
 
117 
 
is associated with an anti-athrogenic profile in the African green monkey. Considering 
that in this study the association between SR-B1 and niacin therapy response was 
investigated through gene expression profiles, results obtained have indeed reflected 
the possibility of this influence that SR-B1 A350A can have on RCT and HDL-C 
synthesis. Since this polymorphism is known to have gender-specific effects on 
cholesterol transport, female monkeys were used for this study, and biochemistry 
analysis demonstrated elevated levels of HDL-C and apoA-1 with reduced levels of 
LDL-C and triglycerides. SR-B1 mRNA expression levels of the experimental group 
appeared to have been up-regulated when compared with the control group, especially 
at time points when niacin treatment was maintained at a higher dose of 100 mg/kg. 
However, statistically significant differences were not observed for all time points 
except at the washout period (p= 0.03) (Figure 3.6).  
 
SR-B1 is known to play a crucial role in RCT pathway by mediating selective uptake 
of HDL cholesteryl esters by the liver. According to Morabia et al., (2003), the 
presence of SR-B1 A350A will only favour the atherogenic effect on females, which 
is contradictory to our findings. A negative correlation coefficient of -0.27 (p < 0.001) 
was obtained between the level of HDL-C and the mRNA expression profile of SR-
B1 (Appendix II, Table A10). When a negative correlation coefficient is obtained, a 
decline in one variable is accompanied by an increase of another variable; therefore, 
in this case the presence of SR-B1 A350A did not seem to have any effect on niacin 
therapy response since HDL-C synthesis was up-regulated and is atheroprotective 
towards the female African green monkey (Figure 3.6).  
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CYP7A1 
The CYP7A1 gene was screened for polymorphisms in the African green monkey. An 
average of two cSNPs (Asn233Ser and A-278C) was genotyped and a C/T SNP in 
exon 3, causing an amino acid change at Asn233Ser was identified. The association of 
this polymorphism to plasma lipid levels and risk to atherosclerosis has possibly 
contributed to the understanding of the mechanisms driving RCT and niacin response 
in the African green monkey model. In gene expression analysis, the level of CYP7A1 
mRNA expression appeared to have been down-regulated during niacin treatment 
intervention (Figure 3.11). It was interesting to note statistically significant 
differences between the experimental and the control group (p = 0.04) at week 6 (time 
point 17.03.04) where a considerable change in the concentrations of HDL-C, LDL-C 
and apoA-1were observed. (Figure 3.11 and Figure 3.13). It is obvious that niacin 
treatment had an effect on the expression level of CYP7A1 mRNA, especially at this 
time point when compared to the baseline which was also statistically significant with 
a p-value of 0.04. CYP7A1 mRNA of the experimental group was highly expressed at 
baseline as compared to the control group, however, the expression pattern was 
reversed and down-regulated at week 6 (time point 17.03.08) when niacin was 
maintained at 100 mg/kg. The expression remained low from this time point to the 
end of treatment. A correlation coefficient of -0.30 was obtained between HDL-C 
levels and mRNA expression profile of CYP7A1 (Appendix 11, Table A10). Since 
Asn233Ser polymorphism has been associated with variations in plasma LDL-
cholesterol concentrations and is known to be involved in drug metabolism, it may 
play an integral role in metabolising niacin and influencing the up-regulation of HDL-
C synthesis.   
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CYP7A1 catalyses the first reaction in the cholesterol catabolic pathway in liver. This 
pathway converts cholesterol to bile acids, which is the primary mechanism for the 
removal of cholesterol from the body. The CYP7A1 catalytic reaction is the rate-
limiting step and the major site for regulating homeostasis of cholesterol and bile 
acids. The gene encoding CYP7A1 was mapped to chromosome 8q11 and it spans 
about 10 kb and contains 6 exons (Nakamotoet al., 2006). Genetic variations in the 
CYP7A1 gene associated to disorders of cholesterol and bile acid metabolism have 
been studied extensively (Nakamoto et al., 2006). Asn233Ser of the CYP7A1 gene 
has been associated with variations in plasma LDL-cholesterol concentrations and is 
known to be involved in drug metabolism (Nakamoto et al., 2006).  
 
apoC-II 
Out of the six polymorphisms identified in this study, CETP I405V, ABCA1 I883M, 
SR-B1 A350A and CYP7A1 Asn233Ser have been discussed. The remaining two 
polymorphisms identified are located in the apoC-II gene which has been mapped on 
chromosome 19 in a gene cluster containing the apoE/C-I/C-I’/C-IV/C-II gene (Chen 
et al., 2007). It was interesting to note that the difference between mRNA expression 
of the control and experimental group was not statistically significant and the 
expression profile was minimal throughout the intervention phase of the study (Figure 
3.9).  It is obvious that both polymorphisms did not have any impact on niacin 
therapy. According to literature, the end result of apoC-II is increased levels of LDL-
C due to its influence on LPL (Vorgia et al., 1998; Chen et al., 2007), however in this 
study, the LDL-C levels remained low, and therefore, the low expression of apoC-II 
had no influence on this process. 
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The exact function of apoC-IV is unknown, although it appears to play a role in lipid 
metabolism. ApoC-II is synthesized primarily by the liver and is a 79 amino acid 
residue protein that plays a pivotal role in lipid metabolism as an activator for the 
lipoprotein lipase (LPL), and leads to increased levels of LDL-C (Chen et al., 2007). 
ApoC-II Leu96Arg has been associated with triglyceride concentrations in women.  
 
LCAT, apoC-I, apoA-1, apoE and apoB 
LCAT, apoC-I, apoA-1, apoE and apoB were investigated through the intervention 
phase of this study. These genes are known to play a key role in the RCT pathway and 
have been implicated in lipid metabolism (Tall, 1990). SNPs/polymorphisms which 
are known to influence the function and regulation of these genes, and which have 
also been reported to have an influential role in drug response, were selected and 
genotyped (Appendix II, Table A9), however, none of these SNPs were identified in 
the African green monkey.  
 
Gene expression analysis was conducted to evaluate if any of these genes had a direct 
impact on niacin response and RCT pathway. LCAT was expressed throughout the 
intervention phase of the study; however, no statistically significant differences were 
obtained even though the expression profile appeared to have decreased from the time 
niacin was maintained at a higher dose of 100 mg/kg (Figure 3.5). Although LCAT 
accentuates reverse cholesterol transport (RCT) from plasma to liver and induces 
cholesterol degradation, LCAT’s role in RCT and protection against atherosclerosis is 
the subject of on-going research (Brown et al., 2010). In the absence of LCAT, RCT 
can still continue (Brown et al., 2010). In this study, LCAT did not play a significant 
role in either niacin therapy or on the RCT pathway.  
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To attempt the evaluation of independent effects of apoC-I on RCT and niacin 
response, HpaI SNP was genotyped; however, it was not identified in our animal 
model. Gene expression analysis revealed less expression of apoC-I in the 
experimental group as compared to the controls, and a statistical significant difference 
with a p-value 0.04 was only observed at the 6
th
 time point (14.04.08) when treatment 
of niacin was maintained at 100 mg/kg (Figure 3.7). apoC-I is a constituent of 
triglyceride-rich lipoprotein, and high density lipoproteins whose importance in 
plasma lipoprotein metabolism is increasingly evident (Xu et al., 1999). Its function is 
to displace apoE from triglycerides-rich emulsions and lipoproteins (Gao et al., 2002). 
The fact that apoC-I mRNA expression appeared to have been down-regulated in 
experimental groups as compared to the control group, especially with statistically 
significant difference at time point 14.04.08, highlighted the fact that apoC-I might 
have carried out its function by displacing apoE which was also evident by its poor 
gene expression profile in Figure 3.12. 
 
ApoE is known to be an exchangeable protein that plays an important role in lipid 
metabolism, especially in the removal of atherogenic remnants of triglyceride-rich 
lipoproteins (Hixson et al., 1990). The presence of apoE allele e4 is known to be 
associated with the pathogenesis of peripheral and coronary artery disease and the e2 
allele is known to be protective from atherosclerosis. Both polymorphisms were 
genotyped, but not identified in the African green monkey. Due to its poor expression 
profile and the fact that it was not statistically significant, it is therefore clear that 
apoE had no effect on niacin response in the African green monkey (Figure 3.12). 
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Both apoA-1 and apoB are known to play an essential role in the RCT pathway. SNPs 
from apoA-1 (Msp1 and G75A) and apoB (T71I and 4311S) known to be involved in 
lipid metabolism and drug response were genotyped but were not identified in the 
African green monkey in this study. Gene expression analysis of both genes was very 
poor and statistically insignificant with apoB only expressed half way through the 
intervention study when niacin treatment was maintained at its highest dosage (Figure 
3.8 and Figure 3.10). Since apoB is a protein component of LDL particles and is 
known to be cleared from plasma mainly by binding to LDL receptors and subsequent 
internalization and degradation in the liver, it’s expression at the beginning of the 
intervention study would not have been expected, and our findings are in agreement 
with that, albeit not statistically significant. Due to niacin therapy, LDL-C level was 
reduced as indicated in chapter 2; apoB expression was expected to be less and was 
only observed towards washout period at the end of the study. Considering the fact 
that only a small sample size of healthy monkeys instead of diseased monkeys were 
used in this study, data generated would have been more significant if an access to a 
larger sample size was possible with baseline values depicting a diseased state.   
       
3.5 CONCLUSION 
This study suggests that a cascade of genes and the potential effect of polymorphisms 
located in these genes may be responsible for the regulation and function of RCT 
pathway and drug treatment response in the African green monkey 
. Considering that only six out of 22 cSNPs involved in human and rhesus RCT were 
identified in the African green monkey, it is possible that the outcome of this study 
may be due to yet to be identified genetic variation or those that are not present in 
multi-species but species specific to the African green monkey. Results may therefore 
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be associated with the experiment rather than possible genetic heterogeneity between 
treatment and control groups.  
 
Niacin treatment showed an effect on the expression level of CYP7A1 mRNA when a 
considerable change in the concentrations of HDL-C, LDL-C and apoA-1 were 
observed. This change may have been influenced by the presence of 
CYP7A1:Asn233Ser polymorphism which may have been involved in metabolising 
niacin and influencing the up-regulation of HDL-C synthesis in this animal model.    
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Chapter 4 
 
GENERAL DISCUSSION AND CONCLUSIONS 
 
 
 
4.3 DISCUSSION 
 
Lipid metabolism is a dynamic process that involves multiple pathways with both 
intracellular, and extracellular regulation and modulation. While the cross-talk and 
interactions among these pathways are essential to maintain lipid homeostasis, 
dysregulation of each pathway can contribute substantially to the development of 
cardiovascular diseases such as dyslipidemia and atherosclerosis. 
 
Low levels of HDL-C are a major independent risk factor for atherosclerotic 
cardiovascular disease and events. Epidemiological and interventional studies have 
clearly established the critical role of lipoprotein metabolism in atherosclerotic 
disease, in which risk increases with plasma levels of LDL-cholesterol and is 
inversely proportional to HDL-cholesterol (Duffy et al., 2006). The success of LDL-
cholesterol-lowering therapy has stimulated increased interest in HDL-cholesterol-
directed approaches, and several HDL-cholesterol-elevating drugs are currently 
available or under development (Carlson, 2005). Some of the most widely used HDL-
cholesterol-elevating drugs include statins (∼5–10% increase), fibrates (peroxisome 
proliferator-activated receptor α (PPARα) agonists; ∼5–20% increase), and nicotinic 
acid or niacin (∼15–35% increase) (Ohashi et al., 2005). Although existing drugs 
have modest effects on HDL-C levels, this area remains a major unmet medical need 
in cardiovascular medicine.  
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HDL metabolism is exceedingly complex, and the protective ability of HDL may 
relate to the flux of cholesterol through the RCT pathway, and to other aspects of 
HDL functionality. The actual mechanism by which HDL protects against 
atherosclerosis is likely multifactorial and not yet fully elucidated; however, there are 
several proposed major atheroprotective mechanisms of HDL. The most popular has 
been that HDL promotes and facilitates the process of reverse cholesterol transport 
(RCT), whereby excess macrophage cholesterol is effluxed to HDL and ultimately 
returned to the liver for excretion in the bile and feces (Duffy, 2006). However, 
several additional properties of HDL have been described over the last decade, 
including inhibition of LDL oxidation, inhibition of endothelial inflammation, 
promotion of endothelial nitric oxide production, promotion of prostacyclin 
bioavailability, and inhibition of platelet aggregation and coagulation (Khera et al., 
2011). The in vivo relevance of these mechanisms remains uncertain, but in concept 
many of these functions of HDL could contribute to reduction in atherosclerosis, 
increased vascular protection, and reductions in clinical events. 
 
It has been shown in both humans and nonhuman primates that low levels of HDL-C 
are an important and prevalent risk factor in the development of cardiovascular 
disease. Over the last decade, cholesterol-lowering therapy has been considered to be 
the central approach in the prevention of cardiovascular disease. Currently, niacin is 
considered to be the most potent available pharmacological agent for increasing HDL 
cholesterol. The mechanism by which niacin raises HDL-C levels is the topic of 
continued investigation. In vivo studies in humans suggest that the catabolic rate of 
apoA-I is slowed by niacin therapy (Carlson, 2005). Studies in hepatocytes in vitro 
have shown reduced uptake of HDL apoA-I after niacin treatment (Kamanna et al., 
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2008). The paradigm has been that in addition to indirect effects on HDL metabolism 
through reduction in triglycerides, niacin acts on an unknown pathway in the liver to 
slow HDL and apoA-I catabolism. The recent discovery of a niacin receptor, a G 
protein–coupled receptor known as HM74A (also known as GPR109A) (Shen et al., 
2009), has fueled tremendous new interest in the mechanisms of niacin action and the 
development of new compounds that act on this receptor. Intriguingly, activated 
macrophages express the niacin receptor, and niacin treatment of macrophages 
upregulates ABCA1 expression (Shen et al., 2009).  
 
Given the apparent similarities in lipoprotein cholesterol metabolism between human 
beings and nonhuman primates, niacin therapy may have the same effects on HDL 
metabolism of nonhuman primates. Nonhuman primates that have consumed an 
atherogenic diet for several years develop lesions that are comparable to those found 
in human beings. Amongst the nonhuman primates, the African green monkey has 
been recognised as a good model for the study of diet-induced atherosclerosis 
(Moghadasian et al., 2001). However, notwithstanding their closeness to humans, 
validity for their use as models for lipid-lowering drug interventions still has to be 
demonstrated. It is noteworthy that the Primate Unit of the Medical Research Council 
has already utilised the African green monkey in lipid-lowering research, with lipid 
modulating compounds such as CETP inhibitors.  A specific diet was not needed to 
induce the disease and the model responded with HDL-C increases. Besides, the diets 
that induce dyslipidaemia can only modulate LDL not HDL.  
 
The African green monkey is the most commonly used Old World primate in 
biomedical research, but, in many areas, the least well defined. In order to utilise this 
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species fully, there is a need to understand and define as much of its biology as 
possible. However, there is currently very little sequence data available for this 
species in the GenBank and in order to conduct genetic studies on the African green 
monkey, the need exists to rely on available human and rhesus macaque sequence. To 
further characterise the African green monkey as an animal model for atherosclerosis, 
human ortholog genes known to be linked to lipid metabolism were sequence and 
genotype in a case:control colony of the African green monkey. Since African green 
monkeys are closely related to humans both in evolutionary and genetic terms, shared 
ancestral polymorphisms (cSNPs) were prioritized and assessed if they had any effect 
on niacin treatment. It is a fact that SNPs, by their very nature, are uncommon and 
need only to be present in 1% of a population; and it is also known that most SNPs are 
not shared among species with the prime exceptions among primates being those that 
occur at CpG sites. Since these sites are frequently methylated, they are much more 
prone to de novo mutation and hence independent occurrence. 
 
The main objective of this study was therefore to make an original contribution to 
primatology by defining the molecular genetics of the African green monkey in 
relation to CHD. Data on the controlled pharmacological intervention linked to 
genetic determinants of lipid metabolism in the African green monkey are provided 
here for the first time. Since the African green monkey is closely related to humans 
both in evolutionary and genetic terms, shared ancestral polymorphisms known as 
coincident SNPs (cSNPs) were prioritized for this study. Furthermore, the application 
of bioinformatics with molecular techniques such as real-time PCR were used along 
with orthologous human reference sequence to identify for the first time in the African 
green monkey specific lipid metabolism candidate genes and cSNPs corresponding to 
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ancestral polymorphisms present in both humans and nonhuman primates, and 
preserved in both lineages.  
 
Results obtained from this study reflect the careful selection of biologically relevant 
candidate genes, and the effective conditioning of their putative effects upon known 
risk factors. The case-control design based on normolipidaemic African green 
monkeys is a critical element of the study and merits several comments. 
 
A literature search was conducted to look for previously reported genes and 
polymorphisms involved in lipid metabolism in humans. Ten “candidate genes” 
(CETP, ABCA1, CYP7A1, apoA-1, apoB, apoE, SR-B1, LCAT, apoCI and apoCII) 
were chosen based on their role in the reverse cholesterol transport process. Twenty 
two Single nucleotide polymorphisms (SNPs) were identified and subsequently 
genotyped in niacin treated cases and controls of the African green monkey.  
 
As a first step towards elucidating the effect of niacin on HDL-C, the possible 
involvement of these prioritised candidate genes and their polymorphisms were 
assessed biochemically by analysing known risk factors of coronary artery disease 
such as HDL-C and LDL-C, and also by analysing gene expression.  Eight healthy 
monkeys were selected and entered in this study. Four monkeys were treated with 
niacin at an escalating dosage (35, 70 and 100 mg/kg) and the other 4 were chosen as 
controls. Levels of HDL-C, LDL-C, TC, TG and apoA-1 were then measured at 
baseline and after every two weeks for four months up to a washout period.  Niacin 
treatment was associated with a considerable reduction in LDL-Cholesterol and a less 
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significant decline in Triglycerides. Niacin was associated with up-regulation of HDL 
synthesis, and associated increased apoA-1 levels.  
 
Out of the twenty two cSNPs genotyped, six were identified in the African green 
monkeys (I405V, I883M, Asn233Ser, cL96R, -62A>C and A350A). All six cSNPs 
are known to have a significant influential role in the regulation of reverse cholesterol 
transport and lipid-lowering drug therapy.   
 
Niacin consumption was associated with increased plasma HDL-C and apoA-1 as 
well as decreased plasma LDL-C and triglycerides (Figure 2.8). Gene expression 
analysis was correlated with biochemistry results by the association between a 
combination of cSNPs identified in the prioritized candidate genes, and plasma lipid 
levels in the African green monkey.  Niacin appeared to have minimal effect if any on 
gene expression of SRB1, CETP, ABCA1, LCAT, apoC-I, and apoC-II within the 
context of specific cSNPs identified. However, an interesting observation was made 
of CYP7A1 mRNA expression, especially at time point 17.03.08 (week 6) when a 
considerable change in the concentrations of HDL-C, LDL-C and apoA-1 were 
observed. It is apparent that niacin treatment had an effect on the expression level of 
CYP7A1 mRNA, especially at this time point when compared to the baseline. This 
change may have been influenced by the presence of CYP7A1:Asn233Ser 
polymorphism which may have been involved in metabolising niacin and influencing 
the up-regulation of HDL-C synthesis in this animal model.   
 
 
 
 
 
130 
 
This study provides for the first time data on a controlled pharmacological 
intervention linked to genetic determinants of lipid metabolism in the African green 
monkey model. 
  
However, there are also several limitations: 
1. The genome of the African green monkey has not yet been sequenced; 
therefore there is no available reference sequence. This limitation has made 
primer design of “candidate” genes used in this study more challenging. 
However, available reference sequences from human and rhesus monkeys 
were adopted and used as the template for primer design and for 
bioinformatics analysis. The rationale for this was the fact that nonhuman 
primates are closely related to humans, both in evolutionary and genetic terms.  
The human reference was used for the bulk of the genome colinearity and gene 
content analysis. The information was then projected to the rhesus to obtain a 
nucleotide level read out that is even closer to the African green monkey 
genomic sequence since they belong to the same family group, the Old World 
monkey.  
2. The African green monkeys of the MRC Primate Unit are genetically very 
similar. Since genotype variations were not expected, results obtained from 
genotyping SNPs were the same for both control and experimental groups. 
Identification of genotypes linked with a particular SNP was therefore not 
possible. To address this, four wild caught monkeys from a different animal 
centre (Potchefstroom) were included in the study. However, results obtained 
from these wild caught monkeys were similar to those obtained from the MRC 
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captive-bred monkey colony. Based on this information, associating the effect 
of niacin with the individual genotypes could not be achieved. 
3. Niacin therapy response was evaluated only on healthy monkeys since dietary 
interventions only modulate LDL.  There is no known primate model of 
spontaneously low HLD.  To induce advanced lesions atherosclerotic lesions 
in this animal model would have taken 3 to 4 years of feeding and atherogenic 
diet, and invasive techniques such as liver biopsies would have been required 
for gene expression analysis.  Since liver is the driving engine for cholesterol 
efflux and RCT pathway, a much more higher and positive gene expression 
would have been achieved if liver tissue was used instead of blood cells which 
were convenient for this study.  
4. Niacin is known to cause side effects when taken in high doses, due to ethical 
considerations and abiding to the National Guidelines for the Care and Use of 
Animals for Scientific Purposes escalation dose higher than 100 mg/kg was 
not recommended for this study.  
5. Relative scarcity in terms of availability for research, and high cost of the 
African green monkey are two factors that make a larger sample size difficult, 
therefore only eight monkeys were available for this study, hence poor gene 
expression profile were obtained and statistical significant values were 
difficult to achieve.  
 
However, several advantages were also identified: 
1. There was no need to induce disease or use a disease model. Ethically, this is 
considered as a refinement and promotes the concept of the ‘three Rs’ 
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(replacement, reduction and refinement) according to the National Guidelines 
for the Care and Use of Animals for Scientific Purposes.   
2. Due to the close evolutionary relationship between humans and the African 
green monkey, results obtained from this study can be extrapolated to humans, 
and this could make a contribution to the understanding of cardiovascular 
diseases.  
3. The study applies a number of original approaches to identifying candidate 
susceptibility genes for lipid metabolism. Furthermore, it is the first time that 
many genetic aspects have been defined in the African green monkey; 
therefore, this study does not only focus on human diseases, but animal 
diseases as well.  
4. The results have contributed to defining the molecular genetics of the African 
green monkey especially in the light that its genome sequence has not yet been 
mapped. 
 
Pharmacological therapy development through genetic studies has had a significant 
impact in clinical medicine. Pharmacogenetics and genetic testing have provided the 
experimental basis that has shown that the variability in a drug response is a function 
of an individual’s genetic makeup. Genetic polymorphisms can influence the response 
to medication through a number of mechanisms (Schmitz et al., 2003). It is 
noteworthy that this study provided further impetus for the development of niacin 
(nicotinic acid) in pharmacogenetic processes. However, it must be acknowledged 
that a large scale SNP discovery initiative should be undertaken for the African green 
monkey in order to have enough information to validate this species as a good model 
in pharmacogenomic studies. 
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Low HDL cholesterol levels are the most common lipid abnormality in patients with 
CAD, and are the primary lipid disorder in half of this population. Raising HDL levels 
has been difficult, and statins only moderately affect HDL, raising levels by 
approximately 5% to 10% (Schmitz et al., 2003). Niacin has a long-standing history 
as an effective lipid-altering therapeutic agent with well-established clinical benefits 
(Kamanna et al., 2008). In addition to its beneficial effects on standard lipoprotein 
levels, niacin has shown further benefits in patients with coronary artery disease by 
significantly increasing HDL and LDL particle size (Tavintharan et al., 2001). 
 
Niacin favourably alters all major lipid subfractions at pharmacologic doses. Alone or 
in combination, it promotes regression of coronary artery disease, decreases coronary 
events, stroke, and total mortality (Kamanna et al., 2008). Major recent progress in 
niacin is in four areas. Firstly, recent data indicate that it increases HDL and lowers 
triglycerides and LDL by mechanisms different from statins, fibrates, and bile-
sequestrants, providing a rationale for combination therapy to achieve synergistic 
effects for complete lipid goal achievement (Schmitz et al., 2003). Secondly, new data 
on an extended-release preparation of niacin taken once nightly indicates that it is as 
effective, and has greater tolerability than immediate-release niacin (Tavintharan et 
al., 2001). Thirdly, preliminary data with single tablet formulation extended-release 
niacin and an HMG CoA reductase inhibitor (lovastatin) shows it to be safe and very 
effective, especially for raising HDL. Finally, emerging evidence indicates that niacin 
can be used effectively and safely in patients with type 2 diabetes mellitus, who often 
have low HDL levels (Ganji et al., 2003). 
 
The focus of lipid-altering therapies has been largely on their abilities to lower LDL-C 
and triglyceride levels and raise HDL-C levels. This study demonstrates that in 
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addition to these effects, genetic determinants of lipid transport and metabolism may 
also provide additional significant benefit in nonhuman primates such as the African 
green monkey. Treatment with 100 mg/kg of niacin produced improvements in HDL-
C, and apoA-1 concentrations, and additionally resulted in significant reduction of 
39% in LDL-C. Even though most of the time points were not statistically significant, 
following just 18 weeks of treatment, niacin appeared to have upregulated SR-B1 
gene expression and downregulated the expression level of the other nine important 
genes involved in driving RCT pathway and lipid metabolism. Thus, niacin treatment 
at such low dose (100 mg/kg) appeared to cause different effects on lipoproteins, 
beyond the conventionally measured responses observed in serum lipid. It will be 
important to clarify whether this response is specific to blood cell gene expression or 
seen more generally in various tissues and in the liver in vivo, because it could suggest 
that regulation of these genes by niacin is tissue-dependent. It would have also been 
interesting to observe if a larger sample size and a higher dosage of niacin treatment 
would have had a better effect with significant statistical values, however due to side 
effects that may be caused by niacin when taken in high doses, escalation higher than 
100 mg/kg was not recommended. 
 
There is ample evidence in human studies that niacin acutely or chronically alters 
gene expression and cellular signalling in various tissues and cells. The underlying 
mechanism may involve signalling through the niacin-receptor, but there is substantial 
evidence that in vivo effects on gene expression may be mediated indirectly by 
changes in circulating lipid or hormone levels induced by niacin treatment (Kang et 
al., 2011). Future studies are warranted to elucidate these mechanisms, which would 
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contribute not only to the full understanding of niacin effects in human and nonhuman 
primates, but also to the discovery of novel pathways for gene regulation by lipids. 
 
The data obtained from this study indicated that niacin increased the accumulation of 
apoA-I, however, niacin did not affect the de novo synthesis of apoA-I and the mRNA 
expression of apoA-I, suggesting that niacin has no effect on apoA-I synthetic 
processes. Therefore it was hypothesized that niacin may influence the removal or 
reuptake of HDL by hepatocytes and this is supported by the findings of Zhang et al., 
2008. Niacin may have selectively inhibited the uptake of HDL-apoA-I but not HDL-
cholesterol esters. These findings suggest that niacin may increase the capacity of 
retained apoA-I to augment cholesterol efflux and reverse cholesterol transport 
pathway. Based on these data it was suggested that niacin inhibits the removal of 
HDL-apoA-I at the level of yet unidentified putative pathways, but not SR-B1-
mediated events, which is selective to HDL-cholesterol esters.  
 
 
The apoB content of the lipid profile can also differ substantially in response to 
interventions, because this measurement provides an estimate of atherogenic (non-
HDL) particle number (Ganji et al., 2003). ApoB is present at a fixed ratio of one 
molecule per particle, and does not exchange between particles as the other 
apolipoproteins do. In addition, therapies that result in lowering apoB levels can 
translate into lower risk of cardiovascular disease (Ganji et al., 2003). In this study, 
apoB expression was suppressed and only observed towards the end of the treatment 
phase. It is speculated that niacin-mediated inhibition of TG synthesis may have 
decreased the lipidation of apoB and translocation through endoplasmic reticular (ER) 
membrane which may have led to increased intracellular apoB degradation. Increased 
 
 
 
 
136 
 
hepatocyte apoB degradation by niacin would then decrease the number of VLDL and 
their catabolic products, LDL particles, which explains the lower apoB and LDL 
concentrations observed clinically after niacin treatment in the African green monkey. 
In 1999 Jin and colleagues also reported similar findings of niacin to have shown to 
accelerate intracellular apoB degradation by inhibiting TG synthesis in human HepG2 
cells (Kang et al., 2011); however, this matter has been extensively discussed in 
literature and is still being debated. 
 
 
4.4 CONCLUSION 
 
The purpose of this study was not to add new knowledge to lipidology, genetics or the 
mechanism of action of niacin, but to produce new insights into medical primatology 
by defining the African green monkey biology aspects that have not been studied 
before. The main objective of the study was to investigate the influence of genetic 
variation in a therapeutic intervention using niacin as a lipid-lowering drug in the 
African green monkey. Niacin was only used as a tool to effect changes in lipid 
metabolism, not as an object of the research. 
 
The following objectives were achieved: 
1. Ten “candidate genes” linked to lipid metabolism were identified and screened 
for coincident single-nucleotide polymorphisms (cSNPs) known to be 
involved in reverse cholesterol transport pathway, six of which were identified 
for the first time in the African green monkey. 
2. A four months pharmacological intervention study using niacin as the drug-
lowering agent was conducted. Niacin successfully increased plasma HDL and 
over a period of 12 weeks during the treatment phase. 
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3. The expression profile of the selected “candidate” genes.  
 
 
A combined use of biochemistry and molecular biology offered the basis for 
systematic dissection of the effects of niacin treatment in a nonhuman primate model 
closely related to humans. The characterisation of individual polymorphisms 
implicated in lipid metabolism is challenging, but essential for optimising the 
regulation and function of the RCT pathway.  It is noteworthy that linkage 
disequilibrium may exist between genes involved in RCT; therefore the influence of 
one cSNP on the effect of drug therapy may be inter-depended within different genes 
in the African green monkey as it is in humans.  
 
The results in this study showed that niacin treatment is associated with considerable 
reduction in LDL-C and up-regulation of HDL synthesis. Niacin treatment influenced 
the expression of genes involved in RCT pathway and the genetic variation in these 
genes could further modify the anti-atherosclerotic effect of niacin in the African 
green monkey. However, the findings of this study based on the biochemical and 
expression differences would be more attributed to the treatment, and not the presence 
of response modifying cSNPs (at the loci tested, as well as at other untested loci), 
especially due to the genetic identical nature of this colony. 
 
 
 
 
 
 
 
 
 
138 
 
5. REFERENCES 
 
 
Agellon LB, Drover VA, Cheema SK, Gbaguidi GF and Walsh A. (2002) Dietary 
cholesterol fails to stimulate the human cholesterol 7ahydroxylase gene 
(CYP7A1) in transgenic mice. J. Biol. Chem.  277:20131-20134.  
 
Akinboboye O, Idris O, Akinkugbe O. (2003)  Trends in coronary artery disease 
and associated risk factors in sub-Saharan Africans. J Hum Hypert. 17:381–387. 
 
Assmann G, Antonio M, Gotto Jr MD. (2004) HLD Cholesterol and protective 
Factors in Artherosclerosis. Circulation 109:8-14. 
 
Asztalos BF, Schaefer EJ, Horvath KV, Yamashita S, Miller M, Franceschini G, 
Calebresi L. (2007) Role of LCAT in HDL remodeling: investigation of LCAT            
deficiency states. J Lipid Res. 248:592-599. 
 
Austin MA, Hokanson JE, Edwards KL. (1998) Hypertriglyceridemia as a 
cardiovascular risk factor. Am J Cardiol. 81:7B-12B. 
 
Bansal A, van de Boom D, Kammerer S, Honsisch C, Adam G, Cantor CR, Kleyn P, 
Braun A. (2002) Association testing by DNA pooling : An effective initial screen. 
Contributed by Charls R.Cantor. 99: 16871-16874. 
  
Barr B, Russ EM, Eder HA. (1951) Protein lipid relationship in human plasma. II. 
In atherosclerosis and related conditions. AM J Med. 11:480-493. 
 
 
 
 
139 
 
 
Barzilai N, Atzmon G, Schechter C, Schaefer EJ, Cupples AL, Lipton R, Cheng S, 
Shuldiner AR. (2003) Unique lipoprotein phenotype and genotype associated with 
exceptional longevity. JAMA. 15(15):2030-2040. 
 
Benadé AJS, Fincham JE, Smuts CM, Weight MJ, van Jaarsveld PJ, Kruger M. 
(1997) Vervet monkeys and whole-food diets for studying the effects of dietary 
lipids on plasma lipoprotein metabolism and atherosclerosis. Asia Pacific J Clin 
Nutr. 6(1): 17-21. 
 
Benn M, Stene MC, Nordestgaard BG, Jensen GB, Steffensen R, Tybjaerg-Hansen A. 
(2008 ) Common and rare alleles in apolipoprotein B contribute to plasma levels 
of low-density lipoprotein cholesterol in the general population. J Clin Endocrinol 
Metab. 93(3):1038-1045. 
 
Bentzen J, JorgensenT, Fenger M. (2002) The effect of six polymorphisms in the 
Apolipoprotein B gene on parameters of lipid metabolism in a Danish 
population. Clin Genet. 61:126-134. 
 
Berard AM, Foger B, Remaley A. (2003) High plasma HDL concentrations 
associated with enhanced atherosclerosis in transgenic mice overexpressing 
lecithin-cholesteryl acyltransferase. Nat Med. 3:744-749. 
 
Bernstein D. (2002) Cardiovascular and metabolic alterations in mice lacking ß1 
and ß2-adrenergic receptors. Trends Cardio Med. 12:287-294. 
 
 
 
 
140 
 
Boekholdt SM, Kuivenhoven JA, Hovingh GK, Jukema JW, Kastelein JJ, van Tol A. 
(2004) CETP gene variation: relation to lipid parameters and cardiovascular 
risk. Curr Opin Lipidol. 15(4):393-398. 
 
Brewer HB. (2011) The evolving role of HDL in the treatment of high-risk 
patients with cardiovascular disease. J. Clin. Endocrinol Metab. 96(5):1246-1257. 
 
Brewer HB, Remaley AT, Neufeld EB, Joyce C. (2004) Regulation of plasma high-
density lipoprotein levels by the ABCA1 transporter and the emerging role of 
high –density lipoprotein in the treatment of cardiovascular disease. Arterioscler 
Thromb Vasc Biol. 24:1755-1760. 
 
Brousseau ME. (2004) Common Variation in Genes Involved in HDL Metabolism 
Influences Coronary Heart Disease Risk at the Population Level. Rev.Endoc. 
Metab.Dis. 5:343–349. 
 
Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, 
Mancuso JP, Rader DJ. (2004) Effects of an inhibitor of cholesteryl ester transfer 
protein on HDL cholesterol. N Engl J Med.  8 (15):1505-1515. 
 
Brown BG, Zhao XQ, Chait A. (2001) Simvastatin and niacin, antioxidant 
vitamins, or the combination for the prevention of coronary disease. N Engl J 
Med. 345:1583-1592. 
 
 
 
 
 
141 
 
Brown WV, Brewer HB, Rader DJ, Schaefer EJ. (2010) HDL as a treatment target. 
J Clin Lipidol. 4:5-16. 
 
Bruce C, Sharp DS, Tall AR. (1998) Relationship of HDL and coronary heart 
disease to a common amino acid polymorphism in the cholesteryl ester transfer 
protein in men with and without hypertriglyceridemia. J Lipid Res. 39:1071-1078. 
 
Brunzell JD, Sniderman AD, Albers JJ, Kwiternovich PO. (1984) Apoliproteins B 
and A-I and coronary heart disease in humans. Arterioscler. 4:79-83. 
 
Bullock BC, Lehner ND, Clarkson TB, Feldner MA, Wagner WD, Lofland HB. 
(1975) Comparative primate atherosclerosis. I. Tissue cholesterol concentration 
and pathologic anatomy. Exp Mol Pathol. 22(2):151-75. 
 
Calvo D, Gomez-Coronado D, Lasuncion MA, Vega MA. (1997) CLA-1 is an 85-kD 
plasma membrane glycoprotein that acts as a high-affinity receptor for both 
native (HDL, LDL, and VLDL) and modified (OxLDL and AcLDL) lipoproteins. 
Arterioscler Thromb Vasc Biol. 17:2341–9. 
 
Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L Prineas RJ. (1986) Fifteen 
year mortality in coronary Drug  Project patients: long-term benefit with niacin.  
J Am Coll  Cardiol.  8:1245-55. 
 
 
 
 
 
142 
 
Capuzzi DM, Guyton JR, Morgan JM, Goldberg AC, Kreisberg RA, Brusco OA, 
Brody J. (1998) Efficacy and safety of an extended-release niacin (niaspan): A 
long-term study. Am J Cardiol.  82:74U-81U. 
 
Carlson LA. (2005) Nicotinic acid: the broad-spectrum lipid drug. J Intern Med 
258:94-114. 
 
Carroll RM and Rudel LL. (1981) Dietary fat and cholesterol effects on lipoprotein 
cholesterol ester formation via lecithin:cholesterol acyltransferase (LCAT) in 
vervet monkeys. Federation Proc. 40:1695. 
 
Carlquist JF, Muhlestein JB, Horne BD, Hart NI, Bair TL, Molhuizen HOF, Anderson 
JL. (2003) The cholesteryl ester transfer protein Taq1B gene polymorphism 
predicts clinical benefit of statin theraphy in patients with significant coronary 
artery disease. Am Heart J. 146:1007-1014. 
 
Castelli WP, Anderson K, Wilson PW, Levy D. (1992) Lipids and risk of coronary 
heart disease: The Framingham Study. Ann Epidemiol. 2:23-28. 
 
Chan L, Chang BH, LiaoW, Oka K, Lau PP. (2000) Apolipoprotein B: from 
editosome to proteasome. Recent Prog Horm Res. 55:93-125. 
 
Charpentier MJE, Widdig G, Alberts SC. (2007) Inbreeding Depression in Non-
Human Primates: A Historical Review of Methods Used and Empirical Data. 
Am. J. Prim. 69:1370-1386. 
 
 
 
 
143 
 
Chen C, Cao Y, Hu W. (2007) Apolipoprotein C-II promoter T→A substitution at 
position 190 affects on the transcription of the gene and its relationship to 
hyperlipemia. Biochem Biophys comm. 354:62-65. 
 
Choi Bg, Vilahur G, Viles-Gonzalez JF, Badimon JJ. (2006) The role of High-
Density Lipoprotein Cholesterol in Atherothrombosis. J Med. 73(4): 690-701. 
 
Clee SM, Zwinderman AH, Engert JC. (2001) Common genetic variations in 
ABCA1 is associated with altered lipoprotein levels and a modified risk for 
coronary artery disease. Circulation 103:1198-1205. 
 
Cohen JC, Cali JJ, Jelinek DF, Mehrabian M, Sparkes RS, Lusis AJ, Russell DW, 
Hobbs HH. (1992) Cloning of the human cholesterol 7-alpha-hydroxylase gene 
(CYP7) and localization to chromosome 8q11-q12. Genomics. 14:153–161. 
 
Connelly MA, Williams DL. (2004) Scavenger receptor BI: a scavenger receptor 
with a mission to transport high density lipoprotein lipids. Curr Opin Lipidol. 
15:287–295. 
 
Dachet C, Poirier O, Cambien F, Chapman J, Rouis M. (2000) New Functional 
Promoter Polymorphism, CETP/-629, in Cholesteryl Ester Transfer Protein 
(CETP) Gene Related to CETP Mass and High Density Lipoprotein Cholesterol 
Levels Role of Sp1/Sp3 in Transpotational Regulation. Thromb Vasc Biol. 20:507-
515. 
 
 
 
 
144 
 
Davignon J, Cohn JS. (1996) Triglycerides: a risk for coronary heart disease. 
Atheroscler. 124:S57-S64. 
 
de Beer MC, Ji a, Jahangiri A, Vaughan AM, de Beer FC, van der Westhuyzen DR, 
Webb NR. (2011) ATP binding cassette G1-dependent cholesterol efflux during 
inflammation. J. Lip. Res. 52:345-353. 
 
Deeb SS, Peng R. (2000) The C-514T polymorohism in the human hepatic lipase 
gene promoter diminishes its activity. J Lipid Res. 41(1):155-158. 
 
de la Llera-Moya M, Rothblat GH, Connelly MA, Kellner-Weibel G, Sakr SW, 
Phillips MC, Williams DL. (1999) Scavenger receptor BI (SR-BI) mediates free 
cholesterol flux independently of HDL tethering to the cell surface. J Lipid Res. 
40:575-580. 
 
Duffy D, Rader DJ. (2006) Emerging therapies targeting high-density lipoprotein 
metabolism and cholesterol transport. Circulation 113:1140-1150. 
 
Ebeling M, Küng E, See A, Broger C, Steiner G, Berrera M, Heckel T, Iniguez L, 
Albert T, Schmucki R, Biller H, Singer T, Certa U. (2011) Genome-based analysis 
of the nonhuman primate Macaca fascicularis as a model for drug safety 
assessment. Gen. Res. 21:1-11. 
 
Eley RM. (1989) Know your monkeys: a guide to the primates of Kenya. National 
Meuseums of Kenya. Ed. L.A. Bennun. 4:1-24. 
 
 
 
 
145 
 
Eley RM. (1992) Reproductive biology of the vervet monkey (Cercopithecus 
aethiops) : a review. Utafiti (National Museums of Kenya) 4(1):33. 
 
Escher G, Krozowski Z,  Croft KD, Dmitri Sviridov D. (2003) Expression of Sterol 
27-Hydroxylase (CYP27A1) Enhances Cholesterol Efflux. J Biol Chem. 
278:11015-11019. 
 
Fernandez ML, Wood RJ. (2008) Guinea Pigs as Models for Human Cholesterol 
and Lipoprotein Metabolism.  Sourcebook of Models for Biomedical Research P.M. 
Conn ed. @ Humans Press Inc., Totowa, NJ 201-212 
 
Fielding CJ, Fielding PE. (1995) Molecular physiology of reverse cholesterol 
transport. J Lipid Res. 36:211-228. 
 
Fielding CJ, Shore VG, Fielding PE. (1973) Lecithin:cholesterol acyltransferase: 
effects of substrate competition on enzyme activity. Biochem. Biophys. Acta. 
270:513-518. 
 
Fincham JE, Benade AJS, Kruger M, Smuts CM, Gobregts E, Charlton DO, 
Kritchevsky D. (1998) Atherosclerosis: Aortic lipid changes induced by diets 
suggest diffuse disease with focal severity in primates that model human 
atheromas. Nutrition 14:17-22. 
 
Fincham JE, Faber M, Weight MJ, Labadarios D, Taljaard JJ, Steytler JG, Jacobs P, 
Kritchevsky D. (1987) Diets realistic for Westernized people significantly effect 
 
 
 
 
146 
 
lipoproteins, calcium, zinc, vitamin C, E, B6 and haematology in Vervet 
monkeys. Atheroscler. 66:191-203. 
 
Fojo SS, Law SW, Brewer HB. (1984) Human apolipoprotein C-II: Complete 
nucleic acid sequence of preapolipoprotein C-II. Proc. Natl. Acad. Sci USA. 
81:6354-6357. 
 
Franceschini G, Sirtori CR, Capurso A, Weisgraber KH, Mahley RW. (1980) A-
IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with 
significant lipoprotein modifications and without clinical atherosclerosis in an 
Italian family. J Clin Invest. 66:892–900. 
 
Freeman DJ, Samani NJ, Wilson V, McMahon AD, Braund PS, Cheng S, Caslake MJ, 
Packard CJ, Gaffney D. (2003) A polymorphism of the cholesteryl ester transfer 
protein gene predicts cardiovascular events in non-smokers in the West of 
Scotland Coronary Prevention Study. Eur. Heart J. 24:1833-1842. 
 
Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Huttunen JK, Kaitaniemi P, 
Koskinen P, Manninen V. (1987) Helsinki Heart study:primary prevention trial 
with gemfibrozol in middle aged-men with dyslipidemia: safety of treatment, 
changes in risk factors, and the incident of coronary heart disease. N Engl J Med. 
317:1237-1245. 
 
 
 
 
 
147 
 
Frikke-Schmidt R, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A. (2004) Genetic 
variation in ABC transporter A1 contributes to HDL cholesterol in the general 
population. J Clin Invest. 114 (9):1343-53. 
 
Funke H. (1997) Genetic determinants of high density lipoprotein. Curr Opinion 
Lipidol. 8(3): 64-70 
 
Futterman LG and Louis Lemberg L. (2005) Apo A-I Milano. Am J Crit Care 
14:244-247. 
 
Ganji SH, Vaijinath S. Kamanna VS, Kashyap ML (2003)  Niacin and cholesterol: 
role in cardiovascular disease J Nutr. Biochem. 14(6):298-305. 
 
Gao L, Gabriel C, Lavoie T, Ye SQ. (2002) An improved RSP method to detect 
HpaI polymorphism in the apolipoprotein C-I gene promoter. BMC Med Gen. 3: 
13-16. 
 
Gbaguidi GF and Agellon LB. (2004) The inhibition of the human cholesterol 7a-
hydroxylase gene (CYP7A1) promoter by fibrates in cultured cells is mediated 
via the liver x receptor a and peroxisome proliferator-activated receptor 
aheterodimer. Nucl Acids Res. 32(3):1113-1121. 
 
Gelissen IC, Harris M, Rye K, Quinn C, Brown AJ, Kockx M, Cartland S, 
Packianathan M, Kritharides L, Jessup W. (2006) ABCA1 and ABCG1 synergize to 
mediate cholesterol export to ApoA-1. Arterioscler Thromb Vasc Biol. 26:534-540. 
 
 
 
 
148 
 
Glomset JA. (1973) The metabolic role of lecithin: cholesterol acyltransferase: 
perspectives from pathology. Adv Lipid Res. 11:1-65. 
 
Gordon DJ, Rifkind BM. (1989) High-density lipoprotein: the clinical implications 
of recent studies. N Engl JMed. 321:1311-1316. 
 
The South African National Standard for the Care and Use of Animals for 
Scientific Purposes (The South African Bureau of Standards, SANS 10386:2008) 
 
Guyton JR, Blazing MA, Hagar J. (2000) Extended-release niacin vs gemfibrozil 
for the treatment of low levels of high density lipoprotein cholesterol. Arch Intern 
Med. 160:1177-1184. 
 
Hansen PS, Gerdes LU, Klausen IC, Gregersen N, FaergemanO. (1993) 
Polymorphisms in the apolipoprotein B-100 gene contributes to normal variation 
in plasma lipids in 464 Danish men born in 1948. Hum Genet. 91:45-50. 
 
Harris A, Davies M, Redwood D, Leatham A, Siddons H. (1970) Aetiology of 
chronic heart block. A clinico-pathological correlation in 65 patients. British 
Heart J. 31:206. 
 
Hixson JE, Vernier DT. (1990) Restriction isotyping of human apolipoprotein E 
by gene amplification and cleavage with HhaI. J. Lip. Res. 31:545-548. 
 
 
 
 
 
149 
 
Hodgkinson A, Eyre-Walker A. (2010) The genomic distribution and local context 
of coincident SNPs in human and chimpanzee. Genome Biol Evol. 2:547–57. 
 
Hodgkinson A, Ladoukakis E, Eyre-Walker A. (2009) Cryptic variation in the 
human mutation rate. PLoS Biol. 7(2):226-232. 
 
Houghton SG, Cockerill FR. (2006) Real-time PCR: Overview and applications. 
Surgery 139(1):1-5. 
 
Hovingh GK, Hutten BA, Holleboom AG, Peterson W, Rol P, Stalenhoef A, 
Zwinderman AH, de Groot E, Kastelein JJ, Kuivenhoven JA. (2005) Compromised 
LCAT function is associated with increased atherosclerosis. Circulation 112:879-
884. 
 
Hu Y, Wang Q, Ma X, Li X, Liu X, Xiao J, Liao D, Xiang J, Tang C. (2010) TGF-β1 
up-regulates expression of ABCA1, ABCG1 and SR-B1 through liver X receptor 
α signalling pathway in THP-1 macrophage-derived foam cells. J. 
Atheroscler.Throb. 17:493-502. 
 
Humphries S. (1988) DNA polymorphisms of the apolipoprotein genes-their use in 
the investigation of the genetic component of hyperlipidaemia and 
atherosclerosis. Atheroscler. 72:89-108. 
 
Iida R, Yasuda T, Tsubota E, Takatsuka H, Masuyama M, Matsuki T, Kishi K. (2003) 
M-LP, Mpv17-like protein, has a peroxisomal membrane targeting signal 
 
 
 
 
150 
 
comprising a transmembrane domain and a positively charged loop and up-
regulates expression of the manganese superoxide dismutase gene. J Biol Chem. 
278(8):6301-6306. 
 
Imoisili OE and Summer AE. (2009) Preventing diabetes and atherosclerosis in 
sub-saharan Africa: Should the metabolic syndrome have a role? Current Cardio 
risk reports 3:161-167. 
 
Insull W, Toth PP, Superko HR, Thakkar RB, Krause S, Jiang P, Parreno RA and 
Padley RJ. (2010) Combination of niacin extended-release and simvastatin results 
in a less atherogenic lipid profile than atorvastatin monotherapy. Vasc Health 
Risk Manag. 6:1065–1075.  
 
Isaacs A, Sayed-Tabatabaei FA, Hofman A, Oostra BA, Klungel OH, Maitland-
Vander AH, Stricker BH, Witteman JC, van Duijin CM. (2007) The cholesteryl ester 
transfer protein 1405V polymorphism is associated with increased high-density 
lipoprotein levels and decrease risk of myocardial infarction: the Rotterdam 
study. Eur. J. Cardiovasc. Prev. Rehabil. 14:419-421. 
 
Ji Y, Wang N, Ramakrishnan R, Sehayek E, Huszar D, Breslow JL, Tall AR. (1999) 
Hepatic scavenger receptor BI promotes rapid clearance of high density 
lipoprotein free cholesterol and its transport into bile. J Biol Chem. 274:398-402. 
 
 
 
 
 
151 
 
Joyce CW, Amar MJ, Lambert G. (2002) The ATP binding cassette transporter A1 
(ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and 
apoE-knockout mice. Proc Natl Acad Sci USA. 99:407-412. 
 
Joyce C, Freeman L, Brewer HB, Santamarina-Fojo S. (2003) Study of ABCA1 
function in transgenic mice. Arterioscler. Thromb. Vasc. Biol. 23:965-971. 
 
Jukema JW, Bruschke AVG, van Boven AJ, (2004) Effects of lipid lowering by 
Pravastatin in Ischaemic Disease (LIPID) study group. N Engl J Med. 350:1495-
1504. 
 
Kamanna VS, Kashyap ML. (2008) Mechanism of action of niacin. Am J Cardiol. 
101(8A):20B-26B. 
 
Kane JP. (1983) Apolipoprotein B: structural and metabolic heterogeneity. Annu 
Rev Physiol. 45:637-650. 
 
Kang I, Kim S, Youn JH. (2011) Effects of nicotinic acid on gene expression: 
potential mechanisms and implications for wanted and unwanted effects of the 
lipid-lowering drug. J. Clin. Endocrinol Metab. 96(10):3048-3055. 
 
Kannel WB, Gordon T, Castelli WP. (1981) Role of lipids and lipoprotein functions 
in assessing atherogenesis. The Framingham Study. Prog Lipid Res. 20:339-348. 
 
Kapur NK, Ashen D, Blumenthal RS. (2008) High density lipoprotein cholesterol: 
 
 
 
 
152 
 
an evolving target of therapy in the management of cardiovascular disease. Vasc 
Health and Risk Manag. 4:39-57. 
 
Karathanasis SK. (1985) Apolipoprotein multigene family: tandem organization of 
human apolipoprotein Al, CIII, and AIV genes. Proc Natl Acad Sci.USA 82:6374-
6378. 
 
Kashyap ML. (1998) Mechanistic studies of high density lipoproteins. Am J 
Cardiol.  82:42U-48U. 
 
Kawano M, Miida T, Fielding CJ, Fielding PE. (1993) Quantitation of pre beta-
HDL-dependent and nonspecific components of the total efflux of cellular 
cholesterol and phospholipid. Biochem. 32:5025-5028. 
 
Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French 
BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ. 
(2011) Cholesterol efflux capacity, high-density lipoprotein function, and 
atherosclerosis. N. Engl. J. Med. 364:127-135. 
 
Klos KLE, Sing CF, Boerwinkle E, Hamon SC, Rea TJ, Clark A, Fornage M, Hixon 
JE. (2006) Consistent effect of genes involved in reverse cholesterol transport on 
plasma lipid and apolipoprotein levels in CARDIA participants. Arterioscler 
Thromb Vasc Biol. 26:1828-1836. 
 
 
 
 
 
153 
 
Koch W, Ehrenhaft A, Griesser K, Pfeufer A, Muller J, Schomig A, Kastrati A. 
(2002) TaqMan systems for genotyping of disease-related polymorphisms present 
in the gene encoding apolipoprotein E. Clin Chem Lab Med. 40(11):1123-1131. 
 
Koch W, Mehilli J, Schomig A, Kastrati A. (2004) Apolipoprotein E gene 
polymorphisms and thrombosis and restenosis after coronary artery stening. 
J.Lip.Res. 45:2221-2226. 
 
Kozarsky KF, Donahee MH, Rigotti A, Iqbal SN, Edelman ER, Krieger M. (1997) 
Overexpression of the HDL receptor SR-BI alters plasma HDL and bile 
cholesterol levels. Nature 387:414–417. 
 
KusumY, Scanu AM,. McGill HC, Wissler RW. (1993) Atherosclerosis in a rhesus 
monkey with genetic hypercholesterolemia and elevated plasma (Lp(a).  
Atherosclerosis, 99(2):165–174. 
 
Kyriakou T, Hodgkinson C, Ponterfract DE, Iyengar S, Howell WM, Wong Y, 
Erikson P, Ye S. (2005) Genotypic Effect of the -565>T Polymorphism in the 
ABCA1 Gene Promoon ABCA1 Expression and Severity of the Atherosclerosis. 
Arterioscler Thromb Vasc Biol. 25:418-423. 
 
Laasko M, Lehto S, Penttila I, Pyorala K. (1993) Lipids and lipoproteins predicting 
coronary heart disease mortality and morbidity in patients with non-insulin-
dependent diabetes. Circulation 88:1421-1430. 
 
 
 
 
 
154 
 
Lewis GF, Rader DJ. (2005) New insights into the regulation of HDL metabolism 
and reverse cholesterol transport. Circ Res. 96(12):1221-1232. 
 
Lloyd DB, Reynolds JM, Cronan MT, Williams SP, Lira ME, Wood LS, Knight DR, 
Thompson JF. (2005) Novel variants in human and monkey CETP. Bioch Biophy 
Acta. 1737:69-75. 
 
Malhi RS, Trask
 
J S, Shattuck
 
M, Johnson J, Chakraborty
 
D, Kanthaswamy S, 
Ramakrishnan U, Smith
 
DG. (2011) Genotyping single nucleotide polymorphisms 
(SNPs) across species in Old World Monkeys.  American J. Prim. 73:1031-1040. 
 
Maniatis T, Fritsch F, Sambrook J. (1989) Molecular cloning: a laboratory manual. 
Cold Spring Harbour Laboratory, Cold Spring Harbour, New York.  
 
McKenney J. (2004) New perspectives on the use of niacin in the treatment of 
lipid disorders. Arch Intern Med. 164:697-705. 
 
Miller NE, Hammett F, Saltissi S. (1981) Relation of angiographically defined 
coronary artery disease to plasma lipoprotein subfractions and apolipoproteins. 
BMJ 282:1741-1744. 
 
Moghadasian MH, Frohlich JJ, McManus BM. (2001) Advances in experimental 
dyslipidemia and atherosclerosis. Lab Invest. 81:1173-1183. 
 
 
 
 
 
155 
 
Morabia A,  Cayanis E,  Costanza C,  Ross BM.,  Flaherty MS,  Alvin GB,  Das K,  
and  Gilliam TC. (2003) Association of extreme blood Lipid phenotypic variation 
with 11 reverse cholesterol transport genes and 10 non-genetic cardiovascular 
disease risk factors. Hum Mol Genet. 12:2733–2743. 
 
Moreel JF, Roizes G, Evans AE, Arveiler D, Cambou JP, Souriau C, Parra HJ, 
Desmarais E, Fruchart JC, Ducimetiere P. (1992) The polymorphism ApoB/4311 in 
patients withmyocardial infarction and controls: the ECTIM Study. Hum Genet. 
89:169-175. 
 
Murray CJL, Lopez AD. (1997) Global mortality, disability, and the contribution 
of risk factors: Global Burden of Disease Study. Lancelet. 34:1436-1442. 
 
Nakamoto K, Wang S, Jenison RD, Guo GL, Klaassen CD, Wan YY, Zhong X. 
(2006) Linkage disequilibrium blocks, haplotype structure, and htSNPs of 
human CYP7A1 gene. BMC Genet. 7:29-41. 
 
Navab M, Anannthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, 
vahabzadeh K, Hama S,Hough G, Kamranpour N, Berliner JA, Lusis AJ, Fogelman 
AM. (2004) The oxidation hypothesis of atherogenesis: the role of oxidised 
phospholipids and HDL. J Lipid Res. 45:993-1007. 
 
Nichols AV and Smith L. (1965) Effect of very low-density lipoproteins on lipid 
transfer in incubated serum. J. Lipid Res. 6:206-210. 
 
 
 
 
 
156 
 
Ohashi R, Mu H, Wang X, Yao Q, Chen C. (2005) Reverse cholesterol transport 
and cholesterol efflux in atherosclerosis. Q J Med. 98:845-856. 
  
Okumura K, Matsui H, Kamiya H, Saburi Y, Hayashi K, Hayakawa T. (2002) 
Differential effect of two common polymorphisms in the cholesteryl ester 
transfer protein gene on low-density lipoprotein particle size. Atheroscler.  
161(2):425-431. 
 
Ordovas JM, Civeira F, Genest J Jr, Craig S, Robbins AH, Meade T, Pocovi M, 
Frossard PM, Masharani U, Wilson PWF, Salem DN, Ward RH, Schaefer EJ. (1991) 
Restriction fragment length polymorphisms of the apolipoprotein AI,CIII,AIV 
gene locus: Relationships with lipids, apolipoproteins and premature coronary 
artery disease. Atheroscler. 87:75-86. 
 
Ordovas JM, Cupples LA, Corella D. (2000) Association of cholesteryl ester 
transfer protein-Taq1B polymorphism with variations in lipoprotein subclasses 
and coronary heart disease risk: the Framingham study. Arterioscler Thromb 
Vasc Biol; 20(5):1323-1329. 
 
Oram JF, Lawn RM, Garvin MR. (2000) ABCA1 is the cAMP-inducible 
apolipoprotein receptor that mediates cholesterol secretion from macrophages. J 
Biol Chem. 275:34508-345511. 
 
Osgood D, Corella D, Demissie S, Cupples LA, Wilson PW, Meigs JB. (2003) 
Genetic variation at the scavenger receptor class B type 1 gene locus determines 
 
 
 
 
157 
 
plasma lipoprotein concentrations and  particle size and interacts with type 
diabetes: the Framingham study. J Clin Endocrinol Metab. 88:2869-2879. 
 
Pagani F, Sidoli A, Giudici GA, Barenghi L, Vergani C, Baralle FE. (1990) Human 
apolipoprotein AI promoter polymorphism: Association with 
hyperalphalipoproteinemia. J Lipid Res. 31:1371-1377. 
 
Pronczuk  A, Patton GM, Stephan ZF, Hayes KC.(1991) Species variation in the 
atherogenic profile of monkeys: relationship between dietary fats, lipoproteins, 
and platelet aggregation. Lipids 26:213–222. 
 
Rader DJ. (2003) Regulation of reverse cholesterol transport and clinical 
implications. Am J Cardiol. 92:42-49. 
 
Rader DJ, Jaye M. (2000) Endothilial lipase:a new mwmber of the triglyceride  
lipase gene family. Curr Opin Lipidol. 11:141-147. 
 
Rader DJ. (2009) Lecithin:Cholesterol Acyltransferase and atherosclerosis. 
Another high density lipoprotein story that doesn’t quite follow the script. 
Circulation 120:549-552. 
 
Ren X, Sivashanmugam A, Chen B, Li C, Yang Y, Neville T, Hoyt D, Jerome WG, l 
Sparks D, Li Q, Wang J. (2006) NMR structural studies of human apolipoprotein 
A-I at the lipid-free and HDL-associated states: A progress report.  Funct Struc 
Biol. 1:65-93. 
 
 
 
 
158 
 
Rigotti A, Trigatti BL, Penman M, Rayburn H, Herz J, Krieger M. (1997) A targeted 
mutated gene in the murine gene encoding a high-density lipoprotein (HDL) 
receptor scavenger receptor class B type 1 reveals its key role in HDL 
metabolism. Proc Nat  Acad Sci USA 94:12610-2615. 
 
Roberts R, Stewart AF, Wells GA, Williams KA, Kavaslar N, McPherson R. (2007) 
Identifying genes for coronary artery disease: An idea whose time has come. Can 
J Cardiol. Suppl A:7A-15A. 
 
Rubic T,  Trottmann M and  Lorenz RL.  (2004) Stimulation of CD36 and the key 
effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid 
cells by niacin. Biochem Pharm. 67(3):411-419. 
 
Ruotolo G, Ericsson CG, Tettamanti C, Karpe F, Grip L, Svane B, Nilsson J, de Faire 
U, Hamsten A. (1998) Treatment effects on serum lipoprotein lipids, 
apolipoproteins and low density lipoprotein particle size and relationships of 
lipoprotein variables to progression of coronary artery disease in the Bezafibrate 
Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol. 
32:1648–1656. 
 
Schmitz G, Langmann T. (2006) Pharmacogenomics of cholesterol-Lowering 
therapy. Vasc. Pharmac. 44:75-89. 
 
 
 
 
 
159 
 
Segrest JP, Li L, Anantharamaiah GM, Harvey SC, Liadaki KN, Zannis V. (2000) 
Structure and function of apolipoprotein A-I and high-density lipoprotein. Curr 
Opin Lipidol. 11:105–115.  
 
Seguret-Mace S Latta-Mahieu M, Castro G, Luc G, Fruchart Jc, Rubin E. (1996) 
Potential gene therapy for lecithine-cholesterol acyltransferase (LCAT)-deficient 
and hyphoalphaproteinemic patients with adenovirus-mediated transfer of 
human LCAT gene. Circulation 94:2177-2184. 
 
Seier JV. (1986) Breeding Vervet monkeys (Cercopithecus pygerethrus) in a closed 
environment. J Med Primatol. 15:339-349.  
 
Shah PK and Chyu K. (2005) Apolipoprotein A-I mimetic peptides: potential role 
in atherosclerosis management. TCM 15(8):291-296. 
 
Shamekh R, Linden EH, Newcomb JD, Tigno XT, Jen KC, Pellizzon MA, Hansen 
BC (2011) Endogenous and diet-induced hypercholesterolemia in nonhuman 
primates: effects of age, adiposity, and diabetes on lipoprotein profiles. Metabol. 
Clin. Exp. 60:1165-1177. 
 
Silver DL, Tall AR. (2001) The cellular biology of scavenger receptor class B type 
1. Curr Opin Lipidol.  12:497-504. 
 
Sing CF, Stengard JH, Kardia SL. (2003) Genes, environment and coronary artery 
disease. Arterioscler Thromb Vasc Biol. 23:1190-1196. 
 
 
 
 
160 
 
Sliwa K, Wilkinson D, Hansen C, Ntyintyane L, Tibazarwa K, Becker A, Stewart S. 
(2008) Spectrum of heart disease and risk factors in a black urban population in 
South Africa (the Heart of Soweto Study):a cohort study. Lancet  371:915-922. 
 
Smart EJ, Ying Y, Donzell WC, Anderson RG. (1996) A role for caveolin in 
transport of cholesterol from endoplasmic reticulum to plasma membrane. J Biol 
Chem. 271:29427–35. 
 
Stampfer MJ, Sacks FM, SaMni S, Willett WC, Hennekens CH. (1991) A 
prospective study of cholesterol, apolipoproteins, and the risk of myocardial 
infarction. N Engl J Med. 325:373-381. 
 
Stein O, Stein Y. (1999) Atheroprotective mechanisms of HDL. Atheroscler. 
144:285–301.  
 
Suckling KE, Jackson B. (1993) Animal models of human lipid metabolism. Prog 
Lipid Res. 32(1):1-24. 
 
Sweetnam PM, Bolton CH, Yarnell JW. (1994) Association of the HDL2 HDL3 
cholesterol subfractions with the development of ischemic heart disease in British 
men. The caerphilly and speedwell collaborative heart disease studies. 
Circulation  90:769-774. 
 
Tall AR. (1990) Plasma-high density lipoproteins: metabolism and relationship to 
atherosclerosis. J Clin Invest  86:379-384. 
 
 
 
 
161 
 
Tall AR. (1998) An overview of reverse cholesterol transport. Eur Heart J. Suppl 
19A:A31-35. 
Tall AR, Jiang X, Luo Y, Silver D. (2000) Lipid transfer proteins, HDL 
metabolism, and atherogenesis. Thromb Vasc Biol. 20:1185-1188. 
 
Tall AR, Jiang XC, Luo Y and  Silver D. (2000) Arteriosclerosis, Thrombosis, and 
Vascular Biology. Am Heart Ass. Learn Live. Arterioscler. Thromb. Vasc. Biol. 
20:1185-1188. 
 
Tall AR, t Yvan-Charvet L, Terasaka N, Pagler T, Wang N. (2008) HDL, ABC 
transporters, and cholesterol efflux: Implications for the treatment of 
atherosclerosis. Cell Metab. 7(5):365-375. 
 
Tavintharan S, Kashyap ML. (2001) The benefits of niacin in atherosclerosis. Curr 
Atheroscler Rep. 3(1):74-82. 
 
Toth PP. (2003) Reverse cholesterol transport: high density lipoprotein’s 
magnificent mile. Curr Atheroscler Rep. 5(5):386-393. 
 
Quinet E, Tall A, Ramakrishnan R, Rudel L. (1991) Plasma lipid transfer protein as 
a determinant of the atherogenicity of monkey plasma lipoproteins. J Clin Invest. 
87:1559-66. 
 
 
 
 
 
162 
 
Vaisman BL, Lambert G, Amar M. (2001) ABCA1 overexpression leads to 
hyperalphalipoproteinemia and increased biliary cholesterol excretion in 
transgenic mice. J Clin Invest. 108:303-309. 
 
van der Steeg WA, Holme I, Boekholdt SM. (2008) High-density lipoprotein 
cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: 
Significance for cardiovascular risk: The IDEAL and EPIC-Norfolk studies. J 
Am Coll Cardiol. 51:634–642. 
 
Van Eck M, Pennings M, Hoekstra M, Out R, Van Berkel TJ. (2005) Scavenger 
receptor BI and ATP-binding cassette transporter A1 in reverse cholesterol 
transport and atherosclerosis. Curr Opin Lipidol. 16:307–315. 
 
Van Eck M, Pennings M, Hoekstra M, Out R, Van Berkel TJ. (2006) Macrophage 
ATP-binding cassette transporter A1 overexpression inhibits atherosclerotic 
lesion progression in low-density lipoprotein receptor knockout mice. 
Arterioscler. Thromb. Vasc. Biol. 26:929-934. 
 
Vergani C, Lucchi T, Caloni M, Ceconi I, Calabresi C, Scurati S, Arosio B. (2006) 
I405V polymorphism of the cholesteryl ester transfer protein (CETP) gene in 
young and very old people. Arch Gerontol Geriat. 43:213-221. 
 
Vergeer M, Holleboom AG, Kastelein JJP, Kuivenhoven JA. (2010) The HDL 
hypothesis: does high-density lipoprotein protect from atherosclerosis? J. Lip. 
Res. 51:2058-2073. 
 
 
 
 
163 
 
Vilahur G, Padro T, Badimon L. (2011) Atherosclerosis and Thrombosis: Insights 
from Large Animal Models. J Biomed Biotechnol. 2011:1-12. 
 
von Eckardstein A, Nofer JR, Assmann G. (2000) Acceleration of reverse        
cholesterol transport. Curr Opin Cardiol. 15:348-354. 
 
von Eckardstein A, Nofer J-R, Assmann G. (2001) High density lipoproteins    and 
arteriosclerosis: Role of cholesterol efflux and reverse cholesterol transport. 
Arterioscler Thromb Vasc Biol. 21:13-27.  
 
von Eckardstein A, Rohrer L. (2006) Transendothelial lipoprotein transport and 
regulation of endothelial permeability and integrity by lipoproteins. Curr Opin 
Lipidol. 20(3):197-205. 
 
Vorgia P, Zannis VI, Kardassis DA. (1998) Short proximal promoter and distal 
hepatic control region-1 (HCR-1) contribute to the liver specificity of the human 
apolipoprotein C-II gene. J. Biol. Chem. 273:17810-17816. 
 
Wang J, Burnett JR, Near S, Young K, Zinman B, Hanley AJG, Connely PW, Harris 
SB, Hegele RA. (2000) Common and Rare ABCA1 Variants Affecting plasma 
HDL Cholesterol. Arterioscler Thromb Vasc Biol. 20:1983-1989. 
 
Weight MJ, Benade AJS, Lombard CJ, Fincham JE, Marais M, Dando B, Seier JV, 
Kritchevsky D. (1988) Low density lipoprotein kinetics in African Green monkeys 
showing variable cholesterolaemic responses to diets realistic for westernized 
 
 
 
 
164 
 
people. Atheroscler. 73(1):1-11. 
 
William DL, Connelly MA, Temel RE. (1999) Scavenger receptor B1 and 
cholesterol trafficking. Curr Opin Lipidol. 10:329-339. 
 
Wilson PWF, Schaefer EJ, Larson MG, Ordovas JM. (1996) Apolipoprotein E 
alleles and risk of coronary heart disease. Arterioscler Thromb Vasc Biol. 16: 
1250-1255. 
 
Xu Y, Berglund L, Ramakrishnan R, Mayeux R, Ngai C, Holleran S, Tycko B, Leff T, 
Shachter NS. (1999) A common Hpai RFLP of apolipoprotein C-I increases gene 
transcription and exhibits an ethnically distinct pattern of linkage disequilibrium 
with the alleles of apolipoprotein E. J Lipid Res. 40:50-58. 
 
Xu CF, Nanjee MN, Savill J, Talmud PJ, Angelico F, Del Ben M, Antonini R, 
Mazzarella B, Miller N,  Humphries SE. (1990) Variation at the apolipoprotein 
(apo) AI-CIII-AIV gene cluster and apo B gene loci is associated with lipoprotein 
and apolipoprotein levels in Italian children. Am J Hum Genet. 47:429-439. 
 
Yamakawa-Kobayashi K, Yanagi H, Yu Y, Endo K, Arinami T, Hamaguchi H. 
(2004) Associations between serum high-density lipoprotein cholesterol or 
apolipoprotein AI levels and common genetic variants of the ABCA1 gene in 
Japanese school-aged children. Metabolism. 53(2):182-186. 
 
 
 
 
 
165 
 
Yamashita S, Hirano K, Sakai N, Matsuzawa Y. (2000) Molecular biology and 
pathophysiological aspects of plasma cholesteryl ester transfer protein. Biochim 
Biophys Acta. 1529 (1-3):257-275. 
 
Yim BT and Chong PH. (2003) Niacin ER and Lovastatin Treatment of 
Hypercholesterolemia and mixed Dyslipidemia. Ann Pharmacother. 37:106-115. 
 
Yin W,  Carballo-Jane E, David G. McLaren  DG, Mendoza VH, Gagen K, 
Geoghagen NS, McNamara LS, Gorski  JN, Eiermann GJ,  Petrov A,  Wolff M, Tong 
X, Wilsie LC, Akiyama TE,  Chen J, Thankappan A,  Xue J, Ping X,  Andrews G,  
Wickham LA, Gai CL, Tu T, Kulick Aa, Donnelly M, Voroni GO, RosaR, Curniskey 
A, Bekkari K, Mitnaul LJ, Puig O, Chen F, Raubertas R, Wong PH, Hansen BC, 
Koblan KS, Roddy TP,  Hubbard BK, Strack AM. (2011) Plasma lipid profiling 
across species for the identification of optimal animal models of human 
dyslipidemia. J. Lipid Res. 52 (12):2111-2135. 
 
Zwart KY, Clee SM, Zwinderman AH. (2002) ABCA1 regulatory variants 
influence coronary artery disease independent of effects on plasma lipid levels. 
Clin Genet. 61:115-125. 
 
 
 
 
 
 
 
 
 
 
166 
 
 
 
APPENDIX I: BIOCHEMISTRY ANALYSIS 
 
 
 
1. Analyses performed at PathCare Pathology Laboratories  
 
1.1 Plasma cholesterol:     
 
CHOL reagent is used to measure cholesterol concentration by a timed-endpoint 
method. In the reaction, cholesterol esterase (CE) hydrolyzes cholesterol esters to free 
cholesterol and fatty acids. Free cholesterol is oxidized to cholestene-3-one and 
hydrogen peroxide by cholesterol oxidase (CO). Peroxidase catalyzes the reaction of 
hydrogen peroxide with 4-aminoantipyrine (4-AAP) and phenol to produce a coloured 
quinoneimine product (SYNCHRON LX Systems Manual, 2000). 
 
 
1.2 HDL-cholesterol: 
       
Two point calibration colorimetric end point. SYNCHRON Systems HDL Cholesterol 
(HDLD) Reagent, when used in conjunction with SYNCHRON Systems Lipid 
calibrator, is intended for the quantitative determination of HDL cholesterol in the 
high density lipoprotein (HDL) fraction of serum or plasma on SYNCHRON systems 
(SYNCHRON LX Systems Manual, 2000). 
 
1.3 Triglycerides:   
  
Triglycerides GPO reagent is used to measure the triglycerides concentration by a 
timed endpoint method. 
 T
riglycerides in the sample are hydrolyzed to glycerol and 
free fatty acids by the action of lipase. A sequence of three coupled enzymatic steps 
using glycerol kinase (GK), glycerophosphate oxidase (GPO), and horseradish 
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peroxidase (HPO) causes the oxidative coupling of 3,5-dichloro-2-
hydroxybenzenesulfonic acid (DHBS) with 4-aminoantipyrine to form a red 
quinoneimine dye (SYNCHRON LX Systems Manual, 2000). 
 
1.4 LDL-cholesterol:    
     
The liquid, ready-to-use SYNCHRON® Systems Direct LDL Cholesterol reagent is a 
homogeneous assay that eliminates off-line pretreatment and centrifugation steps. The 
method depends on the properties of a unique detergent, which solubilizes only the 
non-LDL lipoprotein particles and releases cholesterol to react with cholesterol 
esterase and cholesterol oxidase to produce a non-color forming product. A second 
detergent solubilizes the remaining LDL particles and a chromogenic coupler allows 
for colour formation (SYNCHRON LX Systems Manual, 2000).
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2. FIGURES AND RAW DATA TABLES 
 
Table A1: Total cholesterol (mmol/L), values during treatment phase highlighted: means (yellow), SD (green)  
      and P-value (pink)  
 
Treatment No. 04.02.08 18.02.08 03.03.08 17.03.08 31.03.08 14.04.08 29.04.08 12.05.08 26.05.08 09.06.08 23.06.08 
Group 1 795 8.00 6.80 6.70 7.50 7.80 8.30 8.10 6.60 7.00 6.70 4.20 
Niacin 322 4.50 4.80 5.6 8.10 7.30 7.30 7.00 6.30 5.40 3.80 3.20 
 339 4.50 5.20 5.2 5.20 5.70 7.10 5.70 7.40 5.90 4.70 4.80 
 77 4.70 4.90 4.5 6.30 7.90 6.00 6.50 4.90 5.20 4.40 6.00 
 Mean 5.43 5.43 5.50 6.78 7.18 7.18 5.66 6.30 5.88 4.90 4.55 
 SD 1.72 0.93 0.92 1.29 1.02 0.94 1.00 1.04 0.81 1.26 1.17 
Group 2 108 4.70 6.30 6.0 5.4 5.1 5.20 5.60 4.90 4.60 4.80 4.80 
Control 243 6.00 6.90 7.2 7.4 5.9 6.20 6.30 5.50 5.50 5.40 5.50 
 215 5.20 5.00 4.7 5.5 4.7 5.40 5.60 5.70 5.70 5.80 5.10 
 97 3.70 3.90 4.0 4.0 4.1 4.00 4.20 4.00 4.40 4.30 3.70 
 Mean 4.90 5.53 5.48 5.58 4.95 5.20 5.43 5.03 5.05 5.08 4.78 
 SD 0.96 1.34 1.42 1.40 0.75 0.91 0.88 0.76 0.65 0.66 0.77 
p-value  0.62 0.91 0.98 0.25 0.01 0.02 0.08 0.10 0.16 0.82 0.76 
 
 
Table A2: HDL-cholesterol (mmol/L), values during treatment phase highlighted: means (yellow), SD (green)  
      and P-value (pink)  
 
Treatment No. 04.02.08 18.02.08 03.03.08 17.03.08 31.03.08 14.04.08 29.04.08 12.05.08 26.05.08 09.06.08 23.06.08 
Group 1 795 3.50 3.10 3.60 5.00 5.40 5.00 5.10 3.80 4.20 3.10 2.00 
Niacin 322 1.80 2.70 3.3 4.70 4.60 4.10 3.90 3.40 3.30 1.90 1.50 
 339 2.00 2.80 2.7 3.40 3.60 4.00 3.30 4.30 3.60 2.50 2.40 
 77 1.40 2.10 2.2 3.50 3.50 2.70 3.20 2.50 2.80 1.80 3.20 
 Mean 2.18 2.90 3.45 4.85 4.28 3.95 3.88 3.50 3.48 2.33 2.28 
 SD 0.92 0.42 0.62 0.82 0.90 0.95 0.87 0.76 0.59 0.60 0.72 
Group 2 108 1.00 1.60 1.60 1.40 1.70 1.60 1.80 1.80 1.90 1.80 1.50 
Control 243 2.80 3.00 3.10 3.50 2.80 3.50 3.70 3.00 3.00 3.00 3.00 
 215 2.70 2.40 2.20 2.40 2.20 2.50 2.60 3.00 3.20 3.40 2.90 
 97 1.60 2.00 2.00 2.00 2.10 2.20 2.30 2.20 2.40 2.30 2.00 
 Mean 2.03 2.25 2.23 2.33 2.20 2.45 2.60 2.50 2.63 2.63 2.35 
 SD 0.87 0.60 0.63 0.88 0.45 0.79 0.80 0.60 0.59 0.71 0.72 
p-value  0.82 0.29 0.15 0.02 0.01 0.05 0.08 0.09 0.09 0.54 0.89 
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Table A3: LDL-cholesterol (mmol/L), values during treatment phase highlighted: means (yellow), SD (green)  
      and P-value (pink)  
 
Treatment No. 04.02.08 18.02.08 03.03.08 17.03.08 31.03.08 14.04.08 29.04.08 12.05.08 26.05.08 09.06.08 23.06.08 
Group 1 795 3.1 2.00 1.60 1.40 1.00 1.80 1.50 1.40 1.20 2.10 1.90 
Niacin 322 2.10 1.40 0.60 1.60 1.10 2.50 2.10 1.80 1.60 1.50 1.30 
 339 2.10 1.70 1.50 0.90 1.60 2.10 1.00 2.20 1.50 1.90 1.80 
 77 3.00 2.20 1.40 2.00 3.70 3.00 2.70 1.80 2.00 2.40 2.20 
 Mean 2.58 1.83 1.28 1.48 1.85 2.35 1.83 1.80 1.58 1.98 1.80 
 SD 0.55 0.35 0.46 0.46 1.26 0.52 0.74 0.33 0.33 0.38 0.37 
Group 2 108 3.60 4.20 3.70 3.60 3.10 3.20 3.40 2.70 2.60 3.00 3.00 
Control 243 2.80 3.00 3.20 3.00 2.50 2.50 2.20 2.10 2.00 1.90 2.00 
 215 2.00 2.30 1.90 2.50 2.10 2.60 2.50 2.30 2.10 2.30 1.80 
 97 1.40 1.20 1.30 1.40 1.40 1.40 1.40 1.30 1.40 1.50 1.20 
 Mean 2.45 2.68 2.53 2.63 2.28 2.43 2.38 2.10 2.03 2.18 2.00 
 SD 0.96 1.26 1.11 0.93 0.71 0.75 0.83 0.59 0.49 0.64 0.75 
p-value  0.41 0.14 0.05 0.04 0.29 0.44 0.17 0.21 0.09 0.31 0.31 
 
 
Table A4: triglycerides (mmol/L), values during treatment phase highlighted: means (yellow), SD (green)  
      and P-value (pink)  
 
Treatment No. 04.02.08 18.02.08 03.03.08 17.03.08 31.03.08 14.04.08 29.04.08 12.05.08 26.05.08 09.06.08 23.06.08 
Group 1 795 0.8 0.59 0.56 0.41 0.91 1.9 1.33 0.46 0.54 1.09 0.79 
Niacin 322 0.42 0.71 0.42 0.53 0.69 2.04 0.44 0.97 0.81 0.63 1.94 
 339 0.33 0.37 0.19 0.40 0.31 0.87 0.65 0.48 0.42 0.26 0.43 
 77 1.22 0.92 1.51 0.92 2.21 2.66 1.75 1.87 1.56 0.74 0.92 
 Mean 0.69 0.65 0.49 0.47 1.03 1.87 1.04 0.95 0.83 0.68 1.02 
 SD 0.40 0.23 0.58 0.24 0.82 0.74 0.61 0.66 0.51 0.34 0.65 
Group 2 108 0.41 0.78 0.61 0.36 0.87 1.72 0.36 1.24 0.57 0.63 0.44 
Control 243 0.37 0.96 0.90 0.80 1.58 0.60 0.36 0.66 0.82 0.54 0.39 
 215 1.21 1.77 0.76 0.64 1.85 1.13 0.81 0.56 0.69 0.62 0.95 
 97 1.69 1.19 0.7 0.75 1.56 0.79 1.34 1.08 0.64 0.88 1.24 
 Mean 0.92 1.18 0.74 0.64 1.47 1.06 0.72 0.89 0.68 0.67 0.76 
 SD 0.64 0.43 0.12 0.20 0.42 0.49 0.47 0.33 0.11 0.15 0.41 
p-value  0.57 0.09 0.82 0.66 0.40 0.13 0.43 0.88 0.60 0.95 0.52 
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Table A5: apoA-1 (gl/L), values during treatment phase highlighted: means (yellow), SD (green) and P-value (pink)  
 
Treatment No. 04.02.08 18.02.08 03.03.08 17.03.08 31.03.08 14.04.08 29.04.08 12.05.08 26.05.08 09.06.08 23.06.08 
Group 1 795 2.6 2.69 2.65 2.20 3.24 3.18 3.61 3.32 1.60 3.20 2.93 
Niacin 322 1.80 2.41 2.63 2.36 3.07 3.14 2.96 3.00 2.68 2.01 1.74 
 339 1.78 2.14 2.28 1.93 2.51 3.05 2.87 3.32 3.09 2.35 2.19 
 77 1.73 2.12 2.36 2.49 3.27 2.66 2.84 2.77 2.65 2.05 2.00 
 Mean 1.99 2.34 2.64 2.28 3.02 2.64 3.07 3.10 2.51 2.40 2.22 
 SD 0.37 0.27 0.19 0.24 0.35 0.24 0.36 0.27 0.64 0.55 0.51 
Group 2 108 1.14 1.77 1.63 1.25 1.62 1.61 1.74 1.8 1.91 1.75 1.62 
Control 243 2.02 2.49 2.22 2.22 2.29 2.55 2.53 2.52 2.58 2.5 2.46 
 215 2.09 1.95 1.84 1.59 1.92 2.17 2.13 2.42 2.42 2.51 2.14 
 97 1.92 2.17 2.01 1.66 2.14 2.14 2.3 2.28 2.36 2.32 2.12 
 Mean 1.79 2.10 1.93 1.68 1.99 2.12 2.18 2.26 2.32 2.27 2.09 
 SD 0.44 0.31 0.25 0.40 0.29 0.39 0.33 0.32 0.29 0.36 0.35 
p-value  0.56 0.28 0.01 0.06 0.00 0.01 0.01 0.00 0.62 0.70 0.69 
 
 
Table A6: Bodyweight (Kg) 
 
Treatment No. 04.02.08 18.02.08 03.03.08 17.03.08 31.03.08 14.04.08 29.04.08 12.05.08 26.05.08 09.06.08 23.06.08 
Group 1 795 3.56 3.38 3.30 3.20 3.17 3.12 3.18 3.28 3.29 3.38 3.62 
Niacin 322 3.02 3.04 2.96 2.90 2.94 2.96 2.88 2.92 3.04 3.12 3.25 
 339 3.29 3.35 3.28 3.20 3.05 3.12 2.90 3.10 3.33 3.40 3.42 
 77 3.30 3.37 3.28 3.17 3.26 3.28 3.46 3.40 3.53 3.50 3.71 
 Mean 3.29 3.29 3.21 3.12 3.11 3.12 3.11 3.18 3.30 3.35 3.50 
 SD 0.22 0.16 0.16 0.15 0.14 0.13 0.27 0.21 0.20 0.16 0.21 
Group 2 108 3.55 3.75 3.75 3.72 3.78 3.7 3.78 3.81 3.76 3.84 3.76 
Control 243 3.84 3.93 3.93 3.9 3.90 3.84 3.9 3.95 4.0 4.00 4.05 
 215 3.68 3.66 3.66 3.58 3.63 3.52 3.58 3.6 3.64 3.58 3.6 
 97 3.50 3.55 3.62 3.54 3.74 3.7 3.82 3.4 3.9 4.02 4.06 
 Mean 3.64 3.72 3.74 3.69 3.76 3.69 3.77 3.69 3.83 3.86 3.87 
 SD 0.15 0.16 0.14 0.16 0.11 0.13 0.14 0.24 0.16 0.20 0.23 
p-value  0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.05 
 
 
 
 
171 
 
3. LOG SHEET SAMPLE 
 
Check list: behaviour 
 
0 = absent, not observed, not displayed   + = weak, poor, minimal 
 
++ = normal, average, moderate  +++ = excessive, strong 
 
Date Exp. 
No. 
Monkey 
No. 
alert fearful aggressive confused depressed vocalization 
         
         
         
         
         
 
 
Check list: motor function and activity 
 
0 = absent, not observed, not displayed   + = weak, poor, minimal 
 
++ = normal, average, moderate  +++ = excessive, strong 
 
Date Exp. 
No. 
Monkey 
No. 
posture coordination locomotion active Use of exercise cage 
        
        
        
        
        
 
 
Check list: physical 
 
0 = absent, not observed, not displayed      + = weak, poor, minimal 
 
++ = normal, average, moderate     +++ = excessive, strong, copious 
 
disc. = discoloured  d = discharge        s = soft  w = watery 
 
 
Date Exp. No. Monkey 
No. 
coat feces urine eyes nose ears genitals rectal 
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APPENDIX II: MOLECULAR BIOLOGY 
 
 
 1. PURIFICATION OF GENOMIC DNA FROM WHOLE BLOOD 
 
AxyPrep Blood Genomic DNA Miniprep Kit was used to extract DNA from whole 
blood of the African green monkeys. This method is based on the efficient release of 
genomic DNA from anti-coagulated whole blood by a special cell lysis and 
heme/protein precipitation buffer (Buffer AP1) coupled with the selective adsorption 
of the genomic DNA to a special AxyPrep column. The purified genomic DNA is 
eluted in a low-salt Tris buffer containing 0.5 mM EDTA, which enhances DNA 
solubility and helps to protect the high molecular weight DNA against subsequent 
nuclease degradation. Blood genomic DNA is directly isolated from the white blood 
cell (WBC) component of whole blood, without the need to remove the red blood 
cells (RBCs) in advance. 
 
The procedure was performed according to the manufacturer’s instructions. For 
maintaining the integrity and reactivity of the genomic DNA, particularly in PCR, the 
purified genomic DNA was eluted and stored in low-salt Tris buffer containing 0.5-1 
mM EDTA. 
 
2. SPECTROPHOTOMETRIC QUANTIFICATION OF NUCLEIC ACIDS  
 (Maniatis, 1989) 
 
DNA quantification was performed at the wavelengths of 260 nm and 280 nm. The 
reading at 260nm allows calculation of the concentration of nucleic acid in the 
sample, where an OD of 1 corresponds to approximately 50u g/mL for double-
stranded DNA. The ratio between the readings at 260nm and 280 nm (OD260/OD280) 
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provides an estimate of the purity of the nucleic acid, with pure preparations of DNA 
giving OD260/OD280 values of 1.8. Accurate quantification of the amount of nucleic 
acid is only possible if there is no protein or phenol contamination of the sample.   
 
 
3. SEQUENCING REACTIONS 
Sequencing was performed using the ABI PRISM Big Dye Terminator Cycle 
Sequencing Ready Reaction Kit (Perkin-Elmer).  Approximately 200 ng DNA was 
used per reaction, and half shots were used (Table A7) 
 
Table A7:   Sequencing reactions, as described in the Perkin-Elmer ABI PRISM 
Big Dye Terminator Cycle Sequencing Ready Reaction Kit manual 
(1998). 
Reagent Quantity 
Terminator Ready Reaction mix (dye terminators, dUTP
*
, dCTP, dATP, 
dITP
**
, AmpliTaq DNA polymerase, rTth pyrophoshatase, magnesium 
chloride, buffer) 
8 L 
DNA template 100 - 200 ng 
-21 M13 Primer (forward)  1.6 pmol 
dddH2O x 
Total volume 10 L 
 
*
 dITP is used in place of dGTP to minimise band compressions 
**
 dUTP is used in place of dTTP as it results in a better T patterns because dUTP 
improves     incorporation of T terminators. 
The reagents were vortexed then spun briefly before the PCR sequencing reaction was 
started (Table A8). 
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Table A8: Sequencing reaction using a Hybaid PCR Sprint Thermal Cycler 
 Temperature Time 
Denaturing 96
o
C 10 seconds 
Annealing 50
o
C 5 seconds 
Extension 60
o
C 4 minutes 
Repeat this sequence for 25 cycles, then store at 4
o
C before purification  
 
 
4. ELECTROPHORESIS 
4.1 AGAROSE GEL ELECTROPHORESIS 
Agarose gels were made by dissolving the appropriate amount of agarose in 1X TBE 
buffer (12.1 g Tris, 0.37 g EDTA and 5.14 g Boric acid made up to 1L and adjusted to 
pH 8.4 with 1 M HCl) for 0.8 - 1.5 % gels, depending on the fragment size loaded 
onto the gel.  Genomic DNA was run on 0.8% gels, whereas 1.5% gels were used 
with fragment sizes of 190 bp and 550 bp. The agarose gels were electrophoresed in 
TBE buffer at a voltage range between 80 - 120 V for approximately 1 hour.  Samples 
were loaded into the wells with 10% tracking dye.  0.5 g/mL ethidium bromide 
added to the gels to allow visualisation of DNA when it was placed on a UV 
transilluminator, which caused any DNA bound to ethidium bromide to fluoresce.    
 
Tracking Dye III (Maniatis et al, 1993) 
0.25% bromophenol blue 
0.25% xylene cyanol FF 
30% glycerol in ddH2O 
Store at 4
o
C 
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Markers 
A 100bp DNA Ladder from Promega was used. This Ladder is ready for 5´ end-
labeling with radioisotopes using T4 Polynucleotide Kinase, allowing visualization by 
autoradiography. A Blue/Orange Loading Dye, 6X, was provided. 
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5. DNA SEQUENCES 
 
 
Table A9(1): Oligonucleotide sequences of SNPs 
  
Gene SNP Id Forward 5’ Reverse 3’ Position Allele 
1/2 
Temp 
(ºC) 
ABCA1 Ile883Met GAGAAGAGCCACCC 
TGGTTCCAACCAGA 
AGAGGAT 
AAGGCAGGAGACA 
TCGCTT 
Exon 18 (H7) 
 
T/C 54 
 E1172D   GAGCAGTTCTGATGC 
TGGCCTGGGCAGCGA 
CCACGA 
TCTGCACCTCTCCTC 
CTCTG 
Exon 24  
(R1 )  
C/G 51 
 V771M  CAAGTGAGTGCTTGG 
GATTG 
TGCTTTTATTCAGGG 
ACTCCA 
 
Exon 16  
(5th trm) 
G/A 55 
  V825I  CCCATGCACTGCAGA 
GATTC 
GCAAATTCAAATTTC 
TCCAGG 
Exon 17 
 (6th trm) 
G/A 46 
  R219K GTATTTTTGCAAGGCT 
ACCAGTTACATTTGACAA 
GATTGGCTTCAGGAT 
GTCCATGTTGGAA                                                     
Exon 7 (Ex  
N-term loop) 
C/T 54 
CETP I405V  
 
CTCACCATGGGCATTT 
GATTGCAGAGCAGCTC 
CGACTCC 
AATGGGAAGCTCTGT 
CAGCCTCGGCCACCC
AG 
Exon 14  
 
A/G 56 
 Ala373Pro CACAGCAAATTTGGTT 
TCTCTCC 
CCCAGTCTATCCAAG 
ACTAC 
Exon 12   C/G 54 
CYP7A1 Asn233Ser  TCAGTTCTGAGATGCT 
TTCCC 
AGTCTTTCCAGCCCTG 
GTAG 
Exon 3 C/T 54 
 A-278C  AGTCCACAGGTATCAG 
AAGTG 
CCCCAGGTCCGAATG
TTAAG 
Promoter T/G 53 
apoE Cys112Arg 
(E4) 
TAAGCTTGGCACGGCT 
GTCCAAGGACCCGGCT 
GGGCGCGGACAT 
AGAGAATTCGCCCCG
GCCTGGTACACCGCTT
CGCGGATGGCGCTGA 
Exon 3 T/C 52 
 Arg158Cys 
(E2) 
CCCGGCTGGGCGCGGA 
CAT 
CGCTTCGCGGATGGC
GCTGA 
Exon 3 C/T 52 
apoA-1 Msp1  ACTCTTAAGTT 
CCACATTGCCAGGAC 
CTCTGTGCCCTTCTC 
CTCAC 
5’UTR G/A 56 
 G-75A  
 
AGGGACAGAGCTGATCC 
TTGAACTCTTAAG 
TTAGGGGACACCTAG
CCCTCAGGAAGAGCA 
Promoter G/A 51 
apoB T71I AATGCTCTGCTACCCTG 
AAT 
AACACACAAGTTCAT
ACCTC 
Exon 4 C/T 55 
 4311S CTGGCTTGCTAACCTCTCT
G 
GAGAAGCTTCCTGAA
GCTCG 
Exon 29 T/C 52 
LCAT Ser232Thr CTCATTGGCCACAGCCTC GGTGAGACCAAGCTG
ATCCT 
Exon 5 T/A 53 
 LCATu3 TATGAGGATGGTGATGAC 
ACGGT 
TTTGCTACCGTAAGCCC
TG 
Exon 6 C/T 50 
apoC-I HpaI ATCGATCACGACCCTCTC GCTACATTCTGAGTG
GGGGA 
Promoter T/A 51 
apoC-II Leu96Arg CTATGACGACCACCTGAGGG TGTCCCTGTCTGGATCC
TTC 
Promoter T/G 53 
 -62 A>C GAGAAGGTTCCCTGTGACGT 
GACCTT 
CAAAGATCGATAAAGCA Promoter A/C 52 
SR-B1 A350A TCCTTGTCTGATGTCCCCT
C 
TAAGGAACTTTGGTG
GCTCG 
Exon 8 C/T 51 
 G2S CCTCACCCACCTTAAGGA
CC 
CCTGTGTCGTCTCTGT
CGC 
Exon 1 G/A 49 
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SD = 
 
Table A9(2): The pattern of coincident SNPs (Hodgkinson et al., 2009) 
 
  SNP  
  Old World Monkey        
    C/T G/A C/A G/T C/G A/T 
Human C/T 3 840 11 181 98 197 73 
  G/A 14 3 708 95 171 189 101 
  C/A 226 107 291 3 48 27 
  G/T 114 254 0 304 48 16 
  C/G 190 194 46 51 217 3 
  A/T 81 89 33 19 0 532 
 
 
6. STATISTICAL ANALYSIS 
6.1 Standard deviation 
Statistical computations were performed using Computer software.  The data 
pertaining to anthropometric measurements were subjected to the mean value 
analysis. 
   .   ΣX   . 
        n 
Where X = Arithmetic Mean 
 ΣX = Arithmetic Mean 
 n = Total number of variables 
To find out the degree of dispersion of recorded data around the mean, standard 
 
      Σ(    ∑ X-X)
2       
.
 
                 n  
 
Where SD    =   Standard deviation 
            X-X  =  Deviation of value from the mean  
            n       =  Total number of observations in the sample. 
 
X 
√
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√ 
 
t = 
√ 
 
S = 
6.2 Student ‘t’ test 
Two –tailed Student ‘t’ test was performed to find the difference in the mean values of 
control and experimental groups of the African green monkeys. 
 
   .       X1-X2        . 
              S    1/n1+1/n2 
 
 
   .     Si2n1 + S2n2     . 
    n1+n2-2 
 
 
Where X1  =  Mean of first sample with standard deviation S1. 
X2  =  Mean of Second Sample with standard deviation S2 
   S  =  Combined standard deviation 
 The level of significance and noted from ‘t’ table against the degree of 
freedom (df). 
  df = n1+n2-2 
 
6.3 The Pearson correlation coefficient 
The Pearson correlation measures the correlation or strength of linear dependence 
between two variables X and Y. 
It returns values between +1 and −1 inclusive. 
 1 implies that Y increases as X increases.  
 0 implies that there is no linear correlation between the variables.  
 −1 implies that Y decreases as X increases.  
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r = 
√ 
 
 
A correlation coefficient ‘r’ is an index that measures the strength of a relationship 
between the two variables in a given set of data.  It was used to find the correlation 
between HDL-C and expression profiles of selected lipid metabolism genes.  The 
values of the correlation coefficient lie between +1 and -1 for complete positive and 
negative correlation. Complete correlation describes a situation where all readings lie 
on a straight line having either positive or negative slope.  Correlation coefficient near 
‘zero’ represents situation where there is no particular tendency for two sets of data to 
cover linearly. 
 
Correlation coefficient ‘r’ is given by the following formula: 
.           [(ΣXY)] – [{(ΣX) (ΣY)}/n]            . 
[{(ΣX2) – (ΣX)2}/N] [{(ΣY2) – (ΣY)2}/N] 
 
where  r  =  Correlation coefficient. 
ΣXY  =  Sum of cross-products of variables ‘X’ and ‘Y’ for ‘n’  subjects.  
        ΣX  =  Sum of individual values of ‘X’ of ‘n’ subjects. 
        ΣY  =  Sum of individual values of ‘Y’ and ‘n’ subjects 
X and Y =  Mean values of variables ‘X’ and ‘Y’ 
          N  =  Number of pairs of observations 
 
A significant correlation was tested by applying ‘t’ test. 
 
      t= r       (n-2) / (l-r) 
 
The value was checked at degree of freedom (df = n-2). 
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Table A10: Correlation coefficient between HDL-C and gene expression profiles  
             
                    during niacin treatment intervention study  
 
 
 
 
* r = (a value between -1 and +1), 
 
 
 
 
 
 
 
 
 
 
 
Time point HDL-C CETP ABCA1 LCAT SR-B1 APOA-1 APOE APOC1 APOB CYP7A1 APOC11
04.02.08 2.18 1.21 0.36 0.45 0.71 0.80 0.31 1.05 0.00 4.57 0.93
18.02.08 2.90 1.80 0.96 1.00 0.82 0.52 3.93 0.76 0.00 1.33 3.28
03.03.08 3.45 1.18 2.35 0.25 0.73 1.22 1.95 0.55 0.00 1.64 0.05
17.03.08 4.85 1.22 1.03 0.86 0.77 0.00 5.65 0.57 0.00 0.54 0.40
31.03.08 4.28 2.60 1.51 0.80 0.68 0.12 5.62 0.48 0.00 0.95 0.04
14.04.08 3.95 0.79 0.79 0.79 1.83 3.34 6.51 0.45 0.64 3.36 0.00
29.04.08 3.88 0.92 0.62 1.56 1.62 1.78 0.94 0.65 0.45 2.88 0.00
12.05.08 3.50 0.86 0.52 0.53 1.34 0.04 1.04 1.00 0.56 2.29 0.00
26.05.08 3.48 0.69 0.58 0.55 0.87 2.58 0.60 1.29 0.63 1.55 0.26
09.06.08 2.33 2.19 2.77 1.03 2.67 1.34 2.69 1.34 2.67 0.43 0.00
p-value p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001 0.49 p < 0.001 p < 0.001 0.03 1.45
correlation coefficient (r) -0.14 -0.17 0.16 -0.27 -0.01 0.56 -0.69 -0.95 -0.30 -0.33
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7. GENE EXPRESSION DATA 
 
 
Table: A11: CETP mRNA expression (a.u) 
 
 
 
 
 
 
 
Table: A12: ABCA1 mRNA expression (a.u) 
 
 
 
CETP Baseline: 04.02.08 Week 2: 18.02.08 Week 4: 03.03.08 Week 6: 17.03.08 Week 8: 31.03.08 Week 10: 14.04.08 Week 12: 29.04.08 Week 14: 12.05.08 Week 16: 26.05.08 Week 18: 09.06.08
control niacin control niacin control niacin control niacin control niacin control niacin control niacin control niacin control niacin control niacin
0.01 0.03 0.01 0.03 0.00 0.00 0.03 0.00 0.01 0.02 0.01 0.01 0.05 0.03 0.01 0.00 0.00 0.01 0.00 0.03
0.01 0.03 0.00 0.03 0.01 0.01 0.00 0.02 0.01 0.00 0.00 0.02 0.00 0.00 0.02 0.00 0.01 0.02 0.00 0.00
0.03 0.00 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.00 0.01 0.00 0.03 0.01 0.02 0.02 0.00 0.01 0.00
0.01 0.01 0.02 0.00 0.01 0.01 0.01 0.02 0.01 0.05 0.00 0.02 0.00 0.01 0.01 0.01 0.01 0.03 0.00 0.04
mean 0.01 0.02 0.01 0.02 0.01 0.01 0.02 0.02 0.01 0.02 0.02 0.01 0.02 0.02 0.02 0.01 0.02 0.01 0.01 0.02
sd 0.01 0.02 0.01 0.02 0.00 0.02 0.01 0.01 0.00 0.02 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02
p-value 0.77 0.43 0.76 0.78 0.37 0.04 0.84 0.33 0.41 0.29
ABCA1 Baseline: 04.02.08 Week 2: 18.02.08 Week 4: 03.03.08 Week 6: 17.03.08 Week 8: 31.03.08 Week 10: 14.04.08 Week 12: 29.04.08 Week 14: 12.05.08 Week 16: 26.05.08 Week 18: 09.06.08
control niacin control niacin control niacin control niacin control niacin control niacin control niacin control niacin control niacin control niacin
0.01 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.01 0.02 0.00 0.01 0.01 0.01 0.02 0.01 0.00 0.01 0.00 0.01
0.03 0.01 0.01 0.01 0.00 0.00 0.00 0.01 0.00 0.01 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.01 0.02 0.01
0.01 0.00 0.01 0.01 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.00
0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.03 0.00 0.02 0.00 0.01 0.01 0.01 0.02
mean 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
sd 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.01 0.01 0.00 0.01 0.00 0.01 0.01
p-value 0.21 0.92 0.36 0.94 0.39 0.62 0.48 0.16 0.20 0.97
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Table: A13: LCAT mRNA expression (a.u) 
 
 
 
 
 
 
 
 
Table: A14: SRB1 mRNA expression (a.u) 
 
 
 
 
 
LCAT Baseline: 04.02.08 Week 2: 18.02.08 Week 4: 03.03.08 Week 6: 17.03.08 Week 8: 31.03.08 Week 10: 14.04.08 Week 12: 29.04.08 Week 14: 12.05.08 Week 16: 26.05.08 Week 18: 09.06.08
control niacin control niacin control niacin control niacin control niacin control niacin control niacin control niacin control niacin control niacin
0.00 1.25 0.26 0.83 0.65 0.58 0.39 1.00 0.56 0.93 0.24 0.58 0.06 0.33 0.24 0.24 0.28 0.11 0.00 1.18
1.12 0.38 0.69 1.24 0.25 0.15 0.51 0.35 0.29 0.54 0.10 0.21 0.08 0.23 0.31 0.00 0.43 0.31 0.29 0.30
0.36 0.00 0.47 0.25 0.66 0.33 0.43 0.22 0.54 0.37 0.20 0.20 0.24 0.29 0.28 0.21 0.16 0.10 0.40 0.40
1.85 0.28 0.91 0.00 2.69 0.00 1.28 0.66 1.29 0.30 1.02 0.25 0.24 0.13 0.87 0.45 0.62 0.30 0.89 0.28
mean 0.83 0.48 0.58 0.58 1.06 0.26 0.65 0.56 0.67 0.53 0.39 0.31 0.16 0.24 0.42 0.23 0.37 0.20 0.53 0.54
sd 0.83 0.54 0.28 0.56 1.10 0.25 0.42 0.35 0.43 0.28 0.42 0.18 0.10 0.09 0.30 0.19 0.20 0.12 0.32 0.43
p-value 0.50 1.00 0.24 0.75 0.62 0.73 0.23 0.31 0.20 0.62
SRB1 Baseline: 04.02.08 Week 2: 18.02.08 Week 4: 03.03.08 Week 6: 17.03.08 Week 8: 31.03.08 Week 10: 14.04.08 Week 12: 29.04.08 Week 14: 12.05.08 Week 16: 26.05.08 Week 18: 09.06.08
control niacin control niacin control niacin control niacin control niacin control niacin control niacin control niacin control niacin control niacin
0.03 0.16 0.08 0.10 0.12 0.08 0.05 0.08 0.10 0.11 0.02 0.03 0.04 0.15 0.03 0.04 0.03 0.06 0.00 0.26
0.18 0.07 0.06 0.08 0.07 0.05 0.09 0.04 0.07 0.05 0.02 0.06 0.08 0.10 0.08 0.17 0.06 0.05 0.04 0.18
0.11 0.00 0.07 0.06 0.09 0.06 0.05 0.03 0.10 0.06 0.04 0.08 0.07 0.10 0.06 0.08 0.03 0.04 0.08 0.18
0.12 0.09 0.08 0.00 0.09 0.08 0.07 0.05 0.14 0.05 0.04 0.06 0.06 0.06 0.10 0.06 0.07 0.03 0.08 0.09
mean 0.11 0.08 0.07 0.06 0.09 0.07 0.07 0.05 0.10 0.07 0.03 0.06 0.06 0.10 0.07 0.09 0.05 0.04 0.12 0.07
sd 0.06 0.06 0.01 0.04 0.02 0.01 0.02 0.02 0.03 0.03 0.01 0.02 0.02 0.04 0.06 0.03 0.02 0.01 0.02 0.07
p-value 0.51 0.58 0.08 0.35 0.16 0.08 0.13 0.52 1.00 0.03
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Table: A15: apoCI mRNA expression (a.u) 
 
 
 
 
 
 
 
Table: A16: apoB mRNA expression (a.u) 
 
 
 
 
 
 
 
apoCI Baseline: 04.02.08 Week 2: 18.02.08 Week 4: 03.03.08 Week 6: 17.03.08 Week 8: 31.03.08 Week 10: 14.04.08 Week 12: 29.04.08 Week 14: 12.05.08 Week 16: 26.05.08 Week 18: 09.06.08
control niacin control niacin control niacin control niacin control niacin control niacin control niacin control niacin control niacin control niacin
3E-04 3E-04 2E-04 7E-04 5E-04 0E+00 7E-04 4E-04 4E-04 5E-04 7E-05 4E-05 2E-04 4E-04 0E+00 0E+00 0E+00 7E-05 0E+00 0E+00
2E-03 2E-04 1E-03 4E-04 5E-04 3E-04 1E-04 3E-04 3E-04 4E-04 8E-05 2E-05 5E-05 5E-04 0E+00 0E+00 2E-05 0E+00 4E-03 2E-03
2E-04 2E-03 2E-04 4E-04 3E-04 4E-04 6E-04 3E-04 2E-04 2E-04 1E-04 4E-05 5E-05 8E-05 2E-05 2E-05 1E-04 0E+00 6E-05 2E-03
4E-04 3E-04 5E-04 0E+00 9E-04 2E-04 3E-04 0E+00 2E-03 2E-04 6E-05 4E-05 1E-03 0E+00 0E+00 0E+00 9E-05 0E+00 2E-04 1E-03
mean 8E-04 8E-04 5E-04 4E-04 5E-04 3E-04 4E-04 2E-04 7E-04 3E-04 8E-05 4E-05 4E-04 2E-04 2E-05 2E-05 6E-05 7E-05 1E-03 2E-03
sd 4E-04 3E-04 5E-04 7E-04 9E-04 0E+00 3E-04 4E-04 2E-03 5E-04 6E-05 4E-05 1E-03 4E-04 0E+00 0E+00 9E-05 7E-05 2E-04 0E+00
p-value 0.96 0.68 0.08 0.32 0.44 0.04 0.68 1.00 0.29 0.76
apoB Baseline: 04.02.08 Week 2: 18.02.08 Week 4: 03.03.08 Week 6: 17.03.08 Week 8: 31.03.08 Week 10: 14.04.08 Week 12: 29.04.08 Week 14: 12.05.08 Week 16: 26.05.08 Week 18: 09.06.08
control niacin control niacin control niacin control niacin control niacin control niacin control niacin control niacin control niacin control niacin
9E-05 3E-04 7E-04 0E+00 7E-04 2E-03 2E-04 3E-04 1E-02 1E-02
7E-04 1E-04 3E-04 6E-04 8E-04 0E+00 3E-04 2E-04 5E-04 1E-02
2E-04 2E-04 2E-04 5E-04 4E-04 4E-04 1E-03 4E-04 6E-04 2E-02
4E-04 3E-04 2E-03 4E-04 2E-03 3E-04 4E-04 2E-04 0E+00 7E-03
mean 3E-04 2E-04 8E-04 4E-04 1E-03 5E-04 5E-04 3E-04 5E-03 1E-02
sd 4E-04 3E-04 2E-03 0E+00 2E-03 2E-03 4E-04 3E-04 6E-04 1E-02
p-value 0.42 0.38 0.39 0.43 0.06
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Table: A17: apoCII mRNA expression (a.u) 
 
 
 
 
 
 
 
Table: A18: apoAI mRNA expression (a.u) 
 
 
 
 
 
apoCII Baseline: 04.02.08 Week 2: 18.02.08 Week 4: 03.03.08 Week 6: 17.03.08 Week 8: 31.03.08 Week 10: 14.04.08 Week 12: 29.04.08 Week 14: 12.05.08 Week 16: 26.05.08 Week 18: 09.06.08
control niacin control niacin control niacin control niacin control niacin control niacin control niacin control niacin control niacin control niacin
2E-05 5E-04 7E-05 2E-03 1E-03 0E+00 2E-05 0E+00 0E+00 3E-05 2E-04 0E+00 0E+00 1E-03 0E+00 0E+00 0E+00 5E-05 0E+00 0E+00
9E-04 2E-05 4E-05 0E+00 3E-05 2E-05 1E-04 0E+00 5E-04 0E+00 1E-04 0E+00 0E+00 0E+00 0E+00 0E+00 1E-04 0E+00 0E+00 0E+00
5E-05 1E-03 0E+00 0E+00 7E-04 0E+00 0E+00 1E-04 4E-05 0E+00 2E-05 0E+00 0E+00 0E+00 0E+00 0E+00 3E-04 0E+00 0E+00 0E+00
9E-05 0E+00 0E+00 0E+00 0E+00 4E-05 9E-04 1E-04 2E-03 6E-04 0E+00 0E+00 0E+00 6E-04 0E+00 0E+00 0E+00 0E+00 0E+00 0E+00
mean 3E-04 2E-04 5E-05 2E-03 6E-04 3E-05 3E-04 1E-04 8E-04 3E-05 1E-04 0E+00 0E+00 1E-03 0E+00 0E+00 0E+00 5E-05 0E+00 0E+00
sd 9E-05 5E-04 0E+00 2E-03 0E+00 0E+00 9E-04 0E+00 3E-05 2E-03 0E+00 0E+00 0E+00 1E-03 0E+00 0E+00 0E+00 5E-05 0E+00 0E+00
p-value 0.63 0.42 0.20 0.43 0.41 0.15 0.23 0.28
apoAI Baseline: 04.02.08 Week 2: 18.02.08 Week 4: 03.03.08 Week 6: 17.03.08 Week 8: 31.03.08 Week 10: 14.04.08 Week 12: 29.04.08 Week 14: 12.05.08 Week 16: 26.05.08 Week 18: 09.06.08
control niacin control niacin control niacin control niacin control niacin control niacin control niacin control niacin control niacin control niacin
1E-05 8E-06 0E+00 8E-05 3E-05 2E-04 0E+00 0E+00 0E+00 0E+00 0E+00 8E-07 7E-06 0E+00 0E+00 0E+00 0E+00 0E+00 1E-03 0E+00
6E-05 6E-05 1E-04 3E-05 0E+00 3E-05 1E-05 0E+00 0E+00 0E+00 2E-06 6E-06 9E-07 2E-05 3E-05 4E-06 1E-05 5E-04 0E+00 2E-03
0E+00 0E+00 0E+00 0E+00 2E-05 1E-05 0E+00 0E+00 4E-04 2E-05 3E-05 1E-04 2E-04 0E+00 1E-04 0E+00 0E+00 2E-06 2E-04 3E-04
4E-05 3E-05 0E+00 0E+00 8E-05 1E-05 2E-05 0E+00 0E+00 3E-05 2E-04 0E+00 0E+00 0E+00 4E-06 2E-05 0E+00 2E-06 0E+00 0E+00
mean 4E-05 3E-05 1E-04 6E-05 4E-05 5E-05 1E-05 2E-04 0E+00 2E-05 2E-05 5E-05 6E-05 1E-04 0E+00 2E-06 7E-06 2E-04 6E-04 9E-04
sd 3E-05 3E-05 0E+00 4E-05 4E-05 7E-05 0E+00 0E+00 2E-04 2E-07 2E-05 8E-05 9E-05 1E-04 5E-05 3E-06 7E-06 3E-04 6E-04 1E-03
p-value 0.77 0.97 0.64 0.23 0.45 0.81 0.43 0.31 0.40 0.63
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Table: A19: CYP7A1 mRNA expression (a.u) 
 
 
 
 
 
Table: A20: apoE mRNA expression (a.u) 
 
 
CYP7A1 Baseline: 04.02.08 Week 2: 18.02.08 Week 4: 03.03.08 Week 6: 17.03.08 Week 8: 31.03.08 Week 10: 14.04.08 Week 12: 29.04.08 Week 14: 12.05.08 Week 16: 26.05.08 Week 18: 09.06.08
control niacin control niacin control niacin control niacin control niacin control niacin control niacin control niacin control niacin control niacin
0.00 10.34 0.04 0.50 4.34 0.00 14.74 0.11 5.42 0.74 0.00 0.01 0.00 0.00 0.00 0.42 0.00 0.15 1.30 0.23
4.85 7.35 0.38 3.90 0.30 0.19 10.02 6.58 0.00 0.29 0.00 0.05 0.00 0.29 0.04 0.00 0.11 2.53 1.70 0.62
0.00 3.00 0.27 0.43 3.58 0.30 6.09 0.44 0.04 0.12 0.00 0.13 0.00 0.00 0.00 0.03 0.00 0.00 0.15 0.00
1.95 6.08 0.00 0.00 0.00 12.95 4.84 0.00 0.00 5.76 0.00 2.60 0.00 1.51 0.01 0.00 0.00 0.00 0.00 0.00
mean 1.70 6.69 0.17 1.61 2.05 3.36 4.42 2.38 1.82 1.73 0.00 0.70 0.00 0.90 0.02 0.42 0.06 0.90 1.00 0.43
sd 0.95 1.52 0.00 0.50 0.00 0.00 0.84 0.11 0.00 0.74 0.00 0.01 0.00 0.42 0.00 0.00 0.00 0.01 0.00 0.23
p-value 0.04 0.34 0.72 0.04 0.86 0.35 0.30 0.40 0.38 0.27
apoE Baseline: 04.02.08 Week 2: 18.02.08 Week 4: 03.03.08 Week 6: 17.03.08 Week 8: 31.03.08 Week 10: 14.04.08 Week 12: 29.04.08 Week 14: 12.05.08 Week 16: 26.05.08 Week 18: 09.06.08
control niacin control niacin control niacin control niacin control niacin control niacin control niacin control niacin control niacin control niacin
6E-05 1E-04 1E-04 1E-03 2E-04 1E-03 9E-04 1E-03 2E-04 3E-04 1E-04 2E-04 1E-04 5E-05 5E-04 6E-04 7E-05 3E-05 0E+00 4E-03
1E-03 2E-04 2E-04 1E-03 2E-04 1E-04 3E-03 0E+00 7E-04 7E-05 2E-04 2E-04 8E-05 4E-05 3E-04 0E+00 9E-05 2E-04 4E-03 0E+00
9E-05 0E+00 9E-05 2E-04 1E-04 9E-05 1E-04 9E-04 1E-04 1E-04 9E-05 2E-04 5E-05 4E-05 1E-04 5E-04 3E-04 1E-04 3E-04 9E-03
1E-04 1E-04 3E-04 0E+00 3E-04 2E-04 1E-03 2E-03 4E-04 1E-04 5E-05 4E-04 2E-04 8E-05 7E-04 1E-04 2E-04 1E-04 2E-04 3E-03
mean 3E-04 1E-04 2E-04 8E-04 2E-04 4E-04 2E-04 9E-04 2E-04 1E-03 5E-05 3E-04 1E-04 1E-04 4E-04 4E-04 2E-04 1E-04 2E-03 4E-03
sd 6E-04 2E-04 3E-04 1E-03 3E-04 1E-03 1E-04 1E-03 4E-04 9E-04 8E-05 2E-04 2E-04 1E-04 7E-04 6E-04 2E-04 3E-05 2E-04 4E-03
p-value 0.43 0.24 0.49 0.58 0.24 0.06 0.14 0.67 0.35 0.23
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8. STANDARD CURVES 
 
 
 
 
Figure A1: GAPDH Standard curve 
 
 
 
 
 
 
 
Figure A2: PGK2 Standard curve 
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Figure A3: CETP Standard curve 
 
 
 
 
 
 
 
 
Figure A4: ABCA1 Standard curve
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Figure A5: LCAT Standard curve  
 
 
 
 
 
 
 
 
 
Figure A6: SRB1 Standard curve  
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Figure A7: apoA-1 Standard curve  
 
 
 
 
 
 
 
 
Figure A8: apoE Standard curve  
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Figure A9: apoC1 Standard curve  
 
 
 
 
 
 
 
 
Figure A10: apoB Standard curve  
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Figure A11: CYP7A1 Standard curve  
 
 
 
 
 
 
 
 
Figure A12: apoC11 Standard curve  
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9. MATERIALS AND SUPPLIERS 
 
 
Acetic Acid Glacial         ACE Chemicals 
Agarose       Whitehead Scientific 
Anaket-V       Norpharm 
AxyPrep Blood Genomic DNA Miniprep Kit  Axygen Biosciences 
BenchTop 100bp DNA Ladder    Promega 
Boric acid       Merck 
Bromophenol blue       ACE Chemicals 
EDTA        BDH 
EDTA blood collection tubes     Pathcare 
Ethanol       BDH 
High-Capacity cDNA Reverse Transcription Kit  Applied Biosystems 
Hydrochloric acid       BDH 
Hypodermic needles (21 and 23G)    Norpharm 
NaOH        Merck   
Nicotinic acid (nicin)      Sigma 
Paxgene Blood collection tubes    Qiagen 
Paxgene Blood RNA Kit     Qiagen 
PCR Master mix      Promega 
Power SYBR Green PCR Master Mix   Applied Biosystems 
RNase Inhibitor      Applied Biosystems 
Sodium Hydroxide Pellets      ACE Chemicals 
 
Tris-base       Promega 
Turbo Dnase treat      AEC Amersham 
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Quanti Tech Primer Assays     Qiagen  
Wizard SV Gel and PCR Clean-Up System   Promega 
Xylene cyanol FF      Sigma 
 
 
 
 
 
 
 
 
 
 
 
